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Abstract 
Haematological parameters are typically monitored to detect changes in haemostasis due to 
illness or exposure to toxins. Of interest to the present study was the possibility that exposure 
to organophosphorous (OP) compounds might disrupt enzymes involved in the coagulation 
cascade includes (e.g. the plasma transglutaminase (TG) factor XIIIa and thrombin) and the 
proliferation and viability of white cells. Toxin-induced disruption of such enzyme activities 
or white cell number could interfere with the haemostatic balance. There have been limited 
studies on OP effects on coagulation enzymes and blood cells. The purpose of this study was 
to investigate the effects of the OPs phenyl saligenin phosphate (PSP), diazinon (DZ), 
chlorpyrifos (CPF), parathion (PTH), diazoxon (DZO), chlorpyrifos oxon (CPO), paraoxon 
(POX) on plasma and purified cholinesterases (AChE & BChE), FXIIIa and thrombin 
activities in plasma and pure enzyme preparations, and the growth and viability THP-1 
leukemic monocyte cells.  
The effects of OPs on enzyme activities were monitored using colorimetric activity assays 
of purified enzymes or whole plasma protein extracts, after samples had been pre-incubated 
with OPs. All OPs showed the expected patterns of toxicity against their recognised ChE 
targets. Most OPs demonstrated the ability to inhibit one or other of the transamidase 
activities in a concentration-dependent manner, being more effective against the pure 
enzyme. Thrombin inhibition was observed with some OPs but was more striking in whole 
plasma. All OPs reduced the levels of D-dimer detectable by ELISA. Covalent binding 
assays involving SDS-PAGE analysis of plasma proteins, rFXIIIa and purified thrombin 
incubated with rhodamine-labelled PSP, demonstrated covalent binding of PSP to both 
enzymes which could be competed out by non-labelled OPs. MS analysis revealed novel 
covalent adducts formed between pure FXIIIa and either unlabeled PSP or the 3 oxon OPs.  
THP-1 cells proliferation and viability were decreased by most OPs in a concentration and 
time-dependent manner, although CPO promoted proliferation at an early time point prior a 
decline. In conclusion, the results obtained provide evidence that FXIIIa transamidase 
activities are inhibited by OPs and that FXIIIa could be a novel target of OP toxicity. 
Moreover, data suggest that OPs can disrupt the regulation of THP-1 proliferation. Future 
work is recommended to identify adduct forming sites on novel OP-binding proteins in 
plasma and THP-1 cells and to further examine the effects on THP-1 cells at a proteomic 
and genomic level. 
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 Background 
Blood has many of haematological factors including a variety of proteins and cells types, 
such as haemoglobin, red cells, white cells, platelets, and specific proteins involved in vital 
processes, such as haemostasis, which have been studied widely as diagnostic and 
monitoring tools for blood diseases (Blann & Ahmed, 2014; Etim et al., 2014). Haemostasis 
is one of the crucial biological processes in blood, as it maintains blood in a fluid condition 
within the vascular system, having defence mechanisms against bleeding and thrombosis. It 
involves complex processes, such as vascular spasm to restrain the flow of blood to the 
wounded area, platelet plug formation, the coagulation cascade leading to fibrin deposition, 
(and therefore ensuring stability of the clot), clot retraction and tissue repair, and finally 
coagulation inhibitors and fibrinolytic systems to restore the blood flow (Pallister & Watson, 
2011). As summarized in Fig 1.1, the complex coagulation cascade is driven by a complex 
of enzymatic pathways, which involves several proteins, cofactors, zymogen-to-enzyme 
conversion steps and allows two starting points involving the extrinsic and intrinsic reactions, 
which merge into a common pathway where coagulation is completed (Pallister & Watson, 
2011; Lupu et al., 2016). 
Following injury, the zymogen coagulation proteins in the blood are sequentially activated 
into their enzymically active form (Lupu et al., 2016). The extrinsic pathway is the main 
contributor that sparks the physiological activation of coagulation. It is triggered within a 
few seconds, when the tissue factor (TF) from the injured area is exposed to blood (Blood 
Laboratory n.d). TF acts as a cofactor for the activated form of factor VII (FVIIa), serine 
protease, and binds to it to form an enzymatic complex TF-FVIIa, which propagates the 
cleavage of factor X to the activated form FXa in the presence of Ca2+ (Lupu et al., 2016). 
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Figure 1- 1: The physiological response of the coagulation cascade to vascular injury. 
 
Three vital pathways are involved in this process; the activation of extrinsic pathway by 
released tissue factor sparks the physiological activation of protein cascade, while the 
intrinsic pathway stimulated by negatively charged surfaces and begin a sequential 
coagulation factors activation. Both of these pathways converge on the common pathway, 
at a point where FXa accelerates the activation of the zymogen prothrombin to thrombin 
which is then able to regulate and activate many coagulation factors in a cascade which 
ends with cleavage fibrinogen to fibrin to form a clot mesh, which is cross-linked and 
stabilized by FXIIIa (a member of the transglutaminase family) to form a fibrin mesh. 
Modified from (Lupu et al., 2016). 
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The intrinsic pathway, also known as the contact activation pathway, plays a secondary role 
in haemostasis under normal physiological conditions (Lupu et al., 2016), which takes a few 
minutes to occur (Blood Laboratory n.d). This process can be initiated and form a clot upon 
contact with a negative charged glass surface that represents the negative charge of the body 
surface (Neuenschwander, 2006) Once the negative charged injured surface in the body 
makes contact with the blood or plasma, the coagulation factors are activated sequentially, 
starting from FXII to FXIIa. The later, in the presence of calcium ions then activates FXI to 
FXIa, which activates FIX to FIXa; moreover, as a part of amplification system, the TF-
FVIIa-Ca2+ complex is also able to activate FIX (Licari & Kovacic, 2009). FVIII, which is 
activated in advance, by the trace amount of thrombin that had been activated through the 
extrinsic pathway, to FVIIIa in turn forms a complex with FIXa to activate FX to FXa (Lupu 
et al., 2016). Both pathways lead to the activation of Factor X (FX) in the common pathway 
and the subsequent generation of thrombin. The common pathway is the final step in this 
cascade, which proceeds to the conversion of soluble fibrinogen into an insoluble fibrin 
network. Once the FXa is generated, either from extrinsic or intrinsic pathways, it will form 
a complex with calcium ions and activated nonenzymatic cofactor FV (FVa), which is also 
activated by thrombin, to proteolytically active prothrombin (FII) to generate enzymically 
active thrombin (FIIa) (Bereczky et al., 2003). Thrombin is the protease that proteolytically 
processes fibrinogen to produce insoluble fibrine monomers, which form fibrin strands and 
polymerize into an unstable clot mesh. In the meantime, thrombin also proteolytically 
converts the transglutaminase pro-enzyme FXIII from its in-active form to the activated form 
FXIIIa, which plays the final role in the coagulation cascade by catalysing the cross-linking 
of the unstable fibrin mesh to form stabilized insoluble clot as shown in Fig 1.1 (Bereczky 
et al., 2003).  
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Most of environmental pollutants are potentially toxic to the human body and are implicated 
in developing diseases, which induce chronic effect on neuronal, cardiac, and muscular 
tissues, and increase the risk of cancer, etc. (Gupta, 2006). Organophosphorus compounds 
(OPs) have pesticide and non-pesticide applications, as they are widely used in agriculture, 
household product and aircraft engine oil (Grube et al., 2011; Hargreaves et al., 2006). 
Exposure to OPs has been linked with serious health issues over the past few decades, 
affecting both neuronal and non-neuronal tissues, which has been proposed to involve 
disruption of a range of biological process (Eleršek & Filipič, 2011). OPs usually inhibit 
serine esterase such acetylcholinesterase as primary targets but there is increasing evidence 
that they may have other targets; they also disrupt Ca2+ homeostasis, thus affecting the 
activities of a range of Ca2+ depending protein such as calpain and transglutaminase 2 
(Chambers & Oppenheimer, 2004; Hargreaves, 2012). 
As thrombin (serine esterase) and FXIIIa (a form of transglutaminase) are enzymes involved 
in the blood clotting cascade, they represent potential blood-borne targets of OPs. Both 
enzymes have major role in coagulation, in addition to other roles in different processes. 
Coagulation disorders associated with disruption of these enzymes can lead to critical 
bleeding issues. An investigation of the ability of OPs to interfere with these enzymes’ 
activities was therefore of interest to the present study.  
 Thrombin 
Thrombin is considered to be a key player in the coagulation cascade where it has control 
for the boosting and attenuation of its own formation, and has Janus-faced characteristics for 
pro- and anti-coagulant activities (Huntington, 2008). Prothrombin, known as FII, is a 
zymogen that is converted to the serine protease thrombin (FIIa), which has at least four 
distinct binding sites for Na+, substrates, cofactors, and inhibitors (Brummel et al., 2002). 
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Thrombin a positive feedback, as it amplifies the coagulation factors FV, FVIII, XI, and 
FXIII, and also cleaves fibrinogen to form fibrin monomers, which polymerize to form the 
fibrin network (Brummel et al., 2002). In addition, it has been found that platelets are 
activated through protease activated receptor (PAR)-1, 3, and 4 by thrombin (Huntington, 
2012). Likewise, thrombin acts as a negative feedback regulator for coagulation factors by 
activating protein C (APC), and thrombin-activatable fibrinolysis inhibitor (TAFI) 
(Brummel et al., 2002; Bode, 2005; & Huntington, 2012). 
1.2.1 Structure: 
The active form thrombin is a 37 kDa serine protease generated by proteolytic cleavage of 
prothrombin (Mutch et al., 2001). It is a Na+ -activated serine protease of the chymotrypsin 
family that has two six-stranded asymmetrical β-barrels, both of which house residues of the 
catalytic triad of the active site His57, Asp102 and Ser195 (Huntington, 2005). The 
traditional thrombin structure is viewed in the standard orientation represent the peptide 
bond of serine proteases includes essential scissile peptide bond of substrate binding residues, 
which was identified by mutagenesis and structural studies, that so-called P1-P1̍ and are 
numbered sequentially toward the N- to C-termini (Fig 1.2) (Huntington, 2005). The subsite 
hydrophobic interactions occur at P1 arginine side chain, which is buried into the deep S1 
pocket to form a salt bridge with aspartic acid 189 at the base of the pocket, also P4 of 
substrate residue interacted with aryl binding pocket S4. Due to that the thrombin in 
haemostasis is highly substrate-specific (Huntington, 2008).  
Thrombin has specifically a deep active site cleft referred to as a ‘canyon’, this is due to 
inserted loops above (60-loop) and below (γ-loop) the active site. The 60-loop has a 
hydrophobic manner that gives rigid form; on the other hand, the γ-loop is more hydrophilic 
which produces flexibility that can make the contact with substrate proteins. These loops can 
directly interact with the substrate peptide. Also, it can serve to restrict access of other 
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flexible and long substrates or mediate the surface of complementary proteins to the catalytic 
site of thrombin (Huntington, 2005; Huntington, 2008).  
Moreover, thrombin has other sites relevant to its activity, including two anion exosite for 
interaction areas and Na+ binding (Huntington, 2005). Exosite I, which is located “east” of 
the catalytic active site, mainly known as fibrin(ogen), thrombomodulin (TM) and protease 
activated receptor 1, 3 and 4 (PAR1, PAR4, and PAR4) interaction site. While exosite II, 
which is located “west” of the catalytic active site, is the more basic of the two sites, and 
was identified as heparin, platelet glycoprotein receptor GpIbα interaction site (Di Cera, 
2003). Most of the natural thrombin substrates and cofactors utilize one or both exosites 
(Huntington, 2005). De Cera and his colleagues (1995) identified the Na+ binding site 
position on thrombin. The Na+ binding site plays an important role in regulating thrombin 
function and is located “southwest” of the catalytic active site. Interaction of Na+ at that site 
can induce two distinct thrombin conformations that are so-called slow and fast forms, which 
enhances substrates or other cofactor proteins binding and catalysis (Dang et al., 1995). 
Since thrombin is an allosteric enzyme, the equilibrium between fast state (Na+ -bound) and 
slow state (Na+ -free) become arbiter of procoagulant/anticoagulant activities of thrombin, 
respectively (Dang et al., 1995). The specificity of fast form is higher for the procoagulant 
substrates fibrinogen, fibrin, PAR1 and PAR4, while the slow form is more specific for 
anticoagulant substrates, such as protein C (Di Cera, 2003).  
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Figure 1- 2: The crystallographic structure of thrombin. 
 
The standard orientation of thrombin reveals the active site is occupied the centre, where a 
peptide substrate will run from the left to the right, from its N- to C- terminal. The P4 to P2', 
substrate residues of antithrombin (yellow rods), including the reactive centre bond (P1-P1') 
indicated by white arrow. Thrombin active site is remarkably deep due to the presence of the 
60-loop from above, and γ-loop from below the active site. A substrate and cofactor 
recognition areas are identified at two major anion binding exosites (Exosite I & II) as 
indicated by the ovals. The Na+ binding site which is active site adjacent, play critical role 
to make thrombin less activity. Modified from (Huntington, 2005). 
 
 Thrombin and coagulation cascade 
As mentioned before, the central role of thrombin is in the regulation of the coagulation 
cascade, boosting the cleavage of fibrinogen to fibrin to form the clot mesh on platelet plug 
and activation of the prozymogen FXIII to FXIIIa that catalyses cross-linking of the mesh 
to form stable clot. The regulatory role of thrombin in coagulation starts when a small 
amount of thrombin is generated and performs in a positive feedback pathway (Fig 1.3) that 
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is able to amplify the system through more production of FVa, FVIIa, FVIIIa, and FXIa. 
This mechanism in healthy adults is sufficient for supplying thrombin production (Licari & 
Kovacic, 2009). Moreover, the activation of FXI by thrombin positive feedback in patients 
with FXII deficiency prevents serious haemorrhage (Brooks et al., 1994). However, part of 
this amplification mechanism fails in cases of FXI deficiency, which results in multiple 
bleeding for the same injury (Gomez & Bolton‐Maggs, 2008). Moreover, thrombin also 
amplifies platelet activation by cleavage of PAR1, resulting in stimulation of numerous of 
GPIIb/IIIa platelet receptors that flip in the membrane of the outer surface of platelet, and 
produce aggregates (Joo, 2012).  
On the other hand, thrombin mediates some biological process that boost anticoagulation 
and fibrinolysis. This thrombin regulating mechanism is called the negative feedback 
pathway (Fig 1.3) (Huntington, 2008). TM introduced by endothelial cells inhibits 
fibrinogen binding at exosite 1 and binds itself instead, forming a thrombin-TM complex 
that has an anticoagulant effect. This reaction becomes greater in the absence of Na+ (Dang 
et al., 1995). Thrombin-TM inhibits further endothelial cell and platelet activation, and 
activates TAFI to TAFIa, which inhibits fibrinolysis (Huntington, 2008). Also, APC is 
generated at the time protein C (PC) is binding to endothelial protein C receptor (EPCR) and 
reacts with thrombin-TM, which is binding to endothelial membrane (Licari & Kovacic, 
2009). Then, APC forms a complex with protein S (PS) to catalyse FVa and FVIIIa 
inactivation, which directly reduces the rate of thrombin generation. In addition, APC raises 
fibrinolysis by inhibiting plasminogen activator inhibitor-1 (PAI-1) that inhibits plasmin 
formation and as a consequence reduces the level of fibrinolysis (Licari & Kovacic, 2009). 
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Figure 1- 3: Thrombin amplification mechanism. 
Adabted from (Licari & Kovacic, 2009). 
 
 Thrombin dysfunction 
Thrombin dysfunction results in thrombo-haemorrhagic disorder identified by immoderate 
thrombin generation that lead to its dissemination all over the systemic circulation (Stief, 
2006). Over activation of endothelial and monocytes cells involved in some diseases due to 
excessive release of TF stimulates thrombin production throughout the coagulation cascade. 
Platelet depletion occurs under abnormal thrombin production leading to altered shape and 
aggregation of platelets (Gentry & Wood, 2005).  In many cell types such as platelets, 
monocytes, fibroblasts, myocytes, etc., thrombin has cellular effects that are mediated 
through protease-activated receptors (PARs). After the receptor is activated by thrombin its 
activation is irreversible. Under normal conditions these PARs are biologically replaced; 
however, excessive thrombin production induces a systemic inflammatory response (Licari 
& Kovacic, 2009). Moreover, these PARs have the ability to stimulate cell growth and 
Chapter 1 
11 
 
differentiation, macrophage, endothelial, and smooth muscle cell proliferation, and 
angiogenesis, which are important to enhance healing of tissues, thus suggesting 
involvement of thrombin in tumour biology under abnormal thrombin conditions (Licari & 
Kovacic, 2009). Fibrinolysis is hindered because of high concentration of PAI-1, which 
inhibit plasmin generation, and elevate the level of TAFI, which increase clot resistance to 
plasmin. Due to the rambunctious inflammatory response, the anticoagulant mechanism 
including antithrombin, PC, and tissue factor pathway inhibitor (TFPI) is damaged as a result 
of reduction of TM and EPCR (Gentry & Wood, 2005).  
 Transglutaminase 
Transglutaminases (TGs) are ubiquitous and widely distributed enzymes in most of 
mammals, they were first isolated from guinea pig liver and characterised in the late 1950s 
(Clarke et al., 1959). Clarke et al. (1959) described these proteins as having the ability to 
catalyse calcium-dependent post-translational modification of other proteins. As shown in 
Table 1.1 currently there are nine genes identified as encoding TG isozymes, named TGs 1-
7 and FXIII, which are catalytic forms, and the ninth one is erythrocyte membrane protein 
band 4.2, which is a structural and non-catalytic form (Grenard et al., 2001). The circulating 
zymogen FXIII was the first characterized TG in blood plasma; it is converted to its activated 
form (FXIIIa) in a thrombin depended manner to promote fibrin clot stabilization (Griffin et 
al., 2002). TGs 1-7 and FXIII shared the same amino acid sequence at the active site (Trp-
Cys-His-Asp), whereas protein 4.2 has an alanine mutation of the active site cysteine and is 
therefore catalytically inactive (Korsgren et al., 1990). 
From the family members FXIII and TG1 have an additional pro-peptide sequence in the 
NH2 terminal that may be cleaved to form the active enzyme (Iismaa et al., 2009). The 
transamidation reaction of TG is basically initiated by Ca2+  binding to form the active form 
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of TG, which catalyses the post-translational modification of proteins, for example by 
formation of isopeptide bonds through an acyl transfer reaction between the ε-amino group 
of protein-bond lysine residues and γ-carboxamide groups of glutamine residues to form ε(γ-
glutamyl) lysine bonds (Lorand & Graham, 2003). The mechanism of this reaction includes 
two main steps. First, the acyl donor glutamine substrate binds to the catalytic site of enzyme 
to form a thioester bond with the exposed cysteine of activated TG, and ammonia is released. 
Second, an amine donor binds to a thioester intermediate bond and reforming the enzyme 
catalytic active site. If the primary amine is the amine donor at selected peptide-bound 
glutamine residues, the amine incorporation reaction will be the resultant protein post-
translational modification (Klöck & Khosla, 2012). On the other hand, if the implicated 
group is peptide-bond lysine, the reaction will result in the crosslinking of the two proteins. 
However, the reaction will result in deamidation if the group is water molecule, TG reactions 
described in Fig 1.4 (Griffin et al., 2002; Iismaa et al., 2009; Eckert, 2014). TGs modulate 
variety of activities such as membrane stabilization, signal transduction, and protein 
polymerization, which in turn regulate an enormous range of physiological functions (Eckert, 
2014; Schröder & Kohler, 2013). 
 
 
 
1
3
 
 
 
Table 1- 1: Members of the transglutaminase (TG) enzyme family. 
TG classification and synonyms, molecular weight, tissue distribution, biological functions. Modified from (Odii & Coussons, 2014). 
Identified TG forms 
Synonyms 
Molecular mass in 
kDa 
Tissue expression Prevalent function 
FACTOR XIII Fibrin stabilizing factor 
Plasma transglutaminase 
 
83 Plasma, platelets, chondrocytes, astrocytes, 
monocytes, macrophages, heart, eye, 
dendritic cells 
Stabilization blood clot, wound 
healing, bone growth, ECM 
stabilization 
TG1 Keratinocyte transglutaminase, type 1 TG 90 Keratinocytes, membrane, squamous 
epithelia, and cytosol. 
Keratinocytes epidermal 
differentiation and cell envelope 
formation 
TG2 Tissue transglutaminase, type 2 TG, Gαh, 
cytosolic transglutaminase, liver TG 
78 Ubiquitous in many different tissues, 
cytosol, membrane, nucleus and 
extracellular  
ECM adhesion, matrix 
stabilisation, cell differentiation, 
cell survival, signaling, apoptosis 
TG3 Epidermal transglutaminase, type 3 TG, 
TGE 
77 Epidermis, hair follicle, cytosol, brain Keratinocyte differentiation, 
GTPase activity, terminal 
differentiation of cell envelope 
formation 
TG4 Prostatic transglutaminase, type 4 TG, TGP 77 Prostate gland, seminal plasma, prostatic 
fluids 
Prostate isoform, reproduction and 
fertility, semen coagulation in 
rodents 
TG5 Type 5 TG, TGX 81 Epithelial tissues Keratinocyte differentiation and 
cornified cell envelope assembly 
TG6 Type 6 TG, TGY 78 Skin epidermis Development and motor function 
TG7 Type 7 TG, TGZ 81 Ubiquitous Not characterised 
BAND 4.2 Erythrocyte membrane protein band 4.2 72 Erythrocyte membranes, bone marrow, 
spleen, foetal liver 
Maintain erythrocyte membrane 
integrity and mechanical 
properties 
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Figure 1- 4: Transglutaminase transamidation reaction. 
 
Pathway A represent the protein crosslinking reaction between γ-carboxamide group of 
peptidyl glutamine residue (P1) and ε-amino group of peptidyl lysine residue (P2). 
Pathway B illustrates the amine incorporation reaction between a γ-carboxamide group of 
glutamine residue and a primary amine. Pathway C shows the deamidation reaction 
between γ-carboxamide group of glutamine residue and water molecule (Adapted from 
Algarni, 2018). 
 
 FXIII 
The history of FXIII started more than 70 years ago, when it was known as fibrin stabilizing 
factor (Loewy et al., 1961). In the early 1960s it was termed factor XIII by the International 
Committee on Blood Clooting Factor until 2007, when it was recommended by the 
International Society of Thrombosis and Haemostasis, Scientific and Standarization 
Committee that it should be abbreviated and termed FXIII (Muszbek et al., 2007). In the 
beginning, FXIII was not a topic of high interest for research until the early 1980s, when it 
became a more attractive field of research (Muszbek et al., 2011). It circulates in blood as 
heterotetramer A2B2, the A2 subunit always forming a complexed with the B2 subunit in 
Chapter 1 
15 
 
normal condition but only the B2 subunit is present as free dimer in plasma (Muszbek et al., 
1999).  
1.6.1 FXIII structure 
The plasma transglutaminase (FXIII) complex consists of heterotetrameric ensemble 
(pFXIII-A2B2) (with a total molecular mass of approximately 326 kDa). The dimer catalytic 
A-subunits (FXIII-A2) each have a molecular weight of ~83 kDa and are encoded by the 
F13A1 gene. The A subunits are encapsulated by dimer carrier B-subunits (FXIII-B2) each 
of which has a molecular mass of ~80 kDa (Iismaa et al., 2009; Muszbek et al., 2011). FXIII-
A contains five domains: The N-terminal activation peptide (AP-FXIII), a β-sandwich 
domain, a catalytic core including catalytic site Cys314, β-barrel 1, and β-barrel 2 (Fig 1.5) 
(Muszbek et al., 2011; Schröder & Kohler, 2013; Shi & Wang, 2017). FXIII-B is present as 
free form FXIII-B2 and complexed form as part of the ensemble FXIII-A2B2 in plasma, and 
serves as a carrier protein of FXIIIA that accelerates cross-linking fibrin monomers by 
boosting formation of the complex between proenzyme FXIII, fibrinogen, and its activator 
thrombin (Schröder & Kohler, 2013; Souri et al., 2015). Also, a free form of FXIII-A2 exists 
but only in intracellularly, denoted as either (cellular) cFXIII or cFXIII-A2, mainly in 
platelets, megakaryocytes, monocytes, macrophages, chondrocytes, osteocytes and 
osteoblasts (Schröder & Kohler, 2013). 
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Figure 1- 5: FXIII-A2 subunit structure. 
 
The genral structure of the factor XIII A2 dimer. Cylinders and arrows represent α-helices 
and β-strands, respectively, and the two active sites are marked by gray spheres. The N- 
(activation peptide) and C-terminal and structural domains of one A-subunit are labeled. 
Adapted from (Muszbek et al., 1999). 
 
1.6.2 FXIII activation 
FXIII circulates in plasma as an inactive zymogen that is activated only at sites of vascular 
injury. The proteolytic FXIII activation is triggered when thrombin cleaves off AP-FXIII by 
hydrolyzing Arg37-Gly38 and weakens the interaction between A- and B- subunits (pXIII-
A'2B2) (Muszbek et al., 2011). Then, the B-subunits dissociate in a calcium-dependent 
manner via interactions with high affinity Ca2+ binding sites on A-subunits, a type of 
activation which requires much more than physiological Ca2+ concentration (Iismaa et al., 
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2009; Muszbek et al., 2011). Thence, (pXIII-A'2B2) becomes completely transformed to an 
active form pFXIIIa or pFXIII-A*2, which exposes the intermediate thioester bond at Cys314 
in the catalytic sites of A-FXIII for the transglutaminase reaction to form a covalent bond 
between a peptide bond of γ-glutamine and ε -lysine residue, as shown inFig 1.5 (Schröder 
& Kohler, 2013). Both pFXIII activation steps are greatly enhanced by fibrinogen/fibrin 
(Schröder & Kohler, 2013; Shi & Wang, 2017). The non-proteolytic intracellular FXIII 
activation is a thrombin-independent way to generate activated cellular FXIII (cFXIIIa, or 
cFXIII-A2º) based on even low concentrations of Ca
2+. However, the studies showed that the 
elevation of intracellular Ca2+ level is induced by thrombin or Ca2+ ionophore, which initiates 
the intracellular activation of cFXIII without proteolysis (Muszbek et al., 2011; Bagoly et 
al., 2012). Interestingly, complete activation of dimer FXIII-A can occur if only one of AP-
FXIII of A-subunit is released so, thus a dimer comprising a cleaved and an uncleaved A-
subunit (FXIII-A*Aº) can have a full enzymatic activity (Muszbek et al., 2011). 
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Figure 1- 6: Activation of plasma and cellular FXIII. 
 
A) In blood plasma thrombin initiated the activation and cleave FXIII to pFXIII-A'2B2, in 
the presence Ca2+ the FXIII-B subunit disassociates and fibrin accelerates this process to 
produce the activated form (pFXIIIa or pFXIII-A*2) of FXIII. However, intracellular 
activation occurs at low Ca2+ concentration that converts FXIII to the activated form 
cFXIII-Aº2. B) Transglutaminase reaction mediated by activated FXIII (FXIIIa) that cross-
links glutamine (Gln) and Lysine (Lys) residues of fibrin monomers, which leads to an 
insoluble fibrin network. 
 
 
1.6.3 FXIII functions 
1.6.3.1 Haemostasis and thrombosis 
The pivotal extracellular role of pFXIIIa in blood coagulation comes in the final stage of the 
blood clotting cascade, where it acts in stabilizing the fibrin mesh (Dahlbäck, 2000). In the 
coagulation process, pFXIIIa catalyses the covalent linkage of fibrin monomers at injury 
sites to form an insoluble clot. pFXIIIa cross-links both fibrin and fibrinogen, although the 
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reaction with fibrinogen is slower (Muszbek et al., 2011, Mouapi et al., 2016; Shi & Wang, 
2017). pFXIIIa by transamidase activity cross-links fibrin γ- γ, γ- α, and α-α chains into 
fibrin clots (Richardson et al., 2013; Hethershaw et al., 2014). The γ-chains are immediately 
cross-linked into dimers, although α-chains are more slowly reactive to polymerize into 
multimers (Muszbek et al., 2011). It was reported that pFXIIIa also cross-links α2-
antiplasmin (α2-AP) to fibrin, which results in raising the rigidity and strength of the fibrin 
clot and protects it from circulation shear stress (Muszbek et al., 2011; Hethershaw et al., 
2014). Furthermore, pFXIIIa has important protection roles in haemostasis process by 
influencing fibrinolysis by reacting with other proteins into fibrin(ogen) by crosslinking. For 
example, α2-plasmin inhibitor (α2-PI) the main fibrinolytic enzyme plasmin, which is cross-
linked to α-chain of fibrin(ogen) to produce fibrin clot degradation (Muszbek et al., 2011; 
Shi & Wang, 2017). Moreover, another fibrinolysis agent that are cross-linked to fibrin clot 
by pFXIIIa include plasminogen activator inhibitor type 2 (PAI-2) and thrombin activatable 
fibrinolysis inhibitor (TAFI) (Muszbek et al., 2011; Shi & Wang, 2017).However, studies 
showed that upnormal excusive pFXIIIa level in plasma causing an elevation of extent of 
fibrin α-chain cross-linked that inhibit the clot degradation (Muszbek et al., 1999).  
1.6.3.2 In monocyte/macrophage function: 
 cFXIII-A2 was discovered in monocyte and macrophage since 1980s (Henriksson et al., 
1985; Muszbek et al., 1985), and its expression in suspended monocyte and attached 
macrophages has been under intensive research that turned out to be a marker reaction of 
these cell physiological and pathological sub studies (Quatresooz et al., 2008).  cFXIII 
activity in monocyte long-term culture showed three to four-fold increase on day 8 in culture 
(Conkling et al., 1989). However, this fold increased in monocyte/macrophage 
differentiation on day 3 (Sárváry et al., 2004). Interestingly, the cFXIII level was observed 
to increase more in monocytic leukemia cells compared to the normal peripheral blood 
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monocytes (Kappelmayer et al., 2005). Many reports revealed the presence of cFXIII in 
monocytes, macrophages, dendritic cells, histiocytes, placenta, and uterus but only few 
studies focused on intracellular function of cFXIII in these cells (Bohn & Schwick, 1971; 
Polgar et al., 1990; Koseki-Kuno et al., 2003; Muszbek et al., 2011). It has been found that 
monocytes in FXIII-deficient patients that are exempt of cFXIII, showed defective capacity 
of Fcγ receptors, complement, and receptor-mediated phagocytosis (Sárváry et al., 2004). 
Another study revealed that the expression of cFXIII and quantity of phagocytosing 
monocytes/macrophages in cell culture were increased, but after the addition of 
monodansylcadaverine (MDC), a competitive inhibitor and transglutaminase substrate, a 
significant inhibition in receptor-mediated phagocytosis was found (Kávai et al., 1992). 
Dendritic cells deficient cFXIII showed significant inhibition of basal migration and 
response of chemokine CCL19, cell component induce the migration (Jayo et al., 2009). 
Also, of interest were the covalent cross-linked cellular angiotensin receptor 1 (AT1) dimers 
that play a role in cell signaling events, such as enhancing Gαq/11 stimulated signaling, and 
the adhesion of monocytes to endothelial cells. AbdAlla et al. (2004) reported that cFXIIIa 
correlated with AT1 dimerization by covalent cross-linking, since no cross-linking of AT1 
was shown in monocytes of cFXIII-deficient patients. For example, it has been pointed that 
the AT1 dimers cross-linked by cFXIIa in mice monocytes promote atherogenesis, but the 
latter was reduced when cFXIIIa was inhibited as AT1 dimers were reduced (Eckert et al., 
2014). Heretofore, there are limited studies on cFXIII in monocyte cell lines, in this study 
the human monocyte derived from an acute monocytic leukemia cell lines THP-1 was used 
to study the effect of organophosphate compounds on FXIII production.   
1.6.3.3 Other FXIII functions 
FXIIIa is involved in biological process, such as wound healing. It was found that poor 
wound healing related to FXIII deficiency (Lauer et al., 2002). Inbal et al. (2005) reported 
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that FXIII deficient mice showed significantly limited wound healing, which was alleviated 
only by FXIII medication. In addition, human concentrated FXIII supplement accelerated 
wound healing and minimized blood loss in surgical cancer patients (Korte et al., 2009). It 
has been found that FXIII colocalizes with and binds to extracellular matrix (ECM) assembly 
sites (Barry & Mosher, 1990).  Moreover, the studies revealed that mediation of wound 
healing is correlated with ECM integrity through direct cell binding and reorganization 
(Corbett & Schwarzbauer, 1998; Helm et al., 2007). Fibroblasts produce ECM proteins, 
which form a scaffold for reparative scars and facilitate wound healing. The ECM-bound 
FXIII increases fibroblast proliferation (Weigel et al., 1989; Sindrilaru & Scharffetter-
Kochanek, 2013; Tracy et al., 2016). Also, immobilized FXIIIa adheres to fibroblasts in an 
integrin-dependent manner, which stimulates activatory signal transduction and formats the 
cellular change (Ueki et al., 1996; Takahashi et al., 2000, Somanath et al., 2009). Due to the 
existence of many of FXIII substrates in ECM, such as fibronectin, collagen, 
thrombospondin, and vWF in addition to plasma proteins like fibrinogen, FXIIIa-mediated 
protein crosslinking can adjust ECM structure, thereby providing a more appropriate surface 
for fibroblast migration (Richardson et al., 2013). 
FXIII is required in embryo implantation through normal pregnancy and women who have 
FXIII deficiency experience frequent miscarriages (Ariens et al., 2002). Since FXIII is 
required for the formation of the cytotrophoblastic shell that enable placental attachment to 
the uterus (Muszbek et al., 2011). Although, FXIII presence in uterus and placenta suggests 
the involvement of cFXIII macrophages in normal pregnancy, its function in these cells 
remains ambiguous. However, it is believed that its function may be associated to the 
crosslinking of the extracellular proteins in these tissues (Muszbek et al., 2011). Medically 
speaking, a regular FXIII concentrate supplementation is the optimum and safest method to 
prevent abortion and end up with successful full-term delivery in FXIII deficient women 
Chapter 1 
22 
 
(Naderi et al., 2012). Further work is needed to fully understand the mechanism of action of 
FXIII in pregnancy.  
Moreover, it has been suggested that activated plasma or cellular FXIII are involved in some 
other fundamental biological processes, such as reduction of permeability of vascular supply 
(Hirahara et al., 1993). A deficiency in pFXIIIa initiates cardiac rupture following induction 
of ligation myocardial infraction (Souri et al., 2008). High activity of FXIIIa has also been 
associated with coronary artery disease, thromboembolic disease, venous thrombotic 
disorders, cerebrovascular disease (Corral et al., 2000; Ariens et al., 2002), and bone and 
cartilage ECM formation, stabilization and assembly (Johnson et al., 2001). 
1.6.3.4 FXIII and TG2 
Tissue TG (TG2) is a multifunctional enzyme that exist in both intracellular and extracellular 
forms (Nurminskaya & Belkin, 2012). TG2 is the most abundant and extensively distributed 
member of the TG family and it is involved in the modulation of various biological function 
(Eckert et al., 2014). FXIIIa and TG2 both belong to the same group of enzymes that share 
some roles through their ability to mediate covalent protein cross-linking activity to 
modulate biological functions throughout the body (Eckert et al., 2014).  
Both of them are released into the vascular ECM, where they covalently modify some 
proteins of ECM, resulting in the enhancement of ECM stability (Aeschlimann & Thomazy, 
2000; Lorand & Graham, 2003). For instance, cross-linking of ECM proteins increases 
fibronectin and collagen fibril rigidity causing an increase in ECM stiffness (Nelea et al., 
2008; Spurlin et al., 2009), which enhances fibroblast and osteoblast adhesion (Chau et al., 
2005; Forsprecher et al., 2009). In addition, several studies reported the pivotal role of 
FXIIIa and TG2 in ECM to boost integrin-mediated signalling in transmembrane adhesion. 
It has also been reported that extracellular FXIIIa and TG2 are involved in regulation of 
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growth factor receptor signalling (Takahashi et al., 2000; Kulkarni & Jackson, 2004; 
Zemskov et al., 2006). Moreover, it has been found that cFXIIIa and TG2 have important 
roles supporting the cytoplasmic biological processes involved in cell signalling (Lorand & 
Graham, 2003; Walther et al., 2011). It has been reported that cFXIIIa and TG2 have been 
identified in cartilaginous and osseous tissues. For example, the cross-linking activity of 
cFXIIIa and TG2, accompanied by deposition of fibronectin and collagen type 1 into the 
ECM, is associated with differentiation of osteoblasts (Nurminskaya & Kaartinen, 2006; Cui 
& Kaartinen, 2015).  
1.6.3.5 FXIII deficiency 
The average concentration of FXIII in plasma is 21.6 mg/l (0.07µM) (Yorfuji et al., 1988), 
and recent work using one-step ELISA specific assay for tetrameric complex estimated to 
be 66-134% of FXIIIA2B2 (Katona et al., 2000).  The normal range of pFXIII activity is 
between (53.2% - 221.3%), and it has been noted that low levels of pFXIII ˂ 5% are 
sufficient to allay bleeding (Anwar & Miloszewski, 1999). Congenital FXIII deficiency is 
due to genetic disorders in the encoding of either in FXIII-A subunit (known as type 2) or 
FXIII-B subunit (known as type 1) (Hsieh & Nugent, 2008). As a result of such mutations 
bleeding disorders are the most typical clinical manifestation. Defects in the FXIII-B gene 
were reported in ˂ 5% of patients; however, the majority of FXIII deficiency reflect type 2 
FXIII-A gene defects, which result in FXIII-A subunits being absent from extracellular and 
intracellular sites (Hsieh & Nugent, 2008). Severe FXIII deficiency is a rare condition that 
could happen to one in 3-5 million people in an inherited autosomal recessive pattern (Board 
et al., 1993). Regular coagulation screening tests such as prothrombin time (PT), activated 
partial thromboplastin time (APTT) and thrombin time, are normal in cases of FXIII 
deficiency; nonetheless, FXIII deficiency can be detected using the clot solubility test with 
5M urea or 1% monochloroacetic acid; in case the patient does not have FXIII deficiency 
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the clot will not dissolve in the solution, then this can be pursued by another sophisticated 
quantitative analysis (Karimi et al., 2009). 
Umbilical bleeding is the most distinctive and frequent symptom occurring in 80% of cases 
within a few days after birth (Anwar & Miloszewski, 1999). The intracranial haemorrhage 
incidence in congenital FXIII deficiency has much higher frequency and patients can face 
death or disability (Hsieh & Nugent, 2008). In patients with FXIII deficiency, clots can form 
normally but start to breakdown 24 to 48 hours later due to weak fibrin stabilization, leading 
to successive occurrence of bleeding such as postoperative, intramuscular, and post dental 
extraction mucosal bleeding (Hsieh & Nugent, 2008). Other common manifestations of 
severe FXIII deficiency are frequent spontaneous miscarriage and wound healing delay 
(Inbal & Dardik, 2006), in addition to its failure in its function in haemostasis, in wound 
healing, tissue repair and angiogenesis (Inbal & Dardik, 2006). 
Acquired FXIII deficiency is the most common. Some cases of acquired FXIII deficiency 
have been associated with leukaemias, severe liver disease, systemic lupus erythematosus 
and disseminated intravascular coagulation (Tosetto et al., 1993; Hsieh & Nugent, 2008). 
Furthermore, liver disease may result in limited production of FXIII-B, causing a decrease 
in the pFXIII half-life (Karimi et al., 2009). However, acquired FXIII deficiency is mainly 
caused by some kind of inhibitor. These inhibitors could be autoantibodies directed against 
pFXIII and interfering with its function (Tosetto et al., 1993). Inhibitors can be produced in 
association with medication such as penicillin, isoniazid and phenytoin (Tosetto et al., 1993; 
Hsieh & Nugent, 2008). A further potential source is exposure to environmental pollutants 
such as organophosphorous compounds, which is the central area of interest to the current 
project. 
Chapter 1 
25 
 
 Organophosphate compounds: uses and toxicity 
Organophosphate (OPs) are chemical compounds that were synthesized by Lassaigne in the 
early 1800s, but in the early 1940s Schrader’s group developed them into insecticides and 
synthesized around 2000 compounds, encompassing the pesticide parathion, paraoxon and 
chemical warfare agents such as sarin and tabun (Antonijevic & Stojiljkovic, 2007). OPs are 
used widely in agriculture and industry but there is concern that their widespread use may 
impact on animal and human health (Chambers & Oppenheimer, 2004). OPs are used as 
insecticides, due to their ability to inhibit insect acetylcholinesterase (AChE) activity, 
causing hyperactive cholinergic action and accumulation of acetylcholine (Pope, 1999). Also, 
they are used in industry (e.g. as flame retardants and oil additives) (Chambers & 
Oppenheimer, 2004). Additionally, to a limited extent, OP compounds are developed to be 
used as pharmaceutical drugs, for example trichlorfon in the treatment of schistosomiasis 
(Costa, 2006).  
Accidental or deliberate release of OPs are responsible for causing environmental pollution 
and food contamination, affecting animal and human health, and it has been reported that 
almost 50% of acute pesticide related illnesses are due to OP toxicity (Calvert et al., 2004). 
It has been estimated that ≥ 3 million people worldwide are exposed to OPs per year with 
around 300,000 deaths (Robb & Baker, 2019).   
Nowadays, there are diverse practices in the use of OP pesticides in various fields due to 
their wide-ranging chemical and physical properties. For example, in developing countries 
they are used against plant pathogens, insects and microbial agents (Lotti, 2010). Some OPs 
are also applied as anti-wear additives in jet engine lubricants, due to their fire-resistant 
properties (Solbu et al., 2007; Denola et al., 2011). However, over time, several publications 
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have reported passengers suffering from chronic symptoms such as cognitive problems and 
even paralysis (Winder & Balouet, 2000; Harper, 2005; Liyasova et al., 2011).  
Potential adverse effects of overuse of OPs pose a significant risk to public health. Due to 
environmental pollution, it is not only agricultural workers that are in danger of exposure to 
these insecticides but also the general population are at risk (Mearns et al., 1994; Stephens 
et al., 1995). Moreover, long term exposure to low concentrations of OP compounds in food 
sources and the environment may not only cause chronic damage to the nervous system but 
also other body organs associated with chronic disease, for example: cancer, respiratory 
problems, cardiovascular, the immune system, etc. (Mostafalou & Abdollahi, 2013). 
It was of interest to the current study to investigate the effects of phenyl saligenin phosphate 
(PSP), the organophosphorothioate insecticides diazinon, chlorpyrifos and parathion and 
their acutely toxic metabolites diazoxon, chlorpyrifos oxon and paraoxon on haematological 
parameters such as  the activities of serum esterases and FXIIIa  found in human plasma and 
the growth, viability  and proliferation of monocyte cells. 
1.7.1 Organophosphate compounds structure 
All OP pesticides share the same fundamental structure involve an ester of a phosphoric acid 
derivate; it comprises a pentavalent central phosphate atom (P), which has a double bond 
with either sulphur (P=S) or oxygen (P=O). R1 and R2 are usually alkoxy side groups, while 
the X is the “leaving group” that is replaced by the oxygen atom of serine group in the active 
site of AChE (Fig 1.6) (Eleršek & Filipič, 2011). Many types of OPs have been used in 
animal and human studies (Lockridge, 2013; Chen & Cashman, 2013). As a part of the 
current study seven OPs were used, three of which are phosphorothioate compounds (P=S:  
parathion (PTH), diazinon (DZ) and chlorpyrifos (CPF)), three are their acutely toxic 
metabolite forms (oxons, P=O: paraoxon (POX), diazoxon (DZO) and chlorpyrifos-oxon 
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(CPO), and phenyl saligenin phosphate (PSP, the active congener metabolite form of 
triortho-cresyl phosphate; TOCP) (Fig 1.7). 
 
 
Figure 1- 7: General chemical structure of organophosphorous compound. 
 
Double bond of phosphorus group attached to either sulphur or oxygen atoms. 
R1 and R2 are mainly alkoxy groups and X is ‘‘the leaving group’’, as it is 
reacting covalently during the phosphorylation of the AChE active site. Adapted 
from (Costa, 2006). 
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Figure 1- 8: Chemical structure of organophosphorus compounds. 
 
The parent compound with sulfur atom and metabolized form with oxygen atom. 
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1.7.2 Organophosphate compounds mechanism 
OP exposure may occur through ingestion, inhalation or contact with the skin (Karki et al., 
2004). The most significant effect of acute toxicity of organophosphate is due to the 
inhibition of cholinesterases (ChEs). The primary target of OPs in the central nerve system 
the enzyme AChE, which belongs to the serine hydrolase family and is mainly found at 
neuromuscular junctions, where it is responsible for hydrolysis of the neurotransmitter 
acetylcholine (ACh) to produce acetate and choline (Ray & Richards, 2001). The result of 
AChE inhibition is the accumulation of ACh in the synaptic cleft, thereby overstimulating 
nicotinic and muscarinic receptors to cause neurotoxic effects, such as neuromuscular 
paralysis (for example continuous muscle contraction), throughout the entire body (Gupta, 
2006). 
Inhibition of AChE by OPs involves forming a covalent bond with a serine residue in the 
active site; as a consequence of this reaction, a transient intermediate complex is generated, 
which is partially hydrolysed through the loss of the  leaving group, resulting in the formation 
of irreversibly organophosphorylated and inhibited AChE enzyme (Eaton et al., 2008), as 
shown in (Fig 1.8). 
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Figure 1- 9: The common organophosphorus compound mechanism. 
(A) Pre-synaptic neuron releasing neurotransmitter acetylcholine and bind to receptors 
on the post-synaptic neuron or muscle cells. (B) AChE terminate ACh function by 
hydrolysis at cholinergic synapses. (C) Organophosphate compounds bind to AChE 
and inhibit enzyme action, causing free ACh accumulation at the synapse. Modified 
from (Felmban, 2016) 
 
 
Abou-Donia and Lapadula (1990) reported that irreversible inhibition of AChE by different 
OPs usually happens within a few hours by automatic hydrolysis of the AChE-OP complex 
in what is termed an ‘ageing’ mechanism, where a non-enzymatic hydrolysis or dealkylation 
process results in loss of one or two of the alkoxy labile groups (R1, R2). The different OPs 
can be hydrolysed either via A-esterases such as paraoxonase 1 (PON1) or B-esterases such 
as AChE, butyrylcholinesterase (BChE), and neuropathy target esterase (NTE) (Costa et al., 
2003).  For example, the catalytic hydrolysis of A-esterases is a well-known reaction that 
leads to detoxication, which involves breakdown OP compounds to their major metabolite 
components without affecting esterase activity (Costa et al., 2003). On the contrary, the B-
esterases exhibit a non-catalytic hydrolysis of OPs that causes significant inhibition of these 
serine esterase activity but cannot catalytically hydrolyse the OPs (Costa, 2006).   
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The severity of poisoning symptoms depends on the extent of the OP-AChE binding, where 
breaking the bond between phosphorous and serine esterase enzyme complex may take few 
hours to days and may be reversible or irreversible based on the chemical nature of the 
alkoxy side groups (R) (Chambers, 2004) (Costa, 2006). The reversible reaction of 
organophosphorylated serine esterase complex is a spontaneous reactivation, which can be 
accelerated by oximes; however, the irreversible reaction can undergo non-enzymatic 
hydrolysis process, that so-called aging, which ends up with deactivation of phosphorylated 
esterase through the loss of one of two alkoxy side groups (R) leaving an increased negative 
charge in the active site (Costa, 2006), as shown in Figure 1.9.   
PON1 and cytochromes (CYPs) are synthesized in liver and circulate in the plasma. They 
have a protective role against the acute toxic effects of OPs via hydrolysis of both parent or 
metabolite (oxon) compounds (Coombes et al., 2014). Some CYPs bioactivate the parent 
compounds of OP to their oxons with different substrate specificities, and some CYPs 
catalyze reduction reaction that cause detoxification of OPs. Moreover, some CYPs have 
difference also in detoxification process such as CYP2B6 which metabolise CPF to oxon 
form and metabolise PTH primarily to p-nitropheol. In addition, PON1 is named from its 
ability to hydrolyse the oxon of PTH; however, it has found that the mice with deleted PON1 
gene are oversensitive to the toxicity of CPO and DZO compared to wild mice (Li et al., 
2000).  
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Figure 1- 10: The biochemical interactions between organophosphorus compounds and 
serine esterase.  
Modified from (Costa, 2006). 
 
1.7.3 Characteristics of the OPs used in this study 
1.7.3.1 Phenyl saligenin phosphate 
PSP (2-hydroxyphenyl) methyl (2-methylphenyl) hydrogen phosphate) (Fig 1.7) is a 
structural analogue of saligenin cyclic-o-tolyl phosphate (SCOTP), the active metabolite 
form of tri ortho cresyl phosphate (TOCP) (Harp et al.,1997; Fowler et al., 2001). TOCP or 
PSP are not pesticides but are mainly used as anti-wear additives in aircraft engine oil 
(Abou-Donia & Lapadula, 1990). It has been found that the inhalation of aircraft cabin 
aerosols can result in memory loss and cognitive dysfunction (De Nola & Mazurek, 2008; 
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Michaelis, 2011). Comprehensive studies revealed that some OPs, involving PSP and TOCP, 
interact by organophosphorylation and inhibition of NTE which leads to organophosphate-
induced delayed neuropathy (OPIDN) in vivo (Abou-Donia & Lapadula, 1990). Studies 
showed that both PSP and TOCP act similarly to produce neurodegenerative poisoning 
(Hargreaves, 2012).  
Nevertheless, up to date, knowledge is still limited on human exposure to aerosolized jet 
engine lubricants; this therefore introduces a wide area for research which needs to be 
undertaken (Baker et al., 2013). PSP has been found to interfere with other cellular targets 
such as NTE, mitogen-activated protein kinase (MAPK) signaling, cytoskeletal proteins and 
tissue transglutaminase enzyme activity (Hargreaves et al., 2006; Harris et al., 2009; 
Pomeroy-Black & Ehrich, 2012). Therefore, it is useful to discuss other targets associated 
with PSP toxicity, in order to more fully understand the potential molecular basis of PSP 
toxicity. 
1.7.3.1.1 Molecular target of PSP 
PSP is known to be a classical NTE enzyme inhibitor (Baker et al., 2013). Moreover, NTE 
is present in large concentrations in neuronal cells, although NTE activity has been 
demonstrated at lower levels in non-neuronal tissue and cells such as placenta, testicles, 
kidney, and lymphocytes (Sigolaeva et al., 2001; Moser et al., 2004; Gallazzini et al., 2006). 
Organophosphorylation of NTE by OPs is certainly necessary for the development of 
OPIDN (Costa, 2006). Complete inhibition NTE by PSP leads to prevention of the outgrowth 
of axon-like processes in differentiating N2a cells (Flaskos et al., 1994). Moreover, NTE 
inhibition by OP leads to calpain-mediated proteolytic degradation and modification of 
axonal morphology, which is thought to be an early event of OPIDN (Ehrich & Jortner, 
2010).  
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In addition, studies have reported the effect of PSP toxicity on MAPK and phosphoinositide-
3-kinase/protein kinase B (PI-3K/PKB) signaling, which function differently in the neuronal 
response to OP exposure, as they are normally regulate the vital cell process (Hargreaves et 
al., 2006; Pomeroy-Black & Ehrich, 2012). Previous studies have shown that 
phosphorylation of PKB and MEK1/2 protein kinases in human SH-SY5Y neuroblastoma 
cells was increased by low concentrations (e.g. 0.01-1.0 µM) of PSP (Carlson et al., 2000; 
Pomeroy-Black & Ehrich, 2012). Furthermore, exposure of differentiating mouse N2a 
neuroblastoma cells to PSP (2.5 µM; 4 h) led to activation of the extracellular-signal-
regulated kinases 1/2 (ERK1/2), which was associated with the inhibition of NTE and neurite 
outgrowth (Hargreaves et al., 2006). Thus, exposure to OPIDN-inducing OPs disrupts cell 
signaling pathways important in neuronal survival and differentiation. 
1.7.3.2 Diazinon 
Diazinon (DZ) (O, O-diethyl-O-(2-isopropyl-4-methyl-6-pyrimidinyl phosphorothionate) 
and its oxygenated, diazoxon (DZO) analogue (Fig 1.7), are components of one of the most 
widely used pesticides. Although DZ was banned from certain uses in the USA, it is still 
commonly used in agriculture in the USA and abroad (Grube et al., 2011). According to the 
Agency for Toxic Substances & Disease Registry (ATSDR), even though the amount of DZ 
exposure is most likely small, via ingestion of food from sprayed crops, those people who 
live close to crops sprayed with such pesticides are at risk for higher exposure to these 
pesticides and subsequent adverse health effects (ATSDR, 2008). DZ has been restricted due 
to its greater ability to be trapped in water compared to other pesticides, which makes it 
move easily to other areas through fog and rain droplets (Larkin & Tjeerdema, 2000). In 
water, the parent compound DZ can be metabolised to its oxon form (Wu et al., 2007). 
Studies also found that photolysis based on temperature, pH, and water purity has an 
important role in DZ degradation in either water or air (Larkin and Tjeerdema, 2000). DZ 
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has a history of use to control pests on cattle and is a large source of occupational exposure 
for those who conduct the “sheep-dipping”, moreover, some farm workers use this hazardous 
technique that was found seriously affecting farm workers health, and studies reported that 
146 sheep dip-exposed sheep farmers had impaired neuropsychological performance 
(Stephens et al., 1995; Hatjian et al., 2000). 
In vivo, DZ metabolism is mediated by several cytochrome P450 isoforms and B-esterases, 
which are responsible for its detoxification in liver, blood and intestines. For that reason, 
resistance to toxicity relies on the balance between bioactivation and detoxification after the 
exposure to DZ (Poet et al., 2003). DZO is hydrolysed by PON1 to dialkylphosphate, 
diethylphosphate (DEP) and diethylthiophosphate (DETP), which are excreted in urine 
(Hatjian et al., 2000). AChE inhibition is the primary mechanism by which DZ and its 
metabolite form DZO induce neurotoxicity, but other non-cholinesterase targets have been 
identified. For example, both DZ and DZO have been reported to inhibit neurite outgrowth 
of axonal processes in the N2a mouse neuroblastoma cell line (Flaskos et al., 2007; 
Sidiropoulou et al., 2009). It has also been reported that DZ can cause mutagenicity 
producing chromosome abnormalities and impaired sister chromatid exchange (Cox, 2000). 
Other studies have shown that DZ toxicity induces renal dysfunction; for example, DZ 
exposure decreases the activity of glutathione-S transferase and quinine reductase, which 
leads to elevated levels of blood urea nitrogen and serum creatinine (Shah & Iqbal, 2010). 
1.7.3.3 Chlorpyrifos 
The chemical structures of chlorpyrifos (CPF) (O, O-diethyl O-3,5,6-trichloropyridin-2-yl 
phosphorothioate, chlorpyrifos-ethyl) and its oxidation form chlorpyrifos oxon (CPO) are 
shown in Fig 1.7.  Globally, CPF is the OP most extensively used as an active pesticide in 
the agricultural and non-agricultural sectors, the latter including professional gardens and 
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homes (Fenske et al.,2002; Eaton et al., 2008). This pesticide is lipophilic (i.e. poorly soluble 
in water) but it does dissolve in most organic solvents (Ki et al., 2013). There is a wide range 
of CPF uses to control pests and insects within residential environments and it also is applied 
to several major crops such as corn, vegetables, and fruits, etc. (Eaton et al., 2008; Salyha, 
2010). The usage of CPF is massively increasing, and it is labelled as an EPA (Enviromental 
Protection Agency, in USA) class II toxicant, as it prompts the same acute toxic effects as 
the common acetylcholinesterase (AChE) inhibiting pesticides, only there are discordant 
data in the literature on the mutagenic and carcinogenic potential of CPF (Dreiher et al., 
2005; Cui et al., 2006). 
CPF enters the body through inhalation, ingestion, dermal contact, and occupational 
exposure to CPF is very common, with toxic effects suffered by agricultural workers, sheep 
dippers, pesticide sprayers, farmers and their families; furthermore, a prospective group 
study showed that CPF manufacturing workers were at risk of CPF toxicity (Albers et al., 
2004; Muñoz-Quezada et al., 2012). As for the previously-mentioned OPs, the in vivo 
biotransformation of CPF via oxidation reaction is mainly by CYP450 isoforms such as 
CYP2B6 and CYP3A4, to form the active metabolite DETP and 3,5,6-trichloro-2-pyridinol 
(TCP) (Croom et al., 2010). Moreover, PON1 is significantly more efficient at 
hydrolyzing CPO (Richter et al., 2009). However, exposure to small amounts of more than 
0.001–0.01 µg/kg/day of these toxic pesticides is considered a health risk for farm workers 
(Eaton et al., 2008).  
The main target of CPF is the inhibition of AChE, although CPO is a more powerful inhibitor 
of AChE in vivo than CPF (Eaton et al., 2008). Other studies reported that CPF shows 
neurotoxic effects at concentrations not causing inhibition of AChE (Garcia et al., 2002; 
Çetinkaya & Baydan, 2010; Zamfir et al., 2011). Nonspecific central nervous symptoms 
such as reduced motor activity, impairment in the learning skills, memory, and behavior 
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change, cognitive slowing, depression, and other symptoms are associated with 
neurodegenerative effects after long term exposure to low doses of CPF (Terry Jr et al., 2012; 
Yan et al., 2012). Moreover, studies have shown that there is a relationship between long-
term low dose CPF exposure, increased weight and induction of thigmotaxic behaviour 
(Peris-Sampedro et al., 2015; López-Granero et al., 2016)   
1.7.3.4 Parathion 
Parathion (PTH) (O, O, diethyl O-p-nitrophenyl phosphorothioate), and its oxidation form 
paraoxon (POX) (Fig 1.7) insecticides are used widely in agriculture and public health. 
Despite the fact that PTH use has been restricted within the USA and EU since the 1980s, it 
is still used worldwide due to its effectiveness, potency, and low cost (Mutch et al., 1999; 
Guyton et al., 2015). The metabolism of PTH is the same across species (Guyton et al., 
2015). The desulphuration of the pentavalent phosphate group to oxygen analogue (oxon) 
causes the activation of PTH to POX, which is the more toxic form (Costa, 2006). These 
compounds are metabolised via a number of activation and detoxification processes that 
mainly occur in the liver but can also occur in extrahepatic tissues. Parathion is oxidised by 
CYP450 to form POX, the detoxification of which involves the action of PON1 to produce 
DEP and p-nitrophenol (Costa, 2006). 
International Agency for Research on Cancer (IARC), in France 2015, reported that PTH 
could possibly be carcinogenic to humans (Guyton et al., 2015). For example, in mice 
parathion induced increases in bronchioloalveolar adenoma and carcinoma in males and 
lymphoma in females; however, in rats, PTH exposure induced either or combined adrenal 
cortical adenoma or carcinoma (National Toxicology Program, 1979). A variety of 
carcinogenic symptoms were observed in pancreatic, thyroid and mammary glands after 
PTH exposure (Cabello et al., 2001). It has been reported in occupational health studies that 
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PTH was detected in several tissues and associated with cancers, yet the evidence in humans 
remains sparse (Guyton et al., 2015). 
1.7.4 OPs and serine esterase inhibition 
1.7.4.1 Cholinesterase 
Cholinesterases (ChEs) are members of the serine esterase family, which belong to hydrolase 
enzymes that act on different carboxylic esters. They are generally divided in two groups: 
‘‘true’’ acetylcholinesterase (AChE) ~70 kDa ‘‘pseudo’’ butyrylcholinesterase (BChE) ~85 
kDa, both of them form tetrameric serine esterase glycoproteins complexes (Davis et al., 
1997; Marsillach et al., 2013). They can be distinguished basically on kinetic substrate 
preference, tissues localization, and sensitivity to selective inhibitors; however, they show 
several points of similarity, including mechanism of action (Davis et al., 1997). AChE is a 
well-known important enzyme for neuronal signalling, that catalyses the hydrolysis of ACh, 
a common neurotransmitter in the central and peripheral nervous systems, to choline and 
acetic acid, to terminate the signal transmission. It is generally found in nerve ending, 
erythrocytes, spleen, lung, and in the all parts of the brain (Patocka et al., 2004; Čolović et 
al., 2013). The catalytic mechanism of BChE is similar to that of AChE, but it has distinctive 
characteristics in terms of substrate specificity and inhibitor sensitivity. It is presence in 
plasma, liver, numerous, pancreas, smooth muscles, intestines, heart, and white matter of 
brain (Patocka et al., 2004; Čolović et al., 2013). Although AChE plays the main role in 
terminating the ACh transmission action between synapses, BChE may be a substitute for 
AChE deficiency (Masson & Lockridge, 2010).  
ChE are involved in degradation of many drugs and toxins esters, also they are covalently 
inhibited by OPs. AChE inhibition resulting in accumulation of ACh in the synapses 
produces an over stimulation of the nicotinic and muscarinic receptors (Pope, 1999). The 
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oxidized phosphate group of OPs blocks the action of ChEs by organophosphorylating the 
hydroxyl group of serine in the active site. Furthermore, the loss of one of the OP’s alkoxy 
groups, as explained in fig. 1.6, completely deactivates the esterase, causing irreversible 
inhibition of ‘aged’ ChE (Costa, 2006). Inhibition of AChE and BChE activity is nowadays 
the standard method utilized for the biological monitoring of OP exposure (Marsillach et al., 
2013). However, growing evidence suggests that ChEs are not the only targets of OPs, since 
other enzymes and proteins targets of OPs have been identified (Ray & Richards, 2001; 
Casida & Quistad, 2005). 
1.7.4.2 Neuropathy target esterase 
Another crucial serine esterase target for some OPs is neuropathy target esterase (NTE). This 
enzyme is present in the endoplasmic reticulum and is important for lipid metabolism (van 
Tienhoven et al., 2002). Furthermore, NTE enzyme displays elevated catalytic activity in 
neuronal cells, plus non-neuronal cells such as kidney, lymphocytes, and testicles. NTE 
plays a crucial role in nervous system development and signal transduction (Moser et al., 
2000). Therefore, any disruption of neuronal NTE leads to defective endoplasmic reticulum, 
nerve cell body vacuolation, and unusual reticular aggregates resulting in defects of cellular 
function (Akassoglou et al., 2004). The inhibition and aging of this enzyme, which has the 
same mechanism as described for ChEs, is correlated with a disorder called organophosphate 
induced delayed neuropathy (OPIDN)., which is characterized by shaking of hands and feet, 
weak muscles, ataxia and loss of sensory function (Abou-Donia & Lapadula, 1990). The 
symptoms appear after a delay of 10 to 20 days following OP exposure (Abou-Donia & 
Lapadula, 1990, Goel & Aggarwal, 2007).    
Chapter 1 
40 
 
1.7.4.3 Acylpeptide hydrolase 
Acylpeptide hydrolase (APH) is a serine esterase that hydrolyses acyl peptides; it is present 
in red blood cells where it modulates detoxification through cleaving N-acetylated peptides 
(Perrier et al., 2005). It is also present in different tissues including brain and liver 
(Marsillach et al., 2013). APH activity showed more sensitivity to some but not all OPs than 
did AChE and BChE, an effect that was observed long after in vivo OP exposure due to the 
long red blood cell half-life; thus, APH inhibition may be detected over a longer period of 
time compared to ChEs (Quistad et al., 2005; Marsillach et al., 2013).   Cardona et al. (2013) 
revealed that acute CPF exposure can inhibit APH activity up to 31 days until complete 
activity recovery. In vivo exposure to some metabolites of OPs showed the ability to inhibit 
APH even at lower concentration compared to those required for ChE inhibition (Richards 
et al., 2000). Based on these observations, APH activity inhibition could be used as a long 
term biomarker for monitoring OP toxicity.  
1.7.5 Other OPs adduct 
OP adducts were detected on the tyrosine-411 residue of albumin protein. Albumin is the 
most abundant blood protein, representing 56 % and 47 % of human and rat plasma protein, 
respectively (Tarhoni et al., 2008). With a molecular weight of approximately 67 kDa, it is 
synthesized in and secreted by the liver. Albumin has aryl acylamidase and esterase-like 
activities but does not have a serine catalytic binding site (Marsillach et al., 2013). The 
common functions of albumin are maintaining pH and osmotic pressure, but it also has the 
ability to bind to and transport intracellular biological component such as bilirubin and fatty 
acids, and also several extracellular compounds and xenobiotics (Tarhoni et al., 2008). The 
half-life of albumin in plasma is around 20 days in humans and 3 days in rats (Tarhoni et al., 
2008). Some in vivo and in vitro research has already demonstrated the covalent binding of 
OPs, such as sarin, soman, CPO and PTH to albumin (Black et al., 1999; Li et al., 2007a). 
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Albumin-OP adduct formation was proposed as suitable biomarker for OP exposure (Li et 
al., 2010). The administration of low concentrations of OPs did not inhibit AChE activity in 
mice but OP labelling of albumin was detected mostly on tyrosine-411 (Schopfer et al., 
2005). Thus, a protective role of albumin-OP binding was argued, effectively decreasing the 
amount of OP available for serine hydrolase inhibition (Peeples et al., 2004). It has been 
revealed that the tyrosine-OP bond is more stable and is, unlike OP adducts to serine active 
sites on ChEs, resistant to ageing thereby allowing for more time of exposure detection and 
easily OP-tyrosine identification (Lockridge & Schopfer, 2010). However, as the rate of OP 
binding with albumin is much slower than for BChE, BChE inhibition is a more sensitive 
biomarker (Li et al., 2007c). 
Other studies detected OP binding at tyrosine residues of bovine tubulin and transferrin from 
human and mouse (Grigoryan et al., 2008). Moreover, Jiang et al. (2010) reported that CPF 
and CPO adducts were detected on mouse brain tubulin tyrosine residues. In addition, OP 
adducts were detected on lysine residues on variety of proteins such as human albumin, 
keratins, bovine tubulins, and mouse transferrin (Grigoryan et al., 2009). The residues of 
tyrosine and lysine OP-adducts in different proteins without serine active sites suggest that 
many other proteins could possibly be adducted to OPs. 
1.7.6 OP effects on Ca2+-dependent enzymes 
PSP, which is associated with OPIDN induction in animal models (El-Fawal et al., 1990; 
El-Fawal & McCain, 2008), inhibits the neurite outgrowth and induces elevated 
phosphorylation of the neurofilament heavy chain that is a substrate for TG2 (Hargreaves et 
al., 2006; Martin et al., 2011). Moreover, it has been suggested that PSP has the capability 
to increase Ca2+-dependent phosphorylation of proteins and possibly the activity of other 
enzymes activated by Ca2+ (Flaskos et al., 2006). In vitro (24 h) exposure of mitotic cultured 
cells to PSP correlated with the disruption of TG2 activity in cell lysates. However, 
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inhibition of TG2 activity was observed in lysates from mouse N2a neuroblastoma cells, but 
in contrast TG2 activity increased in lysates from the human HepG2 hepatoma cell line 
(Harris et al., 2009). Altered protein level in both cells was suggested to be the main reason 
for the differences in TG2 activity changes observed (Harris et al., 2009). In addition, Muñoz 
et al. (2010) reported in his study that the TG2 activity in lysates of rat C6 glioma cells 
exposed top CPF for 24 h showed a significant increase in TG2 activity. These data are 
consistent with the notion that OP exposure may directly or indirectly disrupt the cellular 
activity of Ca2+ dependent enzymes such as TG2 via interactions with non-cholinesterase 
targets. 
1.7.7 OPs effect on heamatological parameters 
Studies have shown that serine esterase and serine protease are sensitive to some OP 
compounds (Chambers & Oppenheimer, 2004). Blood coagulation-associated protease 
interactions with OPs are still under investigation, with a few studies showing that thrombin 
activity is inhibited in vitro by some active form of OPs (Quistad & Casida, 2000; Golderman 
et al., 2016). Petroianu (1997) reported POX-induced prolongation in partial thromoplatin 
time (PTT) but no change in the prothrombin time (PT) in human blood. They speculated 
that POX inhibited serine proteases in the coagulation cascade, which caused 
hypocoagulability, plus alteration in platelet function, which play important roles in 
coagulation intrinsic pathway activation. This hypothesis was further studied in mini pigs 
that were injected with paraoxon and produced similar findings (Petroianu et al., 1999). 
Moreover, it has been reported that DZ and CPF exposure can significantly disrupt a number 
of haematological parameters, such as CBC (complete blood count) values and biochemical 
measurements in blood plasma (Ambali et al., 2007; Banaee et al., 2008; Andreadis et al., 
2014).   
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FXIIIa is present in platelets and in monocytes/macrophages, and differentiation of 
monocytes into dendritic cells results in elevated intracellular level of cFXIII. This suggests 
that cFXIII may be involved in impaired receptor-mediated phagocytosis in monocytes 
(Muszbek et al., 2011). One study revealed that 8 days following acute nerve agent poisoning 
(soman), there was a decrease in the number of hematopoietic stem cell circulating in blood 
and, blood cell count revealed reductions in lymphocytes and monocytes (Colllomet et al., 
2005). Acute myocardial infarction, heart failure, infarct expansion, and cardiac rupture were 
all observed in FXIII-deficient mice, presumably due to in appropriate recovery of the 
myocardial tissue (Karimi et al., 2009). In this respect, a case was reported of a 40-year old 
man was admitted to an Emergency Department with a primary diagnosis of OP insecticide 
poisoning; after a few days, his condition deteriorated and myocardial infarction was 
diagnosed (Kumar et al., 2014). Some recent studies at NTU have shown that OP exposure 
disrupts the cellular activity of TG2 in neural and hepatic cells (Howden, 2006; Harris et al., 
2009; Muñoz, et al., 2010). Based on these previous studies it is possible that other types of 
TGs may be targets of OP toxicity. 
 
 
 
 
 
 
 
Chapter 1 
44 
 
 Aims of the thesis 
1- To confirm the biological effect of OPs on acetyl and butyryl cholinesterase activity 
in human plasma and purified enzymes. 
2- To study the effect of OPs on pure and plasma FXIIIa and to determine whether OPs 
interact directly with FXIIIa. 
3- To study the effect of OPs on pure and plasma thrombin and whether OPs interact 
directly with thrombin. 
4- To study the effect of OPs on the viability and proliferation of THP-1 monocytic cell 
line. 
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2. Chapter 2: Materials and Methods 
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  Materials 
All laboratory reagents used were high grade and most of them purchased from Sigma-
Aldrich Co Ltd (Pool, UK) unless otherwise specified.   
 
Table 2- 1: List of some reagents and material 
Reagents Code Supplier 
Alamar Blue® BUF012B Bio-Rad (Watford, UK) 
Acetylcholinesterase from Electrophorus 
electricus (electric eel) 
C3389 
 
Sigma Aldrich (Haverhill, 
UK) Acetylthiocholine iodide A5751 
Albumin bovine fraction V (BSA) A1302 Melford (Chelsworth, UK) 
AccuGel 29:1 acrylamide (40% (w/v) 29:1 
acrylamide/bisacrylamide) 
A2-0068 
Geneflow (Lichfield, UK) 
Ammonium persulphate (APS) (Ultra Pure) A2-0200 
Bicinchoninic acid (BCA) 23223 
Sigma Aldrich (Haverhill, 
UK) 
Butyrylcholinesterase from equine serum C4290 
-Mercaptoethanol M3148 
Casein sodium salt from bovine milk C8654 
Copper (II) phthalocyanine 
C2284 
5-5ʹ-Dithiobis 2-nitrobenzoic acid (DTNB) 
D8130 
DL-Dithioothreitol D0632 
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Dimethyl sulfoxide (DMSO) CHE1854 
Fisher scientific, 
(Loughborough, UK) 
Extravidin® Peroxidase E2886 
Sigma Aldrich (Haverhill, 
UK) 
F96 Maxisorp Nunc-immuno plate 148865 
Scientific Laboratory 
Supplies, (SLS, Nottingham 
UK) 
FXIII-substrate peptide F11KA B010 
Zedira gmbh (Darmstadt, 
Germany) 
Human D-Dimer ELISA kit ab196269 Abcam (Cambridge, UK) 
Hydrogen peroxide (H2O2) 30% (w/v) H1009 
Fisher scientific, 
(Loughborough, UK) 
Iodacetamide I1149 
Sigma Aldrich (Haverhill, 
UK) 
Methanol analytical reagent grade M400/17 
Fisher scientific, 
(Loughborough, UK) 
N-(5-Aminopentyl)biotinamide 
trifluoroacetate salt 
A5348 
Sigma Aldrich (Haverhill, 
UK) N,N,N’,N’-tetramethylethylenediamine 
(TEMED) 
EC503 
Phosphatase inhibitor cocktail B15001-B Bimake.com (Ely, UK) 
Protease inhibitors cocktail Set III, EDTA 
free 
539134 Calbiochem (Watford, UK) 
ProteoPrep® Immunoaffinity Albumin and 
IgG Depletion kit 
PROTIA 
Sigma Aldrich (Haverhill, 
UK) 
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2.1.1 Western Blot reagent 
Amersham Protran 0.2 μm pore size nitrocellulose membrane from General Electric. 
 
 
Pure human rFXIIIa activated T070 
Zedira gmbh (Darmstadt, 
Germany) 
4X ProtoGel Resolving Buffer (1.5M Tris-
HCl, 0.4% SDS, pH 8.8) 
B9-0010 
Geneflow (Lichfield, UK) 
ProtoGel Stacking Buffer (0.5M Tris HCl 
0.4% SDS, pH 6.8) 
B9-0014 
 
Sar-Pro-Arg-p-nitroanilide dihydrochloride 
Thrombin substrate 
 
S9009 Sigma Aldrich (Haverhill, 
UK) 
S-Butyrylthiocholine iodide 20820 
Sodium phosphate monobasic (anhydrous) S-8282 
Sodium phosphate dibasic (anhydrous) S2002 Melford (Chelsworth, UK) 
SuperSignalTM West Pico Plus 
Chemiluminescent Substrate 
34577 
Fisher scientific, 
(Loughborough, UK) 
3,3ʹ,5,5ʹ-Tetramethylbenzidine (TMB) T2885 Sigma Aldrich (Haverhill, 
UK) Thrombin from human plasma T1063 
Tris(hydroxymethyl)aminomethane B2005 Melford (Chelsworth, UK) 
Whole human plasma 
P9523-
5ML 
Sigma Aldrich (Haverhill, 
UK) 
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Table 2- 2: Antibodies. 
 
Antibodies 
Working dilution 
(western blotting) 
Code Supplier 
Factor XIIIA (A-4) 
mouse monoclonal 
1:500 9271122 
Santa Cruz 
Biotechnology 
(Wembley, UK) 
Anti-mouse IgG-HRP 1:500 A4416 
Sigma-Aldrich 
(Haverhill,UK) 
 
2.1.2 Cell culture reagents 
RPMI-1640 medium containing 4500 mg/l glucose, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10mM HEPES, 1500 mg/l sodium bicarbonate was purchased from American 
Type Culture Collection (ATCC® 30-2001TM). Penicillin (10,000 U/ml)/streptomycin 
(10,000 µg/ml); foetal bovine serum (FBS), phosphate buffered saline (PBS) were all 
obtained from Life Technologies (Invitrogen, UK). AlamarBlue™ Cell Viability Reagent 
from BioRad product number (BUF012B). Trypan blue solution 0.4% (w/v) was obtained 
from BioRad.  
2.1.3 Cell culture plastic ware 
Sterile cell culture plastic was supplied by Scientific Laboratory Supplies (Nottingham, UK). 
Disposable Haemocytometer C-Chip slides, were supplied by Labtech International Ltd, UK. 
Cryotube vials (Nunc brand products), were purchased from Merck Ltd. Leicester, UK. 
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2.1.4 Cell line 
THP-1 is derived from peripheral blood of a 1-year-old male human with acute monocytic 
leukemia (Scannell et al., 1993). It was purchased from American Type Culture Collection 
(ATCC® TIB-202TM). 
2.1.5 Organophosphorus compounds 
Dansyl phenyl saligenin phosphate (PSP), rhodamine-labelled and unlabeled PSP were 
synthesized by Tom Pearson (Supervised by Dr. Chris Garner, School of Science of 
Technology, Nottingham Trent University). Chlorpyrifos, chlorpyrifos oxon, diazinon, and 
diazoxon were purchased from Greyhound Chromatography and Allied Chemicals 
(Birkenhead, Merseyside, UK). Parathion was obtained from Flukar. Paraoxon. Stock 
concentrations of 100 mM OPs were diluted in DMSO (dimethyl sulphoxide), which was 
present in all treatments including the control at a final concentration of 0.5 % (v/v). 
 Methods  
2.2.1 Enzymes activity assays 
2.2.1.1 Protein estimation 
Protein concentrations in each sample batch were measured by the bicinchoninic acid (BCA) 
(Smith et al., 1985). Protein assay kit obtained from Sigma-Aldrich and using bovine serum 
albumin (BSA) as the protein standard. Briefly, Bovine serum albumin (BSA) was prepared 
in a range of 0-2 mg/ml either in (0.1M Tris-HCl pH 8.5, 5 mM CaCl2 (0.1M Tris-HCl, 
pH 8.5), or SDS buffer) to produce a linear standard. 20 µl of Standard or protein 
sample were added to 96-well flat-bottomed plate in triplicate. A volume of 200 µl 
of working BSA 1% (w/v) (reagent A) and copper II sulphate pentahydrate 4% (w/v) 
(reagent B) were mixed together in a 50:1 ratio was added to each well then, the plate 
incubated at 37°C for 30 min. The plate reader was used to read the absorbance at 570 nm 
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and calibration graph was plotted to measure the protein content of the samples against the 
BSA standard curve. 
2.2.1.2 Sample preparation 
2.2.1.2.1 For FXIII activity in human plasma and purified protein 
Human plasma was reconstituted in 5 ml distilled water, aliquoted and stored at -20°C for 
future work. The optimum concentration for each enzyme assay was determined by testing 
a range of dilutions of reconstituted plasma in 0.1M Tris-HCl pH 8.5. A similar approach 
was adopted for reconstituted pure recombinant FXIIIa (rFXIIIa). It was found that a plasma 
protein concentration about 1.5 mg/ml (1/16 dilution) was optimal for amine incorporation 
assays and about 0.8 mg/ml (1/32 dilution) for peptide crosslinking assays. Also, it was 
found that optimum concentration for pure rFXIIIa 0.02 ng/ µl was the in amine 
incorporation and 0.005 ng/µl peptide crosslinking assays. These concentrations gave low 
back ground signal with optimum linear activity. 
2.2.1.2.2 For thrombin activity in human plasma and purified protein 
It has been found after testing a range of dilutions of reconstituted human plasma and 
purified thrombin from human plasma in 0.1M Tris-HCl pH 8.5 that optimum concentration 
of reconstituted human plasma was 0.2 mg/ ml (1/128 dilution), and for purified thrombin 
from human plasma was 0.05 U/ml. 
2.2.1.2.3 Albumin and IgG depletion from plasma samples 
According to manufacturer of ProteoPrep® Immunoaffinity Albumin and IgG Depletion kit 
from Sigma Aldrich, the procedure of depletion was performed at room temperature 20 °C. 
First, to remove the storage solution, the bottom tip of spin column was broken, and the red 
cap was loosened then the spen column was centrifuged in 2 ml collection tube at 8,000 rpm 
(5,000 ' g) for 10 seconds. After this, 400 µl of equilibration buffer was added to the medium 
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of the spin column then centrifuged in the manner as the previous step. This step was 
repeated twice and on the final centrifuge the time was 30 seconds. The buffer in the 
collection tube was discarded and the spin column was placed into fresh collection tube. In 
the third step, to deplete th albumin and IgG from plasma, 100 µl of reconstituted plasma 
was added into spin column and incubate for 10 min at room temperature to ensure the 
sapmle was immediately adsorded into the medium, otherwise rediluted with equilibration 
buffer. Next, the spin column was centrifuged at 10,000 rpm (8,000 ' g) for 60 seconds. The 
eluate in the collection tube was reapply to the same spin column and then reincubated and 
centrifuged as the previous step. In the fourth step, 125 µl equilibration buffer was added to 
the spin column then centrifuged for 60 seconds to wash the remaining unbound proteins 
into same collection tube from third step. Finally, the albumin/IgG depleted plasma in the 
collection tube was aliquoted and storaged at ‑80 °C. 
2.2.1.3 Preparation of OPs 
Master stocks of 1:1 serial dilutions of OPS in DMSO starting from 10 mM were stored at -
20ºC. Final concentrations in each activity assay were 50,25, 12, 6, 3, 1.5, 0.8, 0.4, 0.2, 0.1 
µM of (PSP, diazinon, diazoxon, chlorpyrifos, chlorpyrifos oxon, parathion, parathoxon) 
obtained from Greyhound Chromatography (Birkenhead, UK) or Sigma-Aldrich (with the 
exception of PSP, where was synthesized in-house). They were incubated with samples for 
30 min on ice before starting the reaction. 
2.2.1.4 Transglutaminase activity assays 
2.2.1.4.1 Biotin cadaverine-incorporation assay for TG plasma and 
purified FXIIIa activity 
The biotin-cadaverine incorporation assay of Slaughter et al. (1992), which was modified by 
the method of Lilley et al. (1998), was used to measure TG-mediated amine crosslinking 
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activity. The 96-well plates were coated at 4 ºC overnight with 250 µl of N, N’-
dimethylcasein (10 mg/ml) in 0.1 M Tris-HCl, pH 8.5. After the unbound N, N’-
dimethylcasein was discarded, the wells were blocked with bovine serum albumin (3% (w/v) 
in (0.1M Tris-HCl, pH 8.5) for 60 min and washed three times with distilled water. A typical 
assay comprised 50µl of 0.1 M Tris-HCl pH 8.5 containing either human plasma protein 
(~1.5mg/ml) or rFXIII (0.02 ng/ µl) samples, and the substrate buffer 150 µl containing the 
substrate  42.4 µM N-(5-aminopentyl) biotinamide with either 6.67 mM CaCl2 or 2 mM 
EDTA (0.1M Tris-HCl, pH 8.5) and 1:2000 β-mercaptoethanol, in a total volume of 200 µl 
per well of 96-well plate. Sample were incubated for 2 h at 37°C, after which the content 
was discarded, and the plate was washed three times with distilled water. Then, 200 µl of 
ExtrAvidin peroxidase diluted 1:5000 in bovine serum albumin (1% in 0.1 M Tris-HCL, pH 
8.5) were added per well, followed by 60 min incubation at 37°C. The plate was 
subsequently washed three times with distilled water and prior to color development by 
adding 200 µl developing solution containing 0.1 M sodium acetate pH 6 and 0.03 % (v/v) 
hydrogen peroxide and tetramethylbenzidine (TMB 5 mg/ml). The reaction was stopped 
after 15 min incubation at 25°C by adding 50 μl of 5 M sulphuric acid per well. Then a plate 
reader was used to measure the enzyme activity at 450nm. 
2.2.1.4.2  Peptide crosslinking assay for TG plasma and purified FXIIIa 
activity 
The assay was performed according to the method described by Trigwell et al., (2004) with 
modifications. Briefly, 96 well microtitre plates were coated overnight at 4ºC with casein (1 
mg/ml) in 0.1 M Tris-HCl, pH 8.5 (250 μl per well). The plate was washed three times with 
distilled water and blocked with 250 μl of 3 % (w/v) BSA in 0.1 M Tris-HCl, pH 8.5 and 
incubated for one hour at room temperature. The wells were washed as before; then either 
150 μl 6.67 mM CaCl2 or 13.3 mM EDTA buffer containing 2.5 µM peptide F11KA 
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(DQMMLPWPAVAL) and (Hitomi et al., 2009) and 1:2000 β-mercaptoethanol was added 
to the triplicate 50 μl of the sample (0.8 mg/ml human plasma or 0.005 ng/µl purified human 
FXIIIa) in each well and allowed the reaction to proceed for 1 h at 37ºC. The reaction 
development and termination were performed as described in the previous assay. 
2.2.2 D-Dimer ELISA 
According to manufacturer with minor modification ab-196269 - D-dimer in vitro 
SimpleStep Enzyme-Linked Immunosorbent Assay kit (Abcam) was used to determine and 
quantify D-dimer protein in human plasma. The assay standards were prepared in 6.67 mM 
CaCl2 in (0.1M Tris-HCl, pH 8.5). A 75 µl of human plasma protein (~1.5mg/ml) sample 
was diluted in (0.1M Tris-HCl, pH 8.5) and incubated with organophosphorus compounds 
final concentration either (25 or 50) µM for 30 min at 4 ºC, then clot formation was made 
by adding 225 µl of 6.67 mM CaCl2 in (0.1M Tris-HCl, pH 8.5) to plasma sample and 
incubated further for 3 hours at 37ºC before centrifugation at 10,000 rpm for 30 min, shake 
the tube gently to disconnect the clot from tube wall. A 50 µl of all standards and samples 
were added to appropriate well in each microplate strips then 50 µl of the antibody cocktail 
was added to each well, seal the strips and incubate on shaker for 1 h at room temperature. 
1X of the kit’s washing buffer was used three times and leave it to dry for few minutes on 
paper towels. A 100 µl of kit’s TMB substrate was added to each well and incubate for 10 
minutes in the dark then 100 µl of stop solution was added then shake and read endpoint at 
450 nm. Subsequent reaction forms a yellow colour product, which change is proportional to 
the D-dimer present in the sample.  
2.2.3 Acetylcholinesterase activity 
A modified method of Ellman et al. (1961) was used to measure the acetylcholinesterase 
activity in human plasma (~1.5 mg/ml) and pure acetylcholinesterase of electric eel (0.4 
µg/ml) diluted in 0.1M phosphate buffer pH 7.4 (0.1M of sodium phosphate dibasic pH 9 
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was added to 0.1M of sodium phosphate monobasic pH 4). A volume of 100 µl of sample 
was added to the 96-well plate in four replicates, followed by a mixture of 100 µl of substrate 
solution containing 2.5 mM acetylthiocholine iodide and 100 µl of 1.25 mM of 5,5-dithiobis 
(2-nitro-benzoic acid) (DNTB) in 0.1M phosphate buffer pH 7.4 to start the reaction. The 
absorbance change was the recorded every 30 seconds for 10 min at 405 nm using a 
CLARIOstar microplate reader. 
2.2.4 Butyrylcholinesterase activity  
Butyrylcholinesterase activity was determined by the modified method of Ellman et al. 
(1961) in human plasma (~1.5 mg/ml) and pure equine butyrylcholinesterase (0.4 µg/ml) 
diluted in 0.1M phosphate buffer pH 7.4. A volume of 100 µl of sample was added to the 
96-well plate in four replicates, followed by a mixture of 100 µl of substrate solution 
containing 2.5 mM butyrylthiocholine iodide and 100 µl of 1.25 mM of 5,5-dithiobis (2-
nitro-benzoic acid) (DNTB) in 0.1M phosphate buffer pH 7.4 to start the reaction. The 
absorbance change was the recorded every 30 seconds for 10 min at 405 nm using a 
CLARIOstar microplate reader. 
2.2.5 Thrombin activity 
Master stock of lyophilized human plasma thrombin was prepared in 250 U/ml in 100 mM 
Tris pH 8.5 then stored in aliquots at -20 ˚C. 100 µl of Thrombin (0.05 U/ml) in 100 mM 
Tris pH 8.5 was applied to a 96-well microtiter plate in four replicates, followed by 100 µl 
of thrombin substrate Sar-Pro-Arg-p-nitroanilide (0.5 mM) in 100 mM Tris pH 8.5, which 
was prepared from stock solution (30 mM) in DMSO, to start the reaction. The absorbance 
change was the recorded every 10 minutes for 90 minutes at 405 nm using CLARIOstar 
microplate reader.  
Human plasma protein (~0.2 mg/ml) in 100 mM Tris pH 8.5, it was optimized to equalize 
the same amount of pure thrombin activity. 100 µl of plasma protein dilution was applied to 
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a 96-well microtiter plate in four replicates, followed by 100 µl of thrombin substrate Sar-
Pro-Arg-p-nitroanilide (1.7 mM) in 100 mM Tris pH 8.5, to start the reaction. The 
absorbance change was the recorded every 30 minutes for 4 hours at 405 nm using 
CLARIOstar microplate reader.  
 
2.2.6 Mass spectrometry for purified FXIIIa treated with OPs  
Initial Steps: 
Sample preparation: 
 rFXIIIa (5 μg) was diluted in 5µl of 0.1 M Tris-HCl, pH 8.5, thereafter adding 0.1μl of 80 
mM PSP, DZO, CPO or POX and control samples received the same volume of DMSO. 
Samples were incubated for 30 min at 4 ºC. Then 30 μl of 6.67 mM CaCl2 in 0.1M Tris-
HCl, pH 8.5 were added, followed by further incubation for 1 h at 37 ºC. This resulted in 
final concentrations of 200 µM OP and 0.25 % (v/v) DMSO.  Then 15 µl of 8 M urea and 
1.5 µl of 0.2 % (w/v) Protease MAX ™ (Sigma) were added to the protein solution, which 
was then mixed by vortexing and 58.5 μl of 50 mM TEAB (Sigma) were added and the 
mixture incubated on ice for 15 min. The solution was centrifuged at 14,000 x g for 15 min 
at 4ºC. The samples were then transferred into a fresh labelled tubes for the reduction and 
alkylation steps.  
Reduction and Alkylation:  
In this step, 1.0 μl of 0.5 M dithiothreitol (Sigma) was added to samples and incubated at 
56°C for 20 minutes in a water bath. Following this, 2.7 µl of 0.55 M iodoacetamide (Sigma) 
were added and the sample mixed well and incubated at room temperature in the dark for 15 
min.  
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Trypsinisation:  
This step was carried out using freshly made trypsin by adding 20 μl of 1 mM HCl (Sigma) 
to re-suspend all trypsin completely. Protein (5μg) together with 100 μl of 50 mM TEAB 
(Sigma) solution was mixed with 2 μg of trypsin, vortex-mixed and incubated at 37°C 
overnight with gentle shaking.  
Final step:  
After trypsinisation, the samples were concentrated using a SpeedVac concentrator for 30-40 
minutes. Finally, 20 μl of 5 % acetonitrile (Sigma) /0.1 % formic acid solution (Sigma) was 
added to the samples, which were then transferred into a new tube.  
Each sample was analysed by the John van Geest Cancer Research Centre team on a Sciex 
TripleTOF 6600 mass spectrometer coupled in line with an Exigent expert nano LC 425 system 
running in micro flow (5 µL/min) in data dependent (IDA) mode. In brief, 4 µl of each sample 
were injected and trapped onto a YMC Triart-C18 pre-column (0.3 x 5 mm 300 µm ID) at a flow 
rate of 10 µL/min for 2 min. The sample was then eluted off the pre-column and onto a YMC 
Triart-C18 analytical column (15 cm, 3 µm, 300 µm ID) that was in line with the electrospray 
ionisation source of the 6600 MS. The following linear gradients were used: solvent B (2 % 
acetonitrile + 0.1 % formic acid) and solvent A (0.1 % formic acid), increasing from 2 % to 40 % 
over an 87 min time course.  Electrospray ionisation was performed by applying +5500 V via a 
50 µm electrode using the Duospray source (Sciex).  IDA acquisition mode was used with a top 
30 ion fragmentation followed by 15 sec exclusion using rolling collision energy.  Data was 
analysed using PEAKS Studio X (Bioinformatic solutions Inc, Canada). 
2.2.7 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot  
To examine the expression of the proteins of interest, SDS- PAGE and Western blotting 
were utilized. 
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2.2.7.1 Preparation of buffers 
2.2.7.1.1 10 % (w/v) Ammonium persulphate (APS) 
It was prepared by dissolving 0.2 mg of APS into 20 µl of distilled water. 
2.2.7.1.2 4X Laemmli Buffer  
A total volume of 10.2 ml of 40% (v/v) glycerol, 8% (w/v) SDS, 20 (v/v) β-mercaptoethanol, 
0.01% (w/v) bromophenol blue and 0.1 M Tris HCL, at pH 6.8. 
2.2.7.1.3 Running buffer  
Total volume of 1L containing 25.6 mM Tris-base, 192 mM glycine and SDS 0.1 % (w/v) 
at pH 8.3. 
2.2.7.1.4 Transfer Buffer  
Total volume of 1L containing 48 mM Tris-base 39 mM glycine, 0.037% (w/v) SDS and 20% 
methanol. 
2.2.7.1.5 Blocking buffer 
1X of Tris-buffered saline (TBS) containing 3% BSA.  
2.2.7.1.6 Washing buffer (TBS/Tween 20) 
Total volume of 1L of 1X of TBS containing 5 ml of (10%) Tween 20; final concentration 
(0.05%) of Tween 20 in 1L of 1X of TBS. 
2.2.7.1.7 RIPA cell lysis buffer  
RIPA solution ingredients for 50 ml is:  
- 1.87 ml of 4M NaCl  
- 0.5 ml of 0.5M EDTA  
- 2.5 ml of 1MTris HCL pH8 
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- 0.5 ml IGPAL 
- 0.5 % (w/v) Sodium deoxycholate 
- 0.5 ml 10% (w/v) SDS 
- 42 ml distilled water 
2.2.7.2 SDS-PAGE 
Based on the molecular weight of the investigated proteins, acrylamide resolving gel was 
prepared in all the experiments (Table 2.3). The resolving gel which separates the proteins 
by size, the gels were prepared according to manufacturer’s instructions (Geneflow Ltd, 
Staffordshire, UK). A Bio-Rad mini-PROTEAN III™ electrophoresis chamber was used. 
Spacers, combs and two clean glass plates of 1.5 mm thickness were used. The 8, 10, or 12% 
(w/v) acrylamide resolving gel mixture was prepared according to protein size. The 
acrylamide resolving gel mixture was prepared according to the number of gels that were 
going to be used, as indicated in Table 2.3 Acrylamide polymerisation was then initiated by 
the addition of the volumes indicated of 10% (w/v) APS and TEMED, after which the 
mixture was swirled gently. Then 8 ml of resolving gel mixture were transferred into each 
cast to allow sufficient space for a stacking gel to be added later. Distilled water was 
carefully overlaid on the top layer of the freshly poured gel mixture to create a smooth 
interface and prevent any gel shrinkage. The gel mix was allowed to polymerise at room 
temperature for approximately 30 to 40 min. Once the resolving gel had polymerised, water 
was removed, the required amount of 4% (w/v) polyacrylamide stacking gel was prepared 
and polymerised by the adding of 10% APS and TEMED as indicated in Table 2.3. The 
stacking gel is used in order to allows proteins entry and accumulation at its interface with 
the resolving gel. Immediately after the stacking gel was poured, a plastic comb 1.5mm (Bio-
Rad) was placed to form the sample wells. The gel mixture was then allowed to polymerise 
for 30 min at room temperature. Following polymerisation, the gels were placed in the 
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electrophoretic tank to which electrophoresis running buffer was added. The protein samples 
were performed according to the method described by Laemmli et al., (1970). Briefly, the 
samples were denatured in 4X Laemmli sample buffer and were heated at 95C for 5 minutes. 
The 8, 10, 12 % (w/v) polyacrylamide resolving gel as shown in Table 2.3 for THP-1 cell 
laysate, (plasma, pure FXIIIa), and pure Thrombin samples; respectively. The samples were 
loaded along with 5 µl Precision Plus Protein all blue standards (GeneFlow) in the left-
hand first lane then the rest of samples. To organise the samples in the stacking gel, 
electrophoresis was run initially at 50 volts for 10 min, then the voltage was increased to 200 
volts until the dye front reached the bottom of the gel in 45 min, then gel was removed 
carefully. 
Table 2- 3: Polyacrylamide gel preparation ingredients.  
Resolving (8,10,12 % w/v) and stacking (4% w/v), shown are the volumes required of each 
reagent for a total volume of 20ml.  
 
Component  
Acrylamide 
resolving gel 
 
Acrylamide 
Stacking gel 
 8% 10% 12% 4% 
AccuGel 29:1 40% 
(w/v) 
4 ml 5 ml 6 ml 1.5ml 
4X ProtoGel 
Resolving Buffer 
6 ml 5 ml 5 ml - 
ProtoGel Stacking 
Buffer 
- - - 2.5ml 
Distilled Water 10 ml 9.78 ml 8.78 5.9ml 
TEMED  20 µl  5 µl 
10% APS  200 µl  25 µl 
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2.2.7.3 Western blotting 
On completion of the separation of proteins by SDS-PAGE, the gel was removed from the 
plate and the stacking gel was cut off. The remaining resolving gel, which contained the 
separated proteins, was electrophoretically transferred onto nitrocellulose membrane filters 
by wet blotting (Towbin et al., 1979). Briefly, before starting the procedure all filter papers, 
sponges and nitrocellulose membrane were soaked in transfer buffer for 5 min then transfer 
sandwich was set up on the side of the transfer cassette facing the anode (+) as following 
steps;  sponge – 2 filter paper - nitrocellulose membrane – gel – 2 filter paper – sponge; then 
bubbles were gently removed. This assembled sandwich was then securely fixed in the 
transfer cassette and placed into transfer tank that contained transfer buffer. Proteins were 
transferred at 30 volts was applied overnight at room temperature. After electrotransfer of 
the proteins, the nitrocellulose membrane was stained by Ponceau red stain (Sigma-Aldrich 
Co Ltd, Gillingham, UK) to confirm protein transfer from the gel. The membranes were 
washed with Tris-buffered saline (TBS) then blocked for 1 h at room temperature with 3% 
(w/v) skimmed milk powder in TBS containing 0.05% (v/v) Tween-20 with mild agitation.  
Blocking is essential to prevent non-specific binding of the antibodies to the membrane in 
subsequent steps. Blots were then incubated overnight with gentle agitation at 4°C in 
blocking buffer containing the primary antibodies (1:500) Factor XIIIa mouse monoclonal 
(Table 2.2). After incubation, the primary antibodies were removed, and blots washed six 
times for 10 min in TBS/Tween 20. After washing, blots were probed with the appropriate 
(1:500) horseradish peroxidase (HRP)-conjugated secondary antibodies for 4 h at room 
temperature in blocking buffer (Table 2.2). Following six time washing as previous step to 
remove the unbounded secondary antibody, then developed using the SuperSignal™ West 
Pico Chemiluminescent substrate (Fisher scientific, UK). Images of the blots were captured 
by the iBright FL1000 system and the bands were quantified by densitometry using 
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Advanced Image Data Analysis software (AIDA) (Fuji; version 3.52). All band densities 
were measured and corrected for background, then normalised to band densities for internal 
control. Data are expressed as a percentage of the average value of the peak area compared 
to its corresponding control ± SEM. To confirm uniform protein loading in the gel primary 
antibodies specific to GAPDH were used 
2.2.8 Binding assays 
2.2.8.1 Binding of labelled PSP to plasma TG 
Pure rFXIIIa (0.2 µg), whole plasma (15 µg), and depleted plasma (15 µg), which was 
depleted by using ProteoPrep® Immunoaffinity Albumin and IgG Depletion kit was used 
from (Sigma-Aldrich), pure thrombin (0.5 µg) were prepared in 0.1M Tris-HCL pH 8.5. 
They were then incubated with or without 25 µM rhodamine-labelled PSP for 30 min at 4 
C. Then 4X Laemmli electrophoresis sample buffer was added and the samples were heated 
at 95 C for 5 min, followed by separation by SDS-PAGE. 10% and 12%, polyacrylamide 
gel was used to (FXIIIa and depleted samples) and thrombin; respectively. 
The gel was fixed in 10% (v/v) methanol and 5% (v/v) acetic acid overnight. It was then 
washed in distilled water before imaging. Digital images of the gel were captured by using 
LAS4000 imaging system using green light and the bands were quantified by densitometry 
using (Advanced Image Data Analysis software (AIDA) version 3.52). Protein band were 
revealed by staining with Coomassie Briliant Blue. 
2.2.8.2 Binding Competition assay of PSP 
Pure rFXIIIa (0.2 µg) or depleted plasma (15 µg) were incubated at 4 ºC with rhodamine-
labelled PSP (25µM; 30 min), unlabeled PSP (100 µM; 15 min) followed by labelled PSP 
(25 µM; 15 min) or with DMSO solvent alone (0.25 % v/v; 30min). They were then 
incubated for a further 1 h at 37 ºC. The same experiment was repeated with rFXIIIa (0.2 µg) 
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and pure thrombin (0.5 µg) with one of each unlabelled PSP, DIZ, DZO, CPF, CPO, PTH, 
POX (200 µM; 15 min) followed by labelled PSP (25 µM; 15 min) with DMSO solvent 
alone (0.25 % v/v; 30min). They were then incubated for a further 1 h at 37 ºC. 
Then the reaction was stopped by the addition of 1:3 volume of 4X Laemmli electrophoresis 
sample buffer and the samples were heated at 95C for 5 minutes, followed by separation by 
SDS-PAGE as previously described.  
2.2.9 Two-Dimensional Electrophorsis (2-DE) 
2D gel electrophoresis could separate proteins in a mixture according to their charge 
isoelectric point or (pI), first dimension going across small gel strip named isoelectric 
focusing gel (IEF) and the second dimension based on their molecular weight on SDS-PAGE. 
This reproducible technique enables protein identification when combined with mass 
spectrometry. and assessment of protein expression levels.  
Depleted plasma samples each have (100 µg) in 200 µl were incubated with rhodamine-
labelled PSP (25µM; 30 min) or with DMSO solvent alone (0.25 % v/v; 30min). The 200 µl 
of each sample was then precipitated 1 ml of acetone and kept overnight in -20 °C. After 
that, the precipitated depleted plasma samples were then centrifuged at 20,000 rpm at 4°C 
for 15 min and the supernatant removed. The pellets were partially covered to prevent any 
contamination and left to dry for 1 h in the fume cupboard. Then was added to each sample 
120 µl of rehydration buffer (Biolite®ampholytes (pH 3-10), 8 M urea, 50 mM DTT, 0.0002% 
(w/v) bromophenol blue, 4% (w/v) CHAPS, 0.2% (v/v) Biolite®ampholytes (pH 3-10) in 
deionised water). In the first-dimension (isoelectric focusing), 120 μl of the sample was 
applied on to an IEF focusing tray making sure that the spreading of the protein sample was 
even and makes contact with the cathode and anode of the wires. Then a 7 cm 3-10 pH 
ReadyStripTM IPG strips (pH 3−10; Bio-Rad, UK) was applied in the IEF tray in contact 
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with the protein sample without any air bubbles and sample protein was absorbed into the 
IPG gel to allow a passive rehydration for 1 h at room temperature. After that, mineral oil 
(Bio-Rad laboratories, Hertfordshire, UK) was added on top of the IPG strip to avoid buffer 
evaporation. The protein sample then went through active rehydration at 50 V for 16 hours. 
Once the rehydration was completed, IEF system electrode wicks (Bio-Rad laboratories, 
Hertfordshire, UK) were added in-between the top of the electrodes in the focusing tray and 
the IPG strip to ensure an effective focusing and to get rid of excess salt. A linear voltage 
slope up to 250 V was then applied for 20 min. A second linear voltage slope increasing to 
4000 V was applied for 2 h. A rapid voltage slope to 4000 V for 10,000 Volt-hours was then 
applied. Finally, a rapid voltage slope down to 500V was applied to the gel for 25 h. After 
that, IPG strips were equilibrated by placing the IPG strips in 2500 μl of equilibration buffer 
1 (1.5 M Tris/HCl pH 8.8, 6 M urea, 50 % (v/v) glycerol, 2 % (w/v) DTT, 2 % (w/v) SDS, 
in deionised water) for 10 min at room temperature with gentle agitation. Equilibration 
buffer 1 was then removed and 2500 μl of equilibration buffer 2 added (2 % (w/v) SDS, 50 % 
(v/v) glycerol, 6 M urea, 2.5 % (w/v) iodoacetamide, 1.5 M Tris/HCl pH 8.8, in deionised 
water) for 10 min at room temperature with gentle agitation. After equilibration, proteins 
were resolved in IPG strips and applied for the second dimension gel, were proteins are 
separated according to their molecular size. IPG strips were placed on the top of 10 % (w/v) 
SDS acrylamide gel (including a stacking gel) as described in section (2.2.7.2). Then a 0.5 
cm strip of filter paper was immersed in a mixture of 10 % (v/v) protein ladder (Precision 
Plus ProteinTM dual standards, Bio-Rad laboratories, UK, Hertfordshire) and 90 % (v/v) 4x 
Laemmli buffer (40 % (v/v) glycerol, 8 % w/v SDS, 0.01 % (w/v) bromophenol blue, 250 
mM TRIS-HCl pH 6.8, 10 % (v/v) β-mercaptoethanol, in deionised water) and placed at the 
IPG strips side for comparison of molecular weight. Gel molten ReadyPrepTM (Bio-Rad 
laboratories, UK, Hertfordshire) were then added over the IPG strip. A 1X electrophoresis 
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buffer was added in to electrophoresis container (Bio-Rad laboratories, UK, Hertfordshire) 
and 200 V was applied for 45 min to allow protein separation. After electrophoresis, the gels 
were washed for 5 min in deionised water for three times. The gels were captured by using 
LAS4000 imaging system using green light and then stained by ProtoBlueTMsafe colloidal 
coomassie G-250 stain (Bio-Rad laboratories, IK, Hertfordshire), and the gel left for staining 
overnight at room temperature. After staining, the gel was then washed for 1 h in deionised 
water to remove any additional background staining. Stained gels were imaged by Syngene 
G-box with Genesnap software.  
2.2.10 Cell culture  
2.2.10.1 Growing the cells 
Human cells (THP-1) vile was thaw in 2 min in 37°C then immediately moved slowly in1 
ml medium worm RPMI-1640 growth medium then mixed gently and moved to 10 ml 
growth medium and centrifugation at 300 x g at room temperature for 5 min to wash off 
DMSO of cryoprecipitation. Then the excess medium was thrown and 1 ml of growth 
medium was added again to resuspend the cell pellet gently then moved them to T25 culture 
flask contain 5 ml growth medium, then cells were incubated at 37°C in a humidified 
atmosphere of 95% air /5% CO2. Daily check on the cells, it took five days for the cell 
recovering and first 5 ml of fresh growth medium was added, then three days later another 
10 ml growth medium was added, until the growing of cell become regular and the viability 
higher than 75% then from now on will move the cells to T75 and subculture and maintain. 
Suspended cells (THP-1) maintained in T75 culture flask in RPMI-1640 growth medium 
each 50 µl of medium supplemented with 2 mM L-glutamine, 10% (v/v) FBS, penicillin 
(100 U/ml) and streptomycin (100 µg/ml) and 50 µl of β-mercaptoethanol (0.05 mM) 
which prepared in stock in filter sterilised PBS (170 µl concentrated β-mercaptoethanol to 
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50 µl sterilised PBS, then refiltered again in a new 50 µl tube and keep it in fridge). Cells 
were incubated at 37°C in a humidified atmosphere of 95% air /5% CO2.  
2.2.10.2 Maintenance and subculture of cells 
The suspension cells were passaged every three to five days when the cells density reaches 
8 x 105 to 1 x 106 viable cells/ml not exceed the 1 x 106 cells/ml. The cell cultures were either 
passaged to maintain the cell line or used for the experiment which was established with 
subsequent resuspension 2 x 105 cells/ml as the supplier recommended. The cells were sub-
cultured (1:3 split ratio). Experiments were performed on passage numbers 4-25 because 
later passages would be more susceptible to the effect of genetic drift. 
2.2.10.3 Counting and testing the viability of cells for experimental 
analysis 
Cells were split or resuspended for experimental analysis when they reached 1 x 106 cells/ml 
density in the maintenance flasks. Automated cell counting has become the robust alternative 
process to manual haemocytometer cell counting as it can provide a total cell count in a 
fraction of the time. TC20 automated cell counter (BioRad, Hemel Hempstead, UK) used as 
Automated cell counting device. The device utilised prepared TC20 Trypan blue dye (0.4% 
Trypan blue (w/v) in 0.81% (w/v) sodium chloride and 0.06% (w/v) potassium phosphate 
dibasic solution). Trypan blue dye is based on the blue acid dye chromophores which react 
and are taken up by the internal region of non-viable cells through a damaged membrane, 
whereas viable cells do not take up this dye (Wang, 2006). A volume of 10 μl of cell 
suspension was added to 10 μl of Trypan blue solution and left for 2 min to allow for cells 
to be exposed to the stain. A volume of 10 μl of this mixture was then loaded into a chamber 
of the counting slide. The slide was inserted into the slide slot of the TC20 cell counter and 
cell counting was automatically initiated as soon as the cell counter detected the presence of 
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the slide and Trypan blue dye. Viable cell counts per ml were used to determine the volume 
necessary to seed the cells at a required cell density in growth medium. Density of 2 x 105 
cells/ml of THP-1 cells was resuspended with loading volume 20 ml/flask. Flasks were then 
incubated at 37°C in a humidified atmosphere of 95% air/5% CO2 for 4 days to allow for 
cell recovery.  
2.2.10.4 Cell viability assessment 
AlamarBlue (AB) is an easy assay designed to measure quantitatively the proliferation of 
different kind of human and animal cell line. This assay does not need to wash or fix and 
extract the cell as required in other commonly used assays. As in this project the THP-1 
monocyte were used as suspension cells in the growth medium, it has been found that this 
assay is work properly with suspension cell THP-1 (Hatziieremia et al., 2006). It is 
recommended that the plating density and incubation time be determined for the cell line. 
Harvest cells which are in log phase growth stage and determine cell count. Add 10 μl 
alamarBlue in to 100 μl of the cells medium volume in the well. Return plates to incubator. 
For any given cell density selected, the incubation time can be determined as the time taken 
for the control cells to turn the indicator from the oxidized (blue) form to the fully reduced 
(pink)form. Remove the plate and measure absorbance for cell density 2 x 105 cells/ml after 
24 h and for 8 x 105 cells/ml after 4 h.  Measurement of absorbance at a wavelength of 570nm 
and 600nm. Calculating the reduction percentage of alamarBlue by using the following 
formula:   
Reduction Percentage = 
(Eoxi600 x A570) – (Eoxi570 x A600) 
(Ered570 x C600) – (Ered600 x C570) 
100 
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Where E is the molar extinction coefficient, which has units of L mol-1 cm-1 (Libretexts, 
2020), A is absorbance of test wells, C absorbance of negative control well (medium, 
alamarBlue reagent, no cells). 
Eoxi570 = 80586, Eoxi600 =117216, Ered570= 155677, and Ered600=14652 
2.2.10.5 Preparation of cell lysates  
Briefly, THP-1 cells were grown in T75 tissue culture flasks as described in section 
(2.2.10.1). Following treatments, suspension cells in growth medium were collected and 
centrifugated at 300 x g at room temperature for 5 min. The supernatant was discarded and 
cells pellet was then washed by suspending in chill PBS followed by centrifugation at 300 x 
g at room temperature for 5 min to pellet cells. The supernatant was discarded and the cell 
pellet resuspended in 600 μl of ice cold RIPA lysis buffer. The cells were incubated with 
lysis buffer for 20 min on ice with vortex ever 5 min and then clarified by centrifugation at 
4°C for 10 min at 14000 x g. The supernatant was collected and transferred to a new 
Eppendorf tube for protein estimation and further analysis. 
2.2.10.6  Exposure of cells to organophosphate compounds 
PSP, DZO, CPO and POX were prepared as 1, 10, and 100 mM concentration stock solutions 
in DMSO. 2µl of each concentration (0.1, 1 and 10 μM final concentrations) were added to 
20 ml growth medium/flask with density of 2 x 105 cells/ml of THP-1 cells. Controls cells 
were treated with 2 µl DMSO final concentration 0.01% (v/v). All flasks kept incubated at 
37°C in a humidified atmosphere of 95% air/5% CO2 for four days. Cells imaging inverted 
microscop with NIS-Elements F 4.00.00 were used first and last day of treatment and test 
cells viability of each flask. Ending the experiment by collecting the washing the pellets and 
lysis them as described in (2.2.10.5) then prepared according to the required assay.  
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 Statistical analysis 
Graph Pad Prism (version 7) (Graph Pad software, California, USA) was used to represent 
all data graphs. All analysis methods were confirmed for normality of distribution using 
Shapiro-Wilk normality test with 95 % confidence interval. Then, the significance of the 
differences between the average of the values for each treatment were compared to the 
corresponding control or other treatment group either by performing one-way ANOVA 
followed by "Tukey's Multiple Comparison Test’’, and the Dunnett comparison test”, or by 
two-way ANOVA for group comparison, respectively. Both methods took into account 
multiple comparison, with 95 % confidence interval. Results represent mean ± SEM and p-
value less than 0.05 were considered statistically significant.   
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3. Chapter 3: Characterisation of the inhibition of 
cholinesterase by organophosphorus compound 
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 Introduction 
Cholinesterase is a family of serine hydrolase enzymes whose primary role is to catalyse the 
hydrolysis of the neurotransmitter acetylcholine and other choline esters to allow a cholinergic 
neuron to return to resting state (Čolović et al., 2013). Cholinesterase activity has been deployed 
as an environmental pollution biosensor (Jońca et al., 2015). Some cholinesterases act as an 
endogenous bioscavenger for anticholinesterase agent as the first line of defence against toxic 
compounds reaching the bloodstream (Jońca et al., 2015). Organophosphate compounds used 
in different applications, especially as pesticides, are known to be potential inhibitors of 
cholinesterase activities, which have been used for a long time as clinical biomarkers for 
determination of exposure to nerve agents and pesticides contamination (Tham et al., 2017). 
The most common way to detect exposure to OPs is measuring the activity of AChE or BChE 
activity in human blood (Jońca et al., 2015).  
Determination of blood or plasma cholinesterases activity is now a standard laboratory assays. 
Investigation of the activity of plasma BChE was used for monitoring of OP exposure and 
predicting the severity of poisoning (Abdullat et al., 2006; Eddleston et al., 2008). It was 
revealed that AChE and BChE are sensitive markers in moderately poisoned patients (Dhotre et 
al., 2014). Work by Jońca et al. (2015) indicated that some clinical factors can influence kinetic 
parameters of BChE activity in blood. In the current study, the effects of OPs of interest on the 
activities of purified electric eel AChE and equine BChE were monitored and compared with 
the corresponding activities in human plasma to differentiate OP compounds with respect to 
their potency against each enzyme in isolation and in a more biological environment. Electric 
eel AChE and equine BChE are the most widely used for bioassay applications because of the 
high inhibition sensitivity that OP compounds pesticides have on them (Miao et al., 2010; 
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Čolović et al., 2011). Indeed, OPs may induce different levels of inhibition in vivo or in vitro 
AChE and BChE activities (Skrinjaric-Spoljar et al., 1973; Eyer, 2003; Casida and Quistad, 
2005; Üner et al., 2006). 
A different study used different condition to study the effect and to validate the previous efficacy 
of OPs on blood and plasma cholinesterases. For example, an in vitro investigation of the 
efficacy of CPO on BChE, the results revealed that mutant active site of BChE showed lower 
inhibtion with CPO comparing to the wild-type of BChE (Amitai et al., 1998). Another in vitro 
study investigated the effects of single and simultaneous exposure to DZ, CPF and their oxon 
analogues DZO and CPO on electric eel AChE, which confirmed that the parent compounds 
were weaker inhibitors than their oxon analogues but all forms behaved in a concentration-
dependent manner with different potencies (Čolović et al., 2011). Liyasova et al., (2011) found 
that half of the blood samples taken from jet airplane passengers revealed that the active site 
serine of BChE reacted with the active metabolite of tri-o-cresyl phosphate which is cresyl 
saligenin phosphate (CBDP) - the analogue form of PSP - and produce a stable phosphorylated 
adduct.  
There are a variety of methods to study the cholinesterase activity but the most simple, accurate, 
and low cost is the Ellman method (Miao et al., 2010). Enzymological characteristic of 
cholinesterases are defined by the specificity of their substrate; moreover, the different structure 
of the esterified substrate controls the kinetic parameters of enzymatic hydrolysis (Rozengart 
and Basova, 2009). The Ellman method is based on determining the amount of thiocholine 
released, which is quantified by its reaction with DTNB, producing yellow 5-thio-2-
nitrobenzoate anion (Ellman et al., 1961). The assay uses the synthetic thiol esters 
acetylthiocholine and butyrylthiocholine, which bear a close resemblance to acetylcholine and 
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butyrylcholine, respectively (Basova et al., 2018). However, one study displayed high rates of 
hydrolysis when AChE was incubated with acetylthiocholine but showed far less activity in the 
presence of butyrylthiocholine (Tham et al., 2017).  
Before investigating their impact on the haematological parameters such as FXIIIa and thrombin 
activity, it was important to confirm the biological activity of the OPs of interest against known 
major targets. The main aim of the work presented in this chapter was, therefore, to confirm the 
behaviour of OPs towards pure cholinesterases and their corresponding activities in human 
plasma. This was achieved by using by the Ellman method (Ellman et al., 1961) using 
acetylthiocholine and butyrylthiocholine as substrate for AChE and BChE, respectively. 
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 Results 
3.2.1 Effect of OPs on plasma and purified acetylcholinesterase activity 
In order to establish the relationship between the toxicity of OPs and the level of AChE activity, 
enzyme activity was measured by a modified Ellman assay which was performed using either 
human plasma (~1.5 mg protein/ml) or pure electric eel AChE (0.4 µg/ml) in the presence and 
absence of several OPs over a range of concentrations incubated on 4ºC for 30min, as indicated 
in (section 2.2.3). The results in Fig 3.1 and Fig 3. 2 revealed that plasma AChE may be more 
sensitive to parent organophosphorothiote OPs than was pure AChE of electric eel. 
Interestingly, the effect of PSP on plasma AChE activity started to cause a noticeable reduction 
from 0.8 µM and significant inhibition at 6 µM and above (Fig 3.1 A) compared to no effect on 
pure AChE (Fig 3.2 A). PTH (Fig 3.1 D) was the most toxic parent compound to plasma AChE, 
as a significant reduction was observed starting from 1.5 µM concentration until the activity 
was undetectable at 25 µM and above. One the other hand, CPF inhibited pure AChE by 40% 
at the highest exposure concentration (50 µM). DZO, CPO and POX inhibited both plasma and 
pure AChE activities much more potently than the parent compounds (Fig 3.1 & 3.2 E, F, G). 
In cases where more than 50 % inhibition was observed, the IC50 values were determined as 
summarised in Table 3.1 (IC50 plots are shown in appendix 8.1 & 8.2). Generally, the oxon 
compounds were more potent than their parent compound in assays of AChE in both plasma 
and purified enzyme samples. 
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Figure 3- 1: Effect of OPs on plasma acetylcholinesterase activity. 
 
Diluted human plasma samples (~1.5 mg/ml) were incubated 30 min on ice with a range of OP 
concentrations, as indicated prior to being subjected to the Ellman assay as described in 
materials and methods. A) PSP, B) diazinon, C) chlorpyrifos, D) parathion, E) diazoxon, F) 
chlorpyrifos oxon and G) paraoxon. Data points represent the mean ± SEM of 
acetylcholinesterase specific activity from three independent experiments. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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Figure 3- 2:  Effect of OP on pure acetylcholinesterase activity. 
 
Pure electric eel acetylcholinesterase (0.4 µg/ml) samples were incubated 30 min on ice with 
a range of OPs as indicated prior to being subjected to the Ellman assay as described in 
materials and methods. A) PSP, B) diazinon, C) chlorpyrifos, D) parathion, E) diazoxon, F) 
chlorpyrifos oxon, G) paraoxon. Data points represent the mean ± SEM of 
acetylcholinesterase specific activity from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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3.2.2 Effect of OPs on plasma and purified butyrylcholinesterase 
activity 
The main abundant choliesterase in plasma is BChE (Masson & Lockridge, 2010), for which 
reason it was also necessary to examine the relationship between the toxicity of OPs and the 
level of plasma BChE. The assays were performed using either human plasma (~1.5 mg 
protein/ml) or pure equine BChE (0.4 µg/ml) in the presence and absence of a wide range of 
concentrations of the same OPs incubated on 4ºC for 30min, as indicated in section 2.2.4. 
From the results in Fig 3.3 and Fig 3.4 it can be seen that PSP has a significant effect by 
decreasing the activity on both plasma and pure BChE, but the toxicity effect was higher on 
plasma BChE where it was initiated from 0.2 µM and induced statistically significant 
inhibition at 12 µM and above (Fig 3.3 A).  As for AChE, there was much stronger inhibition 
in both plasma and pure BChE activities by the oxon forms compared to parent compounds 
(Fig 3.3 & 3.4 E, F, G). Plasma BChE was more sensitive to DZO and POX (Fig 3.3 E & G) 
than was pure BChE. However, CPO treatment of pure BChE (Fig 3.4 F) with significant 
inhibition from 6 nM. Nevertheless, it was noticeable the significant inhibition in pure BChE 
activity from 12 µM of parent compound of CPF (Fig 3.4 C). For most OPs the IC50 values 
for BChE were determined and are shown in Table 3.1 (IC50 plots are shown in appendix 8.2 
& 8.3). In general, both pure and human plasma BChE activities were more sensitive than 
AChE to both parent organophosphorothiote and oxon OPs. 
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Figure 3- 3: Effect of OPs on plasma butyrylcholinesterase activity. 
 
Diluted human plasma samples (~1.5 mg/ml) were incubated 30 min on ice with a range of 
OPs concentrations as indicated in graphs prior to being subjected to the Ellman assay as 
described in materials and methods. A) PSP, B) chlorpyrifos, C) chlorpyrifos oxon, D) 
diazinon, F) diazoxon, and G) diazinon. Data points represent the mean ± SEM of 
butyrylcholinesterase specific activity from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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Figure 3- 4:  Effect of OP on pure butyrylcholinesterase activity. 
 
Pure equine butyrylcholinesterase (0.4 µg/ml) samples were incubated 30 min on ice with 
a range of OPs as indicated prior to being subjected to the Ellman assay as described in 
materials and methods. A) PSP, B) diazinon, C) chlorpyrifos, D) parathion, E) diazoxon, 
F) chlorpyrifos oxon, G) paraoxon. Data points represent the mean ± SEM of 
butyrylcholinesterase specific activity from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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Table 3- 1: Summary of IC50 values for OP compounds against plasma and pure AChE 
and ButChE enzyme activities. 
 
NR = significant inhibition observed but IC50 value was not reached. 
 
Organophosphorus 
compound 
IC50 
Plasma 
AChE 
(µM) 
Pure AChE 
(µM) 
Plasma BChE 
(µM) 
Pure BChE 
(µM) 
PSP 1.7 (±0.03) NR 0.79 (±0.01) 6.1 (±0.03) 
Diazinon NR NR 20 (±0.04) 34 (±0.09) 
Diazoxon 0.2 (±0.02) 7.8 (±0.03) 0.12 (±0.02) 0.25 (±0.02) 
Chlorpyrifos NR NR 71 (±0.09) 4.8 (±0.05) 
Chlorpyrifos oxon 0.003 (±0.04) 0.33(±0.03) 0.05 (±0.02) 0.03 (±0.03) 
Parathion 6.6 (±0.03) NR 4.7 (±0.03) 9.7 (±0.09) 
Paraoxon 0.05 (±0.03) 0.44 (±0.04) 0.07 (±0.02) 0.07 (±0.03) 
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3.2.1 Substrate specificity of cholinesterases 
As a result of the unexpectedly strong inhibition of acetylthiocholine hydrolysis by plasma 
cholinesterases following PSP exposure, it was important to assess the specificity of 
cholinesterase for the two substrates (acetylthiocholine iodide and S-butyrylthiocholine 
iodide) used in this study to determine whether the some of the observed effects of OPs were 
due to AChE inhibition or the ability of BChE to hydrolyse its preferred substrate. For this, 
the Ellman assay was used on both pure enzymes’ (electric eel AChE and equine BChE) in 
the presence and absence of a range of concentrations both substrates. The effect of substrate 
concentration is shown in Fig. 3.5. For the tested substrate concentrations, (Fig 3.5 A) pure 
AChE activity showed no interaction with the substrate butyrylthiocholine iodide. However, 
the pure BChE activity showed an apparent Michaelian behavior, with both its preferred 
substrate and with acetylthiocholine iodide (Fig 3.5 B). It was clear that both enzymes 
hydrolysed their own intended substrate (Fig 3.5 C & D) AChE had a Km for its preferred 
substrate of 0.05 mM (Fig 3.5 C) but was unable to hydrolyse butyrylthiocholine (Fig 3.5 
A). When the apparent Km values of BChE for the two different substrates were calculated 
by the Michaelis-Menten method, the results were found to be very similar, with only 0.06 
mM difference (Fig 3.5 B & D). Thus, the substrate specificity experiments show that BChE 
can effectively hydrolyse acetylthiocholine iodide as well as butyrylthiocholine, but AChE 
cannot hydrolyse butyrylthiocholine iodide. 
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  Figure 3- 5: Substrate specificity of cholinesterases. 
 
Pure electric eel AChE (A, C) and equine BChE (B, D) (0.4 µg/ml) were incubated in the 
presence of a range of substrate concentrations S-butyrylthiocholine iodide (A, D), and 
acetylthiocholine iodide (B, C), prior to being subjected to the Ellman assay, as described 
in materials and methods. Data represent enzyme activity as mean absorbance change per 
min ± SEM for three independent experiments. 
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 Discussion 
Cholinesterases have been widely studied, and they are accepted as biomarkers for the OP 
toxicity, since it has been proven that they are one of their major targets (Nigg & Knaak, 
2000). In plasma, it has been suggested that the dominant type is BChE, whereas AChE is 
mainly in erythrocyte membranes. A previous study showed that human 12th-week fetal 
serum might contain 40% AChE (Hahn et al., 1993), whereas others confirmed that adult 
plasma has less than 1% of AChE activity (Brimijoin & Hammond, 1988; Thompson, 1999; 
Nigg & Knaak, 2000). The work presented in this chapter aimed to validate the effect of the 
some of the most widely used OPs and compare that variation of toxicity effect between 
AChE and BChE. In the current work, the activity of cholinesterases was determened by the 
Ellman assay (Ellman et al., 1961) using the preferred substrate for each enzyme 
(acetylthiocholine iodide and butyrylthiocholine iodide) and the chromogenic reagent 
DTNB to detect the thiocholine product released. The results confirm that the parent OPs 
and their oxon metabolites exhibit the expected relative toxicity effects on pure 
cholinesterases, in that the latter are more potent, thus showing that all compounds tested 
were biologically active. However, the substrate specificity observed for the pure 
cholinesterases indicates that BChE can hydrolyse the AChE substrate acetylthiocholine 
iodide but not the opposite. Therefore, given that AChE is less abundant than BChE in 
plasma, it is likely that some of the unexpected effects on acetylthiocholine hydrolysis may 
have been due to inhibition of BChE.   
AChE activity was tested with a wide range of organophosphorus compound and a variety 
of samples (Thompson, 1999). In the current study it was clear that the bioactivated oxon 
metabolite form of OPs was more toxic towards AChE activity in both samples (human 
plasma and electric eel AChE) in a concentration dependent manner but with different 
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inhibitory potencies. The rank order of the most toxic on plasma samples follows as: CPO, 
POX, DZO and PSP (Fig 3.1 E, F, G, A). It was also noticeable in the current work that the 
inhibition was concentration-dependent with CPO being effective of in the low nM range 
(Fig 3.1 E, F, G). Then the of POX and DZO levels were in the low µM concentration ranges, 
which corresponded to those findings of previous studies that pointed to the grater rate of 
inhibitory action following oxidative bioactivation of insecticide compounds either in vitro 
or in vivo despite their different conditions and methods (Casida & Quistad, 2005; Kaushik 
et al., 2007). Another study found that inhibitory potencies of DZO and CPO were 100 times 
more than DZ and CPF on cell culture of erythrocyte AChE activity after three days exposure 
(Čolović et al., 2010; Čolović et al., 2011). Moreover, other previous research had shown 
the very low AChE IC50 (0.1-0.3 µM) of PSP in a human neuroblastoma cell line (Ehrich et 
al., 1997), very similar to the complete inhibition of human plasma ChE in this current study 
using acetylthiocholine as the substrate (IC50 1.7 µM ±0.03 PSP: Table 3.1). 
Some studies found very high AChE concentrations in the eel Electrophorus electricus and 
considered the most abundant source of this enzyme and used as purified source of AChE 
(Assis, Bezerra & Carvalho Jr, 2011). In the current study, the effect of OPs on purified 
AChE activity (Fig 3.2) showed different potencies compared to those in plasma (Fig 3.1). 
PSP and DZ toxicity showed no significant effect; in addition, the bioactivated compounds 
in plasma were more potent than purified enzyme. Since the OPs are substrate analogues of 
acetylcholine which are thought to interact with the serine hydroxyl moiety of the AChE 
active site leading to organophosphorylation (Čolović et al., 2011). The lack of the biological 
effect environment of plasma could be one reason for PSP and DZ inhibition effect and 
reduced the significant effect of PTH on purified protein (Fig 3.2 A, B, C, D), and that could 
lead to missing the reacting with the active site. This speculation is in agreement with a study 
showing that in vitro influence of DZ on human lymphocyte, fibroblast and erythrocyte 
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AChE had a dose-dependent higher induced enzyme activities inhibition than their human 
commercial purified protein which was almost negligible compared to biological 
environment samples (Čolović et al., 2011). However, the CPF toxin effect on purified 
AChE with no biological protein environment as in plasma sample reduced < 50% of AChE 
activity at 50 µM comparing to the same concentration on plasma AChE.  Čolović et al. 
(2011) reported an almost complete inhibition of the electric eel purified AChE in the 
presence of 20 µM CPF concentration, moreover, the studies showed that albumin is the 
most abundant plasma protein binds with organophosphate compound, and MALDI-TOF 
mass spectrometer showed tyrosine adduct CPF-albumin (Li et al., 2013). Another 
explanation for the different effects on plasma and electric eel acetylcholinesterase activity 
could be that BChE was affected, which necessitated a study of the effect of the same OPs 
on pure (equine) and human plasma BChE.  
BChE, which is also known as plasma cholinesterase, is a serine hydrolase present in most 
mammalian tissues with highest levels in liver and plasma (Nigg & Knaak, 2000). It is 
thought that BChE is not the primary toxicity target of OPs, but it has been found that many 
OPs compounds have a more pronounced toxic effect on BChE than AChE (Lockridge & 
Masson, 2000; Wogram et al., 2001; Casida & Quistad 2005). This is in agreement with data 
obtained in the present study, showing that all OPs were more potent inhibitors of 
butyrylthiocholine hydrolysis in both pure enzyme and human plasma samples. 
The substrates specificity was assessed in purified AChE and BChE Fig 3.5 to determine 
which of the two cholinesterases (AChE or BChE) is most affected in plasma samples treated 
with OPs. It is known that acetyl(thio)choline is the preferable substrate for AChE and 
butyryl(thio)choline for BChE (Basova et al., 2018).  
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 In the current study the reaction of each enzyme with the other’s intended substrate was 
tested, the purified BChE being able to hydrolyse both acetylthiocholine and 
butyrylthiocholine iodide (with Km values of 0.28 µM and 0.22 µM, respectively), whereas 
the purified AChE did not hydrolyse the butyrylthiocholine iodide (Fig 3.5). Therefore, the 
data obtained in the current study suggest that BChE (but not AChE) can effectively 
hydrolyse both substrates indicating that it may account for most of the cholinesterase 
activity in all plasma samples. In agreement with these findings, a study by Liu et al., 2007 
illustrated that fish (Carassius auratus) brain AChE had found that brain AChE had a much 
higher affinity and hydrolysing efficiency to acetylthiocholine iodide than to 
butyrylthiocholine iodide (Liu et al., 2007; Tham et al., 2017). Furthermore, another study 
which measured ChE activity in blood collected from healthy male and female volunteers 
compared to purified human ChE, revealed that the neurotransmitter acetylcholine was an 
outstanding substrate for BChE (Masson & Lockridge, 2010). Indeed, BChE was found to 
hydrolyse acetylthiocholine at a rate just two-fold lower than butylrylthiocholine (Wetherell 
& French, 1986). A study focused on substrate selectivity of human BChE and its mutants 
estimated a Km of 33 µM for acetylthiocholine iodide substrate which was hydrolysed by 
the wild-type BChE comparing to 17 µM for butyrylthiocholine iodiede (Hou et al., 2013). 
The BChE active site structurally showed a broader substrate specificity than AChE 
(Pohanks, 2011).  
Thus, the selective measurement of BChE in the presence of AChE in plasma can be 
achieved because butyrylthiocholine is hydrolsed by BChE more specifically. However, 
measurement of AChE in the presence of BChE is difficult due to the ability of BChE to also 
hydrolyse acetylthiocholine iodide, and the lack of a specific inhibitor that inhibits BChE 
without inhibiting AChE activity (Naik et al., 2013).  
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The current study suggest that the cholinesterase inhibition in plasma AChE assays was 
likely to be a reflection of  BChE activity, for example in the case of PSP, which had no 
effect on  the purified AChE yet plasma ChE activity was significantly inhibited using 
acetylthiocholine as the substrate Aldrige (1954) proposed that tri-o-cresyl phosphate 
(TOCP), when modified to a more toxic product CBDP in vivo exhibited increased inhibition 
of BChE but not AChE, an effect was also observed in vitro using rat-liver slices to produce 
the same toxic effect. It was subsequently shown that CBDP formed organophosphorylated 
adducts on active site serines (Ser-203 for human AChE and Ser-198 for human BChE); in 
vivo the inhibition effect by low dose exposure to CBDP on AChE is not as much as it is on 
BChE, for which reason BChE inhibition serves as a useful biomarker for exposure to TOCP 
(Liyasova et al., 2011). Moreover, by looking to the rest of the results of the OPs effect Fig 
3.1 on plasma AChE and plasma ButChE Fig 3.3 there was a closer scenario of results 
manner.   
The results in the current work both plasma samples different substrate highlighted that 
BChE reacted with parent OP compounds and showed various effect. It is well known that 
oxidized form of organophosphorus compounds is the more toxic than their parent forms on 
cholinesterase enzyme activities (Brimijoin and Hammond, 1988; Čolović et al., 2010; 
Čolović et al., 2011).  Most of the studies focus their research on the oxon form and their 
binding to the active site, but it has found that some phosphorothioate compounds cause 
some activity inhibition even before they are oxidized. For example, Tacal & Lockridge 
(2010) found that diazinon formed adducts with highly purified human BChE, and in the 
activity assay 52% ‘slow’ inhibition was observed in BChE 3.6 mg/ml over 15 h exposure 
to 50 µM DZ, suggesting that this could occur via a thiono-thiolo rearrangement.  
A previous study by Amitai et al., (1998) incubated POX with purified human BChE (1.3 
U/ml) with a higher butyrylthiocholine Km (0.5 mM) compared to the current study (Fig 
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3.5); their inhibition kinetics data showed about 50% inhibition at 0.055 µM POX after 40 
min, which is proportionately almost the same as its effect on to plasma and purified BChE 
in the current study (Figs 3.3 and 3.4). In the same study of Amitai et al. (1998) they also 
incubated the same sample with CPO, and they mentioned that results showed direct 
inhibition in BChE activity depended on CPO concentration, they confirmed that BChE 
served as a biomarker for CPO toxicity due to rapid interaction between them. In the 
agreement the current study revealed that CPO inhibits BChE at lower than or about 24 nM 
concentration either whole plasma of purified protein (Figs 3.3 and 3.4).   
There are no major studies on the effect of DZ and DZO on BChE activity. The current 
research showed that DZ comparing to purified BChE had inhibited ≥ 30 % of plasma BChE 
activity showed almost ≤ 40 % activity inhibition at high concentration 50 µM, but the oxon 
form of DZO showed complete inhibition of plasma BChE activity at 0.8 µM, conversely, 
purified BChE showed ≥10% activity at 3 µM (Figs 3.3 and 3.4). Although different samples 
and methods comparing to current study some studies showed significant inhibition by DZ, 
a previous study injected i.p. 100 mg/kg body wt into male rat 340-370 g with dissolved DZ 
in olive oil illustrated about 65% significant inhibition of BChE activity after 3 hours 
injection (Tomokuni & Hasegawa, 1985). Another study used a different method but the 
same type of rat male and female divided into four groups into (two groups/sex) weighing 
(90-100 g). They were feed for 7 days with 25 ppm and 2 ppm of DZ mixed with their diet 
it showed significant inhibition for both male and female with higher concentration by 50 % 
and 42 % however the lower concentration showed 5 % and 29 %, respectively, which 
indicated that rats female are more sensitive to DZ toxicity (Davies & Holub, 1980). 
The samples of plasma treated with parent OPs (Figs 3.1 and 3.3) showed significant 
inhibition of BChE activity with both substrates, though it was more pronounced for 
butyrylthiocholine, This could be explained by these parent organophosphorothiotes 
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being metabolised in plasma by molecules such as cytochrome P450 in plasma exosomes to 
produce the more potent oxon  form (Fabrizi et al., 1999; Foxeberg et al., 2011; Kumar, 
2015).  Also, BChE is known to have a larger active site pocket than AChE (about 500 Å3 
compare to 300 Å3), respectively, which makes BChE less substrate-specific than AChE, as 
it can hold bulkier substrates or inhibitors (Masson & Lockridge, 2010).  
In conclusion, the results presented in this chapter indicate that the OPs used in the current 
study exhibit the expected manner of toxicity against pure cholinesterases, which serves as 
a useful positive control for their acute biological effects. The apparent inhibition of plasma 
AChE by PSP but no effect on pure AChE can be explained by the ability of BChE, of which 
PSP is a potent inhibitor to hydrolyse acetylthiocholine. The effect of parent 
organophosphorothioate compound on plasma cholinesterases may be due to their ability to 
bind to larger active site on BChE. 
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4. Chapter 4: Effects of organophosphorous 
compounds on pure and plasma FXIIIa 
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 Introduction 
One of the important biological processes in blood is haemostasis, which maintains and 
protects the balance between thrombosis and bleeding. The end result of clot formation is a 
network of fibrin stabilized by being cross-linked through the action of FXIII, which is a 
transglutaminase zymogen that is activated by thrombin-mediated cleavage to produce 
FXIIIa (Martins et al., 2014). Transglutaminases (TGs) are a group of enzymes that catalyse 
crosslinking between the side chains of protein-bound lysine and glutamine, and 
incorporation of polyamine into protein-bond glutamine, during which processes a molecule 
of ammonia is released (Lin and Ting, 2006). Although FXIIIa is important at the end of the 
coagulation cascade, FXIIIa deficiency causes disparate diseases such as bleeding disorders, 
etc. (Muszbek et al., 2011; Board et al., 1993).  
Since OPs have the potential to produce various kinds of toxicity, such as acute intoxication 
via their primary target, which involves the inhibition of acetylcholinesterase in the nervous 
system and at neuromuscular junctions; also, low level exposure produces long lasting 
chronic toxicity in non-target tissues and organs in the body (Ray & Richards, 2001; Eleršek 
& Filipic, 2011).  Limited studies have suggested that environmental toxins such as OPs may 
disrupt the activity of coagulation enzymes (Petroianu et al., 1999). Moreover, it has been 
reported that exposure to diazinon, chlorpyrifos and other OPs may disrupt a number of 
haematological parameters, such as CBC (complete blood count) values and biochemical 
measurements in blood plasma (Rahman & Siddiqui, 2006; Ambali et al., 2007; Banaee et 
al., 2008; Andreadis et al., 2014). 
There is serious blood loss after some cardiac surgery; a study by Ternström et al. (2010) 
found noticeable dissociation in plasma coagulation factors activity postoperatively, but 
observations showed FXIII activity in preoperative and postoperative stages correlated 
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inversely to postoperative blood loss after coronary artery bypass graft. Also, their results 
pointed to correlation between preoperative and postoperative FXIII concentration to 
postoperative bleeding. Larsen et al. (2012) found rebleeding and clot instability following 
aneurysmal subarachnoid haemorrhage (SAH). Reduced FXIIIa activity produced a 
reduction of clot stability which caused 50-90% of the rebleeding occurring within 6 hours 
of the primary bleeding. The association between FXIIIa activity or concentration and 
coronary disease has been recognized (Muszbek et al., 2008) but causality has not yet been 
proven (Reinhart, 2003; Ternström et al., 2010). 
Acute myocardial infarction, heart failure, infarct expansion, and cardiac rupture were 
observed in FXIII deficient mice, perhaps due to inappropriate recovery of the myocardial 
tissue (Karimi et al., 2009). In this respect, a case was reported of a 40-year old man who 
was admitted to a hospital emergency department with primary diagnosis of OP insecticide 
poisoning; after a few days, his condition deteriorated and myocardial infarction was 
diagnosed (Kumar et al., 2014).  
Some recent studies at NTU have shown that OP exposure disrupts the cellular activity of 
tissue TG in neural and hepatic cells (Howden, 2006; Harris et al., 2009; Muñoz et al., 2010). 
Based on these previous studies it is possible that other types of TGs, including coagulation 
FXIIIa, could be targets of OP toxicity.  
The aim of the work presented in this chapter was to study the effects of a range of 
concentrations of the OPs PSP, DZ, DZO, CPF, CPO, PTH and POX on transamidase 
activities of plasma and purified FXIIIa. It was also of interest to study covalent binding and 
competitive binding using SDS-PAGE and image analysis of FXIIIa incubated with a 
fluorescent rhodamine-PSP (Rh-PSP) probe. The effect of OPs on plasma clotting was 
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further investigated using a D-Dimer ELISA kit. A further aim was to identify potential 
FXIIIa binding of all OPs used by mass spectrometry.  
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 Results 
4.2.1 Effects of organophosphorus compounds on plasma TG-
mediated amine incorporation and peptide crosslinking activity 
Initial experiments in this study investigated whether the OPs were able to affect the TG-
mediated amine incorporation and peptide cross-linking activity in plasma. Plasma samples 
were pre-incubated 30 min on ice with  a range of OP concentrations and subjected to 
incubation with biotin-cadaverine (for amine incorporation) or biotin-labelled F11KA (for 
peptide crosslinking), as indicated in (section 2.2.1.4.1 & 2.2.1.4.2). The results for amine 
incorporation showed  slight (10-20 %) but statistically significant inhibition  of TG activity  
by PSP,  DZ, CPF and DZO (Fig 4.1 A, B, C, E) . A fluctuating pattern of inhibtion was 
exhibited with PTH treatment, whereas approximately 20-30% steady decline in activity was 
observed in the presence of CPO and POX (Fig 4.1 D, F,G).  
On the other hand, in the plasma TG-mediated peptide crosslinking assay slight but 
significant inhibition of enzyme activity was observed following exposure to PSP, PTH, 
DZO, and CPO (Fig 4.2 A, D, F), but DZ, CPF, and POX had no significant effect (Fig 4.2 
B, C, G). An IC50 value was not reached for any OP although statistically significant 
inhibition was observed for six out of seven compounds (Table 4.1). Overall, these data 
indicate that certain OP compounds can affect plasma TG activity as determined by biotin-
cadaverine incorporation and protein cross-linking activity and that CPO has the greatest 
effect on peptide cross-linking, inhibiting by up to 35% of control values. 
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Figure 4- 1: The effect of OPs on plasma TG-mediated amine incorporation activity. 
 
Diluted human plasma samples (~1.5 mg/ml) were pre-incubated for 30 min on ice with the 
indicated concentrations of each OP in the biotin-cadaverine incorporation assay, as 
described in Materials and Methods. Plots shown are for: A) PSP, B) diazinon, C) 
chlorpyrifos, D) parathion, E) diazoxon, F) chlorpyrifos oxon and G) paraoxon. Data points 
represent the mean ± SEM of normalized plasma TG activity from seven independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control 
(=100%). 
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Figure 4- 2:  The effect of OPs on plasma TG-mediated peptide crosslinking activity. 
 
Diluted human plasma samples (~0.8 mg/ml) were pre-incubated for 30 min on ice with 
the indicated concentrations of each OP in the biotin-labelled peptide F11KA crosslinking 
assay, as described in Materials and Methods. Plots shown are for: A) PSP, B) diazinon, 
C) chlorpyrifos, D) parathion, E) diazoxon, F) chlorpyrifos oxon and G) paraoxon. Data 
points represent the mean ± SEM of normalized plasma TG activity from three 
independent experiments. *p<0.05, **p<0.01, ***p< 0.001, ****p< 0.0001 versus non 
OP-treated control (=100%). 
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4.2.2 Effects of organophosphorus compounds on pure FXIIIa-
mediated amine incorporation and peptide crosslinking activity 
To characterize the OP effect specifically on purified rFXIIIa- mediated amine incorporation 
and peptide cross-linking activity, rFXIII samples were pre-incubated 30 min on ice with  a 
range of OP concentrations and subjected to incubation with biotin-cadaverine (for amine 
incorporation) or biotin-labelled F11KA (for peptide crosslinking), as described in (section 
2.2.1.4.1 & 2.2.1.4.2).  The results revealed a variable significant effect from all OPs on 
rFXIIIa-mediated amine incorporation activity (Fig 4.3). Concentrations of 12 and 25 µM 
showed inhibition effects on FXIIIa activity by 20 % in the case of PSP and CPF (Fig 4.3 A, 
C), and 60 % or more for DZ, DZO and PTH (Fig 4.3 B, E, D), whereas CPO and POX 
exhibited significant but not huge inhibition of activity (Fig 4.3 F, G).  
Significant activity reduction in rFXIIIa-mediated peptide crosslinking activity was 
observed, as shown in Fig 4.4. There was between 60 % to 70 % inhibition effect by DZ, 
CPO and POX (Fig 4.4 B, F, G). Furthermore, the highest inhibition of approximately 80 % 
or more was induced by CPF and PTH (Fig 4.4 C, D), whereas the lowest inhibition effect 
of between 20 % and 40 % was caused by DZO and PSP, respectively (Fig 4.4 E, A). When 
there was more than 50 % inhibition of rFXIIIa-mediated peptide crosslinking activity, the 
IC50 values were determined as summarized in Table 4.1 (IC50 plots are shown in appendix 
8.5 & 8.6). Generally, most of parent and oxon compounds were significantly potent on 
rFXIIIa biotin-cadaverine incorporation, but a distinct effect of OPs was obvious on rFXIIIa 
peptide cross-linking activity. 
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Figure 4- 3: The effect of OPs on pure rFXIII-mediated amine incorporation activity. 
 
Human rFXIII (~0.02 ng/µl) was pre-incubated for 30 min on ice with the indicated 
concentrations of each OP in the biotin-cadaverine incorporation assay, as described in 
Materials and Methods. Plots shown are for: A) PSP, B) diazinon, C) chlorpyrifos, D) 
parathion, E) diazoxon, F) chlorpyrifos oxon and G) paraoxon. Data points represent the 
mean ± SEM of normalized pure rFXIII activity from three independent experiments. 
*p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001 versus non OP-treated control (=100%). 
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Figure 4- 4: The effect of OPs on pure rFXIII-mediated peptide crosslinking activity. 
 
Human rFXIII (~0.005 ng/µl) was pre-incubated for 30 min on ice with the indicated 
concentrations of each OP in the biotin-labelled peptide F11KA crosslinking assay, 
as described in Materials and Methods. Plots shown are for: A) PSP, B) diazinon, C) 
chlorpyrifos, D) parathion, E) diazoxon, F) chlorpyrifos oxon and G) paraoxon. Data 
points represent the mean ± SEM of normalized pure rFXIII activity from three 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus 
non OP-treated control (=100%). 
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Table 4- 1:  Summary of IC50 values for OP compounds against plasma TG and 
rFXIII-mediated amine incorporation and peptide crosslinking activity. 
 
NR = significant inhibition observed but IC50 value was not reached. NE = no significant 
effect. 
Organophosphorus 
compound 
IC50 (µM) 
Plasma TG-
mediated 
amine 
incorporation 
Plasma TG-
mediated 
peptide 
crosslinking 
rFXIII-
mediated 
amine 
incorporation 
rFXIII-
mediated 
peptide 
crosslinking 
PSP NR NR 45 (±0.04) 21 (±0.03) 
Diazinon NR NE 17 (±0.03) 16 (±0.05) 
Diazoxon NR NR 17 (±0.05) 62 (±0.06) 
Chlorpyrifos NE NE 60 (±0.08) 2.7 (±0.06) 
Chlorpyrifos oxon NR NR NR 6.5 (±0.06) 
Parathion NR NR 18 (±0.06) 15 (±0.04) 
Paraoxon NR NE NR 13 (±0.03) 
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4.2.3 SDS-PAGE and 2D-PAGE analysis for rhodamine-PSP binding 
to plasma TG 
In order to determine whether PSP could bind covalently to plasma TG samples, a pure 
rFXIIIa (5µg), depleted plasma as described in (section 2.2.1.2.3) and whole plasma samples 
both (15 µg), all were incubated with rhodamine labelled-PSP, as described in (section 
2.2.8.1). The samples were subjected to SDS-PAGE and visualized under green light, 
followed by staining with InstantBlue TM to confirm the presence of protein in each sample. 
As shown in Fig 4.5 A, a polypeptide band of approximately 83 kDa in each sample was 
labeled with Rh-PSP. A number of other bands were also labeled in whole and depleted 
plasma. The gels were stained with InstantBlue TM, Coomassie blue-based staining solution 
for protein gels, to confirm the presence of proteins in samples (Fig 4.5 B). The 
quantification of purified FXIIIa, depleted plasma and whole plasma bands clearly revealed 
that differences in fluorescence intensity when Rh-PSP was present compared to extracts 
incubated with 0.25 % (v/v) DMSO (control) (Fig 4.5 C).  
In addition, the identification of binding was also tested by 2D-PAGE. Depleted plasma (100 
µg) was incubated with 0.25 % (v/v) DMSO (control) and 25µM of Rh-PSP, as described in 
(section 2.2.9). Visualization of 2D gels under green incident light source (520 nm) revealed 
that the 2D gel separation of depleted plasma incubated with Rh-PSP showed several 
fluorescent protein spots (Fig 4.6 B) compared to 2D-PAGE analysis of the control sample 
of depleted plasma without labeled PSP, which did not show any fluorescent spots (Fig 4.6 
A). After visualization, the gels were stained with InstantBlue TM stain to confirm the 
presence of proteins in samples (Fig 4.6 C, D).  
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Figure 4- 5: Visualization of proteins labelled with rhodamine-PSP (SDS-PAGE). 
 
 
 
 
 
Pure rFXIIIa (2.5µg), depleted and whole plasma samples (15 µg) and were incubated 
in the absence (lane 1, lane3, lane 5) and presence (lane 2, lane 4, lane 6) of 25 µM 
Rh-PSP, as indicated in Materials and Methods. Panel A) Gels were visualized under 
green incident light source (520nm) using a LAS4000 imaging system. Panel B) Gels 
were stained with InstantBlue TM to confirm the presence of protein bands. Panel C) 
Densitometric analysis for Rh-PSP binding, DMSO represents the control incubated 
in the absence of Rh-PSP. Data represent the mean of fluorescence intensity ±SEM 
from three independent experiments. *p<0.05, **p<0.01, ***p<0.001 versus non OP-
treated control (=100%). 
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Figure 4- 6: Visualization of proteins labelled with rhodamine-PSP (2D-PAGE). 
 
Depleted plasma (100µg) was untreated or treated with Rh-PSP (one hour at 37ºC, 25µM) 
and samples processed and analysed by 2D-PAGE using pH 3-10 gradient strips. Gels 
were visualized under green incident light source (520 nm) using a LAS4000 imaging 
system. Panel A) control sample containing100 µg of depleted plasma incubated with 
0.25% (v/v) DMSO; Panel B) 100µg of depleted plasma incubated with 25µM of Rh-PSP, 
(C and D) control and labeled PSP treated sample Gels, respectively, were stained with 
InstantBlue TM to confirm the presence of protein bands.  
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4.2.4 SDS-PAGE analysis for rhodamine-PSP competition binding to 
plasma TG and rFXIII 
In order to determine whether Rh-labelled PSP was binding in the same manner as unlabeled 
PSP a competition assay was carried out. For this, pure FXIIIa and depleted plasma were 
incubated in the presence and absence of labelled and unlabeled PSP, or both forms of PSP, 
also testing the competition with labelled PSP and unlabeled PSP and other OP on purified 
rFXIIIa, prior to analysis by SDS-PAGE and fluorescence imaging, as indicated in (section 
2.2.8.2). The results shown in Fig 4.7 A indicate that the intensities of fluorescent bands 
decreased in purified rFXIII and depleted plasma samples that contain both labeled and 
unlabeled PSP compared to those incubated with labeled PSP only. Densitometric analysis 
confirmed that the signal intensity for an 83 kDa band was significantly reduced in the 
presence of competition by unlabeled PSP for both pure rFXIIIa and depleted plasma (Fig 
4.7 C).  
Further competition assays were then performed with the other OPs.The results of such 
competition binding assays, which are shown in lanes 3, 4, 5 (Fig 4.8 A, Fig 4.9 A) and 6 
(Fig 4.9 A) showed variable fluorescence intensity changes compared to the controls in lane 
1 0.25% (v/v) (DMSO) and lane 2 (Rh-PSP) (Fig 4.8 A, Fig 4.9 A). The difference between 
control untreated protein lane 1 and the treated protein with labeled Rh-PSP (lane 2), as 
before, showed significant strong intensity of binding (Fig 4.8 A, Fig 4.9 A). The 
quantification of band fluorescence intensity for competition binding compared to control 
(labeled protein with Rh-PSP) showed that the most significant intensity difference by 2 fold 
decreased was by the unlabeled CPO comparing to quantification value of the control 
(labeled protein with Rh-PSP) on that gel (Fig 4.9 C), also DZO was the most competitive 
compound compared to the control (labeled protein with Rh-PSP) on the other gel (Fig 4.8 
C),  whilst the quantification of DZ and POX bands showed slight but not significant 
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intensity decreases compared to their control (labeled protein with Rh-PSP) on each gel (Fig 
4.8 C) and (Fig 4.9 C) respectively.  The gels were stained with InstantBlue TM stain to 
confirm the presence of proteins in samples (Fig 4.7 B, 4.8 B, 4.9 B). Overall, the results 
showed fluorescent label Rh-PSP binding in all samples variability in the amount of 
competition by other OPs.  
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Figure 4- 7: Visualization of proteins labeled with competition binding of rhodamine-
PSP and PSP.  
 
Pure rFXIIIa (2.5µg) and depleted plasma samples (15µg) were incubatedfor 30 min on 
ice then for one hour at 37ºC with 0.25% (v/v) DMSO (Lane2, lane5), 25µM Rh-PSP (lane 
1, lane 4) and both 25µM Rh-PSP + 100µM PSP (lane3, lane 6). Panel A) Gels were 
visualized under green incident light (520nm) using a LAS4000 imaging system. Panel B) 
Gels were stained with InstantBlue TM to confirm the presence of protein bands. Panel C) 
Densitometric analysis for rhodamine-PSP binding. Data represent the mean of 
fluorescence intensity ±SEM from three independent experiments. *p<0.05, ***p<0.001, 
****p<0.0001 versus non OP-treated control (=100%). 
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Figure 4- 8: Visualization of proteins labeled with competition binding of rhodamine-
PSP and unlabeled PSP, DZ, and DZO. 
 
Pure rFXIIIa (2µg) was incubated for 30 min on ice then for one hour at 37ºC with 0.25% 
(v/v) DMSO (Lane1), 25µM of Rh-PSP (lane 2) and both 25µM of Rh-PSP + 200µM of 
PSP, DZ, DZO (lane3, lane 4, lane 5); respectively. Panel A) Gels were visualized under 
green incident light (520nm) using a LAS4000 imaging system. Panel B) Gels were 
stained with InstantBlue TM to confirm the presence of protein bands. Panel C) 
Densitometric analysis for rhodamine-PSP binding. Data represent the mean of 
fluorescence intensity ±SEM from three independent experiments. *p<0.05, **p<0.01, 
****p<0.0001 relative to the DMSO control (=100%). 
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Figure 4- 9: Visualization of proteins labeled with competition binding of 
rhodamine-PSP and unlabeled CPF, CPO, PTH, POX. 
 
Pure rFXIIIa (2µg) was incubated for 30 min on ice then for one hour at 37ºC with 
0.25% (v/v) DMSO (Lane1), 25µM of rhodamine-PSP (lane 2) and both 25µM of 
rhodamine-PSP + 200 µM of CPF, CPO, PTH, POX (lane3, lane 4, lane 5, lane 6); 
respectively. Panel A) Gels were visualized under green incident light (520nm) using a 
LAS4000 imaging system. Panel B) Gels were stained with InstantBlue TM to confirm 
the presence of protein bands. Panel C) Densitometric analysis for Rh-PSP binding. 
Data represent the mean of fluorescence intensity ±SEM from three independent 
experiments. *p<0.05, ****p<0.0001 relative to the DMSO control (=100%). 
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4.2.5 Effects organophosphorus compounds on clot product formation 
In order to study the OPs effect on clot stabilization, a human plasma turbidimetric assay 
was applied to measure the amount of clot formed. The results showed that method was not 
sensitive enough to detect changes occurring under OP treatment. For this reason, an 
alternative method was developed for studying the impact of OPs on clot stabilization by 
measuring the fibrinolysis product D-dimer. Plasma (~1.5 mg protein /ml) samples were pre-
incubated 30 min on ice with  either 25 or 50 µM concentrations of OPs, after which samples 
were incubated for three hours at 37ºC to form the clot before measuring  D-dimer formation 
by sandwich ELISA, as indicated in (section 2.2.2). The observation from this experiment 
revealed a significant reduction by 20-40 % in D-dimer formation at both concentrations 
sequentially (Fig 4.10 A, B). It was clear that DZ caused the strongest inhibition at both 
concenterations.  
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Figure 4- 10: D-Dimer levels in human plasma treated with organophosphorus 
compounds.  
 
Diluted human plasma samples (~1.5 mg/ml) were pre-incubated for 30 min on ice 
with either a 25 µM or 50 µM concentration of the OPsPSP, DZ, CPF, CPO, PTH 
and POX. To start the clot, 5 mM CaCl
2
 was added and incubated for three hours 
at 37ºC, after which D-dimer was quantified using the D-Dimer Human Simplestep 
ELISA®Kitassay. Data points represent the mean ± SEM of normalized plasma TG 
activity from four independent experiments. **p<0.01, ***p<0.001, ****p<0.0001 
versus non OP-treated control (=100%). 
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4.2.6 Identification of protein organophosphate adduct by mass 
spectrometry 
To identify novel OP adducts on plasma TG protein, analysis was done by the team of  John 
van Geest Cancer Research Centre using the Sciex TripleTOF 6600 mass spectrometry was 
carried out for 5 μg of rFXIIIa pre-incubated for 30 min at 4ºC with PSP, DZO, CPO and 
POX at final concentrations of 200 µM and a control sample incubated with 0.25% DMSO, 
before a further incubation for 1 h at  37 ºC with 6.67 mM CaCl2 as indicated in (section 
2.2.6). As the analyses have produced a very large data set, this work focuses only on the 
mass shifts corresponding to the covalent binding of PSP, O-diethylphosphorylation, O-
ethylphosphorylation and phosphorylation (STY) (Fig 4.11 A, B, C, D, E). Comparing to 
control sample the results showed after extract the matching with control sample that the 
sample of rFXIII incubated with PSP showed some binding of PSP at serines 341 and 711. 
On the other hand, the oxon OPs showed a variety of O-diethylphosphorylation, O-
ethylphosphorylation and phosphorylation (STY), but the CPO showed the highest number 
of O-diethylphosphorylation on tyrosine (Y) and lysine (K) residues, respectively. Fig 10.12 
summarizes all positions of OP adduct binding. 
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Figure 4- 11: Mapping of proposed OP adducts on rFXIIIa following mass 
spectrometry. 
 
Sample (5 µg) of purified rFXIIIa was treated with (A) solvent vehicle 0.25 % (v/v) DMSO 
as a control, and 200 µM of (B) PSP, (C) DZO, (D) CPO and (POX) with emphasis on band 
shifts for the binding of  PSP, O-ethylphosphoryltion and O-diethylphosphorylation. The cut 
off value AScore ≥ 20. 
Chapter 4 
114 
 
 
 
Figure 4- 12: Summary of rFXIIIa protein modification after incubation with OP 
compounds.  
 
This table is a summary of the modifications mapped in Fig 12. The orange colour 
represents the individual modification on amino acids, and the diagonal stripes represent 
similarity compared to the control (rFXIIIa with 0.25 % (v/v) DMSO). 
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 Discussion 
FXIIIa is a transglutaminase that has multiple biological actions in the body. It is involved 
in last step of haemostasis, its function there being considered very essential to stabilize the 
fibrin mesh by cross-linking lysine-glutamyl side chains to form an unbreakable clot 
(Martins et al., 2014). Any abnormalities on FXIIIa may cause serious bleeding (Muszbek 
et al., 2011). In the present study, the ability of OPs to interfere with FXIIIa activity and the 
probability of their binding to FXIIIa were studied. Overall, the results presented in this 
chapter showed that some of the OPs can inhibit transamidase activity of plasma and pure 
FXIIIa measured by amine incorporation and peptide cross-linking assays, but the inhibition 
was greater with purified FXIIIa. This corresponded to results of inhibition of plasma clot 
formation that were measured by D-Dimer ELISA. Analysis by 1D and 2D SDS-PAGE and 
mass spectrophotometry showed that OPs were also capable of covalent binding with 
rFXIIIa. 
In assays involving pre-exposure to OPs, transamidase assays (Fig 4.1 & 4.2) showed slight 
but significant inhibition of plasma TG-mediated amine incorporation and peptide 
crosslinking activities, although an IC50 value was not reached. CPF showed no significant 
effect on both activities, whereas there were no significant changes induced by DZ or POX 
in plasma peptide crosslinking activity. However, data for other OPs suggested that plasma 
TG-mediated amine incorporation activity was more sensitive to OP toxicity, where CPO 
was the most effective inhibitor of plasma TG activity. In contrast, rFXIIIa-mediated amine 
incorporation and peptide crosslinking activities both showed higher sensitivity to OP 
toxicity than plasma TG (Fig 4.3 & 4.4) and IC50 values were determined. Moreover, the 
rFXIIIa-mediated peptide crosslinking activity showed more sensitivity to OP toxicity than 
did the amine incorporation assay. Surprisingly, parent compounds in both activities of 
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rFXIIIa had more potency than the metabolite form. For example, CPO showed the 
statistically significant effect at 0.8 µM (Fig 4.4 F) on rFXIIIa-mediated peptide crosslinking 
activity but 50 % of activity was lost by ≤ 6µM of CPO concentration (IC50 6.5 µM); 
however, CPF (Fig 4.4 C) was the most potent among the others where more than 50 % of 
activity was inhibited by ≤ 3µM of CPF concentration (IC50 2.7 µM). Also, it was noticeable 
the significant effect of parent compounds DZ and PTH compared to their oxon metabolite 
forms in amine incorporation activity with rFXIIIa and plasma TG, respectively. In addition, 
PSP showed significant effect on both rFXIIIa and plasma TG -mediated peptide 
crosslinking and amine incorporation activities, respectively. 
Some studies suggest that PSP may alter cell signaling and that the latter is responsible for 
the increased activity noticed in the cytosolic TG (Howden, 2003; Hargreaves et al., 2006). 
However, studies on cultured N2a neuroblastoma and HepG2 hepatoma cell lines, PSP (3µM) 
exposure resulted in altered tissue transglutaminase-mediated amine incorporation activity, 
where it was decreased in N2a and increased in HepG2 cells (Harris et al., 2009). Moreover, 
Muñoz, et al. (2010) showed that tissue transglutaminase-mediated amine incorporation 
activity in rat C6 glioma cells increased after 24h exposure to 10µM chlorpyrifos. In the 
latter study, increased activity of guinea pig liver TG2 in vitro following treatment with OP 
suggested the possibility of a direct interaction between OPs and TG. Although, it has been 
pointed that parent OPs compound are weak inhibitors of their acute toxicity target AChE 
and their bioactivated form the oxons are considered the primary acute toxicants in nerve 
tissue (Poet et al., 2003), in the current study some of the parent compounds showed more 
inhibitory potential against TG activity than their oxon form.  
The inhibition effect of DZ, CPF, PTH could be due to the reaction either with forms of 
parent, oxon, or may be with one of their common metabolite products, without oxidation 
the diethylthiophosphate (DETP), or after oxidation the diethylphosphate (DEP), 
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respectively, since the presence of pesticide parent and their metabolites product were 
indicated (including DETP and DEP) in human biological fluids using liquid 
chromatography-mass spectrophotometry (Manini et al., 2004). On the other hand, the effect 
of inhibition could be due to a specific reaction based on a structural effect of DZ, CPF, PTH 
or with their final metabolite products, 2-isopropyl-4-methyl-6-hydroxpyrimidine (IMHP), 
3,5,6-TCP, p-nitrophenol, respectively (Brzak et al., 1998; Poet et al., 2003). In addition, 
the end products of OP metabolites may adversely affect human health (Melching-Kollmuß 
et al., 2010; Rathod & Garg, 2017). It has been suggested that the toxic effect of phenol 
compounds that may be released from these pesticides and their derivatives and the side 
effects of chronic exposure may cause pathological changes due to their accumulation in the 
skin, esophagus, blood plasma, lungs, liver, kidneys and also the urogenital tract 
(Michałowicz & Duda, 2007). The strength of toxic impact of these phenol compound stems 
from the position and the type of the substituent which include a range of components 
including chlorine atoms, nitrate, methyl or ethyl groups in the case of pesticide OPs 
(Michałowicz & Duda, 2007). It has been reported that metabolite forms of DZ, CPF, PTH 
the IMHP, 3,5,6-TCP, p-nitrophenol, respectively, are classified as Carmer class III 
compounds that have structural features that do not permit a strong assumption of safety and 
could even have significant toxicity (Melching-Kollmuß et al., 2010).  
The significant effect of the parent compound CPF on pure FXIII- mediated amine 
incorporation (Fig 4.3 C) and peptide crosslinking (Fig 4.4 C) in vitro might be due to 
binding of the released tri chlorophenols attached to thio organophosphorous compound with 
higher potency than those attached to the oxidized organophosphorous. In this respect, 
previous study has done by Boyd et al. (2001) demonstrated mono-, di-, and tri-
chlorophenols that used in agriculture objective to study their effect on different kinds of 
bacteria and the results manifested that the toxicity of chlorophenols to the bacteria was 
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dependent upon the position of the chlorine atoms on the benzene ring and the degree of  
chlorination. Moreover, it has been indicated that the metabolite form of DZ either the active 
DZO or IMHP, have much higher Michelis constant Km value than CPF metabolite products 
either the CPO or 3,5,6-TCP, suggesting that the toxicity effect of DZ will be much lower 
than that of CPF, due mostly to the quantity of bioactivation of the parent pesticide (Poet et 
al., 2003). However, in the current work that was opposite to DZ effect on plasma (Fig 4.1 
B) and pure FXIIIa (Fig 4.3 B) -mediated amine incorporation activity, which could be direct 
effect of parent thiophosphate toward enzyme activity especially on pure FXIII at higher 
concentration where 50% of the activity was lost. These findings suggest that DZ might be 
more effective in the biological environment, as in plasma, as it has less effect on pure 
FXIIIa-mediated amine incorporation activity. Also, it could be speculated that PTH, which 
also inhibited FXIIIa activity by more than 50% in both amine incorporation (Fig 4.3 D) and 
peptide crosslinking assays (Fig 4.4 D) compared to lower effects on both activities in 
plasma TG (Fig 4.1 & 4.2 D). Thus, the current finding and previous studies suggest that 
OPs can interact with and/or disrupt TG activity.  
The low effect of OPs on plasma samples compared to their stronger potent effect on pure 
FXIIIa could be due the lack of a biological environment, which has many of proteins and 
chemical compounds that may interact with OPs and decrease their effect on FXIII. For 
example, several studies showed that OPs bind and interact with other plasma proteins such 
as ChEs, albumin and transferrin (Li et al., 2008; Marsillach et al., 2013).   
Albumin is the most abundant plasma protein, representing more than 50% of the total 
protein in human blood plasma (Li et al., 2007). It is known that albumin can form stable 
adducts with OPs (Li et al., 2007; Tarhoni et al., 2008; Chen et al., 2013). Depletion of major 
proteins in plasma is one potential technique to improve the detection of low abundant 
proteins that could be disease biomarkers (Echan et al., 2005). For that reason, the possibility 
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that the presence of albumin protein in plasma could decrease the amount of OP available to 
interact with plasma TG should be considered.  
The possibility that the inhibitory effects of PSP on FXIIIa activity involved covalent 
binding of PSP to plasma TG was confirmed by the detection on SDS-PAGE of rhodamine-
PSP binding to pure FXIIIa, and a similar molecular weight band in depleted plasma. This 
is the first time that covalent binding of OP to FXIIIa has been demonstrated. It was 
interesting to note that there were other labelled bands in depleted plasma and a smear of 
bands throughout the entire gel for whole plasma proteins (Fig 4.5), suggesting that other 
serum proteins were capable of binding covalently to PSP. The other PSP binding proteins 
presumably correspond to those previously identified as OP binding, namely albumin and 
ChEs, etc. (Marsillach et al., 2013). However, it will be of interest to determine whether, in 
addition to FXIIIa, other novel PSP-binding serum proteins can be detected in depleted 
plasma samples. The depleted plasma protein extract incubated with labelled PSP was 
separated by 2D-PAGE and the result compared to control showed several labeled PSP 
binding spots that suggest other low abundant proteins in depleted plasma can interact with 
PSP; however, due to constraints of time, protein spots could not be identified by further 
analysis (Fig 4.6).  The data obtained from follow-up competition experiments using pure 
FXIIIa and depleted plasma (Fig 4.7) in which samples were pre-incubated with unlabeled 
PSP prior to addition of labelled PSP confirmed that the Rh-PSP was binding to the same 
site as non-labelled PSP. The competition assay was applied again on pure FXIIIa with the 
other (non-labelled) OPs and labelled PSP showing significant competition in binding site 
in specific cases. For example, DZ and POX demonstrated slightly weaker fluorescense 
comparing to the intensity of only labelled PSP binding, suggesting that binding may not be 
near the PSP binding site. However, the other OPs showed higher competition with non-
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labelled OP on the binding site and the variation in competition which could be a sign of 
more than one binding site or that they might not all bind at to the same positions. 
Clot stabilization under OP treatment was studied by turbidimetric clot method, which 
detects the scattering of light by the forming clot but it was hard to detect any significant 
changes using this approach, suggesting no detectable effect on clot size. However, the D-
dimer assay was then adopted as a more sensitive method to show changes in the plasma 
clotting cascade, being used as diagnostic and management tool for the monitoring of 
thrombotic and bleeding disorders (Bates, 2012).   
In the current study the clot was created after plasma samples were treated with or without 
two concentrations (25 and 50 µM) of OPs, after which and D-dimer levels were measured 
to determine whether the fibrin mesh exhibited the same level of covalently crosslinked D-
dimers within fibrin monomers (Fig 4.10). Seemingly, all OPs had significant effects on clot 
formation, which eventually affects D-dimer formation as a consequence. This is in broad 
agreement with the significant inhibition effect of OPs on TG-mediated transamidase 
activities, although the relative contribution of disrupted amine incorporation and protein 
crosslinking remain to be determined. It was noticeable that DZ had the most potent effect 
at both concentrations in the D-dimer assay, reaching about 50% decrease of D-dimer level 
in the sample with 50 µM of DZ, whereas DZ had a more significant on TG-mediated amine 
incorporation activity. This could reflect the possibility that DZ may interfere with either 
mechanism or activity of TG in the clotting cascade at least in part through an amine 
incorporation mediated pathway. Previous studies have reported that are high levels of 
natural polyamines in the human body, which may serve as substrates for transglutaminase 
in cells and body fluid (Folk et al., 1980). 
Chapter 4 
121 
 
The indication from much of the literature is that OP compounds bind to proteins that have 
an active site serine, such as serine hydrolases; however, other studies demonstrated that 
there are other sites that could be possible targets for OP adduct fromationm, such as tyrosine 
residues in tubulin, albumin, and transferrin (Li et al., 2008; Marsillach et al., 2013). Mass 
spectrometry analysis is a very sensitive technique to determine the location of covalent 
binding site(s) on proteins such as purified protein FXIII, which has an active site 
cysteine314. Only the metabolite OP compounds were analysed by MS in the current study 
and it was obvious from the results (Fig 4.11) that there may be several modifications and 
different adducts in different binding sites, by comparing mass shifts to the control sample 
(Fig 4.11 A). The MS results was numbered the amino acids with extra methionine in the 
beginning and ending of the protein sequence. However, the numbering was corrected 
according to the literature, which highlighted that serine is in the next to the last position, 
which favors the elimination of initiator methionine, and then in the mature molecule NH2 
terminal serine residue acetylated and amino acid numbering starting with the Ser amino 
acid (Muszbek et al., 2011). The Ser-413, which is present in the catalytic core domain, was 
the common phosphorylated site by PSP, DZO, CPO, and POX (Fig 4.11 B, C, D, & E), 
which could be the competing site of binding with PSP. The PSP adducts showed fewer 
binding sites than the oxon metabolite OPs and they were mainly on two threonine and two 
serine amino acids, but it was interesting to note that Thr293-phosphorylated is only a few 
amino acids away from active site Cys314 and Ser340-PSP is nearby Asp343. Studies 
reported that a strong salt bridge between Arg11 in AP-FXIII domain and Asp343 in core 
domain to make Cys314 inaccessible for substrate and other chemical molecules (Muszbek 
et al., 2011).  On the other hand, the most modification change at wide range of 50:50 
tyrosine and lysine diethylphosphorylated was observed for CPO. The 
diethylphosphorylated adduct was disrtributed between the β-sandwich and catalytic core 
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domains, the closest to catalytic active site were Tyr302 and 311. Moreover, CPO formed 
an ethylphosphorylated adduct on Ala22 in AP-FXIII and Lys570 in β-barrel 1 domains. 
Some studies refer to the fact that a major adduct of CPO on albumin is tyrosine-
diethylphosphorylated and becomes irreversibly modified in vivo in humans poisoned by 
CPF (Li et al., 2013). Also in vitro experiments showed that CPO can covalently modify 
tyrosine on some proteins including keratins, tubulin, and transferrin (Schopfer et al., 2010). 
In addition, some modifications were detected on rFXIII incubated with DZO and POX, 
including ethylphosphorylated and diethylphosphorylated close from Arg11 in AP-FXIII 
domains which could affect the stability of the salt bridge between Arg11and Asp343 and as 
a result affect the catalytic site position Cys314. Interestingly, DZO, CPO, and POX 
treatments induced ethylphosphorylated-adducts on different amino acid spread all over the 
main four domains, all metabolite OP adducts formed and their positions on the rFXIII are 
demonstrated in Fig 4.12. Due to constraints of time, adducts formed with the parent 
compound have not yet been studied but should be considered in further work. 
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5.  
Chapter 5: Effects of organophosphorous 
compounds on thrombin 
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 Introduction 
The key factor of coagulation, which is one of the important dynamic biological processes 
in blood, is the proteolytic enzyme thrombin. Thrombin is a serine protease that plays an 
essential role in the whole process, cleaving over 12 substrates and interacting with at least 
6 cofactors involved in clot formation (Huntington, 2005). It amplifies the coagulation 
factors and activates platelet aggregation, moreover controlling the activity of coagulation 
inhibitors (Huntington, 2012). However, any thrombin dysfunction may lead to 
haemorrhagic disorders (Stief, 2006). 
OPs have been identified as serine protease and esterase inhibitors due to 
organophosphorylation of the active site serine (Chambers & Oppenheimer, 2004). The main 
OP serine esterase targets are the cholinesterases AChE and BChE, the inhibition of which 
is nowadays the standard method utilized for the biological monitoring of OP exposure 
(Marsillach et al., 2013). Moreover, many studies refer to other proteins as OP sensitive 
serine hydrolases, such as digestive proteases (chymotrypsin, trypsin and elastase), NTE, 
and some blood clotting factors, such as thrombin, plasmin, kallikrein, etc. (Quistad & 
Casida, 2000; Reiner, 2001; Quistad & Casida, 2005). Unfortunately, studies of OP effects 
on blood coagulation serine protease factors are limited. Henson et al. (1976) confirmed that 
high concentration of the OP diisopropylphosphonofluoridate (DFP) inhibited serine 
esterases (proteases) including thrombin, which stimulates platelet granule secretion.  In 
addition, when the clotting factors thrombin, plasmin, and kallikrein were examined in the 
presence of some of OPs, the results showed that thrombin was the most sensitive to 
inhibition by the most potent inhibitors in the order: tributylphosphorotrithioate (tribufos) 
also known as DEF, phenyl saliginen cyclic phosphate (PSCP or PSP), and DFP (Quistad & 
Casida, 2000). Furthermore, a significant inhibitory and prolongation effect of POX has been 
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observed in the thrombin activity coagulation test suggesting that it interferes with thrombin 
activity (Golderman et al., 2016). 
The work in this chapter was planned to study the effects of a range of concentrations of the 
OPs PSP, DZ, DZO, CPF, CPO, PTH, POX on the activities of purified and plasma thrombin. 
It was also of interest to study covalent binding and competitive binding using SDS-PAGE 
and image analysis of thrombin incubated with a fluorescent rhodamine-PSP (Rh-PSP) probe.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
126 
 
 Results 
5.2.1 Effects of organophosphorus compounds on purified thrombin 
activity 
Thrombin assays were performed to investigate whether the OPs were able to affect the 
activity of purified human thrombin. Purified thrombin samples were pre-incubated 30 min 
on ice with  a range of OP concentrations prior to the addition of 0.5 mM thrombin substrate 
Sar-Pro-Arg-p-nitroanilide, as indicated in (section 2.2.5). The results showed  slight (10 %) 
but statistically significant inhibition  of purified thrombin activity  by PSP (Fig 5.1 A), and 
the most significant inhibition effect was from CPF on purified thrombin (Fig 5.1 C) with 
an IC50 value of 22 µM, but only concentrations of 25 and 50 µM showed inhibition 
effects >50 %, and >80 %, respectively. In contrast, the other OPs showed no significant 
effect under the conditions tested.   
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Figure 5- 1:  Effects of OPs on pure thrombin activity. 
 
Diluted human pure thrombin samples (~0.05 U/ml) were incubated 30 min on ice with a 
range of concentrations of OPs, as indicated in the graphs. Plots shown are for: A) PSP, 
B) diazinon, C) chlorpyrifos, D) parathion, E) diazoxon, and F) chlorpyrifos oxon, G) 
paraoxon. The reaction was initiated by adding 0.5 mM Sar-Pro-Arg-p-nitroanilde. Data 
points represent the mean percentage ± SEM of pure thrombin specific activity from three 
independent experiments. *p<0.05, ****p< 0.0001 versus non OP-treated control 
(=100%). 
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5.2.2 Effects of organophosphorus compounds on human plasma 
thrombin activity 
In order to study OP effects on human plasma thrombin activity, the assay was first of all 
optimised. As the optimisation of plasma thrombin concentration with  a range of OPs 
concentrations consumed a lot of subtrate reagent, plasma samples were pre-incubated 30 
min on ice with  either 25 or 50 µM concentrations of OPs, followed by the addition of 1.6 
mM thrombin substrate Sar-Pro-Arg-p-nitroanilide to initiate the reaction, as indicated in 
section 2.2.1.2.2. The outcome of experiments studying the effects of 25 µM OPs on plasma 
thrombin activity showed that there was approximately 40% inhibition of plasma thrombin 
activity by CPF only (Fig 5.2 A). However, 50 µM CPF, CPO, and POX showed significant 
inhibition of thrombin activity. Overall, CPF showed a greater inhibitory effect than the other 
OPs against plasma thrombin activity at both concentrations.    
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Diluted human plasma samples (~0.2 mg/ml) were pre-incubated for 30 min on ice with 
either (A) 25 µM or (B) 50 µM concentrations of the OPs PSP, DZ, CPF, CPO, PTH and 
POX. The raection was initiated by adding 1.6 mM Sar-Pro-Arg-p-nitroanilde. Data points 
represent the mean ± SEM of pure thrombin specific activity from three independent 
experiments. **p<0.01, ****p< 0.0001 versus non OP-treated control (=100%). 
 
 
Figure 5- 2: Effect of OPs on plasma thrombin activity. 
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5.2.3 SDS-PAGE analysis for rhodamine-PSP competition binding to 
human purified thrombin. 
In order to determine whether Rh-labelled PSP was binding in the same manner as unlabeled 
PSP and other OPs on purified thrombin, a competition assay was carried out. For this, 
human purified thrombin samples were incubated in the presence and absence of labelled 
PSP, also testing the competition with labelled PSP and unlabeled PSP and other OP, prior 
to analysis by SDS-PAGE and fluorescence imaging as indicated in section 2.2.8.2. The 
results shown in Figures 5.3A and 5.4 A infer that the intensities of fluorescent bands after 
Rh-PSP binding are decreased in purified thrombin when competed out with unlabeled OPs. 
The difference in the intensity between untreated protein (lane 1) and the protein incubated 
with labeled Rh-PSP (lane 2) indicated strong intensity of PSP binding to thrombin in lane 
2 (Fig 5.3 A, Fig 5.3 A).The competition binding on purified thrombin between unlabeled 
and labelled OPs in lanes 3, 4 and 5 (Figs 5.3 A and 5.4 A) showed visibly lower intensity 
of fluorescence compared to controls in lane 1 0.25% (v/v) (DMSO) and lane 2 (Rh-PSP) 
(Fig 5.3 A, Fig 5.4 A).  
Moreover, the densitometric analysis confirmed that the signal intensity for the 35 kDa 
thrombin band was significantly reduced in the presence of competition by unlabeled OPs 
for purified thrombin in lanes 3, 4, 5 (Figs 5.3 and 5.4 C) and 6 (Fig 5.4 C). The quantification 
of band intensities of competing binding compared to control (labeled protein with Rh-PSP) 
showed that intensity was reduced 4-fold with unlabeled PSP, DZ, and DZO (Fig 5.3 C), and 
about 2-fold in the case of unlabeled CPF, CPO, PTH and POX (Fig 5.4 C). The gels were 
stained with InstantBlue TM stain to confirm the presence of protein in samples (Fig 5.3 B, 
5.4 B). Overall, the results showed competition in all samples incubated with both 
labelled PSP and unlabeled OPs.  
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Figure 5- 3:  Visualization of thrombin labeled with competition binding of 
rhodamine-PSP and unlabeled PSP, DZ, DZO. 
  
Pure thrombin (2µg) was incubated for 30 min on ice with 0.25% (v/v) DMSO (Lane1), 
25µM of Rh-PSP (lane 2) and both 25µM of Rh-PSP + 200µM of PSP, DZ, DZO (lane3, 
lane 4, lane 5); respectively. Panel A) Gels were visualized under green incident light 
(520nm) using a LAS4000 imaging system. Panel B) Gels were stained with InstantBlue 
TM to confirm the presence of protein bands. Panel C) Densitometric analysis for Rh-PSP 
binding. Data represent the mean of fluorescence intensity ±SEM from three independent 
experiments. ***p<0.001, ****p<0.0001 relative to the DMSO control (=100%).  
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Figure 5- 4:  Visualization of thrombin labeled with competition binding of 
rhodamine-PSP and unlabeled CPF, CPO, PTH, POX.  
 
Pure thrombin (2µg) was incubated for 30 min on ice with 0.25% (v/v) DMSO (Lane1), 
25 µM of Rh-PSP (lane 2) and both 25 µM of Rh-PSP + 200 µM of CPF, CPO, PTH, POX 
(lane3, lane 4, lane 5, lane 6); respectively. Panel A) Gels were visualized under green 
incident light (520nm) using a LAS4000 imaging system. Panel B) Gels were stained with 
InstantBlue TM to confirm the presence of protein bands. Panel C) Densitometric analysis 
for Rh-PSP binding. Data represent the mean of fluorescence intensity ±SEM from three 
independent experiments. **p<0.01, ****p<0.0001 relative to the DMSO control 
(=100%). 
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 Discussion 
Thrombin is a coagulation factor that is generated in the last part of coagulation (common 
pathway) but its role in haemostasis in not limited (Huntington, 2005). Abnormalities in 
thrombin generation could lead to unstable clot formation, resulting in a serious bleed (Lupu 
et al., 2016). In the current work, the effect of OPs on thrombin activity and the chance of 
their binding to purified thrombin were studied. Overall, the results presented in this chapter 
showed that a few of the OPs can inhibit plasma thrombin activity in high concentration, but 
only CPF caused inhibition of activity in both purified and plasma thrombin. The possibility 
of covalent binding of PSP to thrombin protein was confirmed by the detection on SDS-
PAGE of rhodamine-PSP binding to purified thrombin. Moreover, the data obtained from 
competition experiments, in which samples were pre-incubated with unlabeled OPs prior to 
addition of labelled PSP, indicated that the rhodamine-PSP was binding to the same site as 
non-labelled OPs. 
The optimization experiments of thrombin activity demonstrated a protein and substrate 
concentration-dependent increase in both purified and plasma. Unfortunately, these 
optimizations consumed more substrate than expected, causing a shortage in substrate 
reagent.  
In the current work human purified thrombin activity was slightly affected by PSP, but it 
was most sensitive to CPF at 25 and 50 µM concentrations in agreement with the effect of 
CPF on plasma thrombin (Fig 5.1 C & 5.2 A, B). The higher potency of the CPF effect on 
purified thrombin might be due the lack of a biological environment comparable to that in 
plasma samples. This could be due to a potential interaction with either the leaving group 
(diethylthiophosphate) or with phosphate atom replacing the leaving group position. For 
example, it has found that adducts were formed on highly purified human BChE incubated 
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with DZ, and 3.6 mg/ml BChE over 15 h exposure to 50 µM DZ effect reduced activity by 
52% suggesting ‘slow’ inhibition, which could occur through a thiono-thiolo rearrangement 
(Tacal & Lockridge, 2010). Also, the CPF significant effect on inhibition plasma thrombin 
activity was 2 and 6-fold different from 25 and 50 µM purified thrombin, respectively, 
suggesting that the biological environment had interfered with CPF potency on plasma 
thrombin activity. A developed analytical method to measurement directs the oxon 
and TCP formation from CPF compound has found that the bioactivation of CPF by 
CYPs to the oxon metabolites form CPO leads to a more potent effect in the biological 
environment (Poet et al., 2003). Moreover, this could extend to deactivation of CPO by both 
CYPs and PON1 to TCP (Poet et al., 2003; Kumar, 2015). This agrees with current findings 
for CPO inhibition of plasma thrombin (Fig 5.2 B). In addition, in the current work the 
potency effect of POX on plasma thrombin (Fig 5.2 B) revealed that POX could have a 
major effect on plasma thrombin at higher concentrations.  
CPO and POX inhibition effects were previously studied in vitro on 0.2 U purified thrombin 
from bovine plasma pre-incubated 15min at 25ºC before adding 100 µM CBZ-Gly-Pro-Arg-
4-nitroanilide substrate and the absorbance change (404 nm) was monitored for 10 min. The 
results revealed that thrombin was not very sensitive to CPO and POX toxicity, with the IC50 
for both being more than 100 µM (Quistad & Casida, 2000). Moreover, under the same 
study conditions, the PSP effect on purified thrombin was studied, and the results 
indicated that PSP was a more potent than CPO and POX, with an IC50 of 26 µM 
(Quistad & Casida, 2000). However, in the current study PSP showed only a slight effect 
on purified thrombin and no effect at all on plasma thrombin activity.  The variation of results 
between the previous study and the present study could be due to either the enzyme source 
and substrate differences, as in the current study purified human thrombin was used, and 
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Sar-Pro-Arg-p-nitroanilide substrate, which has a higher Kcat and lower Km than CBZ-Gly-
Pro-Arg-4-nitroanilide (Hortin et al., 2001).  
On the other hand, another study by Golderman et al. (2016) investigated the effect of POX 
toxicity on 0.05 U/ml thrombin purified from bovine plasma pre-incubated 10 min on ice 
before adding 14 µM Boc-Asp-(OBzl)-Pro-Arg-AMC fluorescent substrate and the 
absorbance change recorded at (440-460 nm) for 60 min. Their results indicated that 500 µM 
POX completely inhibited purified thrombin activity, whereas, 50 µM POX showed 70 % 
inhibition of purified thrombin activity. That is in good agreement with the current study, 
suggesting that POX inhibited thrombin activity in a concentration-dependent manner. Also, 
because of the potentially higher sensitivity of the fluorescent substrate it may have been 
possible to detect a greater effect of POX on thrombin activity. Gargiulo et al. (1981) pointed 
that employing a fluorescent instead of a chromogenic substrate will allow the measurement 
of smaller quantities of protease enzymes in body fluids. 
Furthermore, the present study monitored the absorbance change of purified and plasma 
thrombin activity (405 nm) for 90 and 240 min, respectively, which might have enhanced 
the ability to detect the inhibitory effect of POX on human plasma thrombin. In the previous 
study of Quistad & Casida (2000) they monitored the absorbance change for 10 min only, 
and they could not detect any POX effect lower than 100 µM. However, Golderman et al. 
(2016) conducted their study on the same species (bovine thrombin) as Quistad & Casida 
(2000) but they apply longer absorbance change for 60 min, and were able to detect 
significant inhibition of thrombin activity by POX. Increasing the pre-incubation time or 
decreasing the amount of thrombin used can improve fluorometric assay sensitivity 
(Gargiulo et al. 1981). Thus, longer incubation time with OP and/or lower enzyme 
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concentration could enhance the stoichiometric reaction with thrombin enzyme in 
chromogenic assay.  
Previous studies investigated the POX effect on coagulation system due to its ability to 
inhibit thrombin activity, prothrombin time (PT) the extrinsic and common pathways, 
activated partial thromboplastin time (aPTT) the intrinsic and common pathways, and 
thrombin time (TT), the final part of coagulation where fibrinogen converts to fibrin 
(Golderman et al., 2016). Reconstituted human plasma incubated with 500 µM POX for 10 
min, revealed no effect on the coagulation system (Golderman et al., 2016). Nevertheless, 9 
µg/ml POX showed a significant in vitro effect on human blood coagulation assessed by 
thrombelastography (TEG), indicating that clot formation time was prolonged about 12-fold 
compared to non OP-treated samples (Petroianu et al., 1997). In an in vivo study done on 
mini pigs injected with 54mg/kg POX, blood samples were collected after 150 min exhibited 
hypocoagulability by PTT prolongation (Petroianu et al., 1999). 
In Rh-PSP-thrombin binding assays, Rh-PSP bind to thrombin band was obvious with high 
intensity of fluorescence after SDS-PAGE, which confirms the covalent binding of PSP to 
thrombin protein. The PSP binding site is presumably the active site serine, corresponding 
to that previously identified in other serine esterases, such as BChE (Marsillach et al., 2011; 
Marsillach et al., 2013). 
 Competition binding between Rh-PSP and other OPs on thrombin bands showed significant 
competition in binding site that reduced the fluorescence intensity to background levels with 
all unlabeled OPs, which suggests that competition may occur on a single site of the protein 
sequence. Unfortunately, due of constraints of time and materials, it was not possible to do 
mass spectrometry to determine the binding site(s). Previous studies have confirmed the 
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adduct of OPs presence on the active site serine of serine hydrolases, for example ChE is 
diethyl phosphorylated by oxon OPs (Thompson et al., 2010). 
Also, all OPs used in present study showed covalent binding to thrombin on gel analysis and 
at the same time most of them did not affect thrombin activity under the conditions tested, 
which could be explained by the possibility that the OPs bind to thrombin without inhibiting 
the activity. In this respect, one study showed that, when the DFP was incubated with egg-
white lysozyme, Taka-amylase A, and papain, tyrosine residues were covalently labeled but 
the OP-modified enzymes possessed the full activity (Lockridge & Schopfer, 2010) 
In summary, the data presented in this chapter indicate that CPF has a notable toxic effect 
against purified thrombin activity, whereas, CPF, CPO and POX affect the plasma thrombin 
activity. OP effects on thrombin activity may rely on incubation time and occur in a 
concentration dependent manner. Furthermore, studies of OP binding to thrombin protein 
indicate the possibility of OP adduct formation. However, further investigation is needed to 
confirm the specific location of the binding (site)s by mass spectrometry. 
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6. Chapter 6: Effects of organophosphorous 
Compounds on THP-1 cells 
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 Introduction 
cFXIII-A2 expression has been found in in white blood cells (e.g. monocytes and 
macrophages), platelets, dendritic cells, histiocytes, placenta, and uterus, but there are 
limited studies on cFXIII intracellular function in these cells (Polgar et al., 1990; Koseki-
Kuno et al., 2003; Muszbek et al., 2011, Dashty et al., 2012). Such work has revealed that 
the role of FXIII is not confined to haemostasis only, but it also performs as an intracellular 
transglutaminase (Törőcsik et al., 2005; Muszbek et al., 2011). Monocytes are involved in 
the immune system, where they have the ability to destroy unusual invaders; moreover, they 
have a role in improving healing and repairing tissues (Sporn et al., 1990). As any defect in 
cFXIII-A2 could affect the physiological and pathological settings of haematological 
parameters (monocytes and macrophage), it became a biomarker for different subsets of 
these cells (Quatresooz et al., 2008).  Some OPs have toxic effects on haematological 
constituents such as RBC, WB, PLT and alter their function (Petroianu, 1997; Svoboda et 
al., 2001; Celik & Suzek, 2008).  
Some studies indicated that POX had the ability to cause hypocoagulability and platelet 
dysfunction through disruption of the coagulation cascade (Petroianu, 1997; Petroianu et al., 
1999). Moreover, soman (an acute OP nerve agent) caused decline in haematopoietic stem 
cell levels in blood circulation, resulting in a reduction in lymphocytes and monocytes 
(Colllomet et al., 2005). Significant decline was observed in WB count which caused 
lymphopenia and granulocytosis after acute exposure to DZ (Svoboda et al., 2001). In 
addition, a previous study revealed that CPF induced a significant decrease in WB cell counts, 
but CPF in presence of vitamin C lead to significant elevation of WB cells, suggesting a 
protective role of antioxidants against OP toxicity (Ambali et al., 2007). Also, another study 
revealed that methyl PTH stimulated the immune system by increasing the WB cell counts 
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as a protection role (Celik & Suzek, 2008). Other studies have described the same toxic 
effect of CPF causing a significant increase on WB cell count, suggesting immune system 
activation after CPF exposure (Okechukwu et al., 2007; Modesto & Martinez, 2010; Ural, 
2013). 
There are a limited number of monocyte leukaemia cell lines, such as the U-937 histiocytic 
lymphoma cell line, the  acute myelomonocytic leukaemia cell line 230, and the human 
monocytic leukaemia cell line THP-1, which retains its monocytic properties; the latter has 
been established to be a useful tool for studying the role of monocytes in the human immune 
response (Tsuchiya et al., 1980). The THP-1 cell line has become widely used to study the 
regulation and function of monocytes and macrophages in the blood system (Qin, 2012).  
The aim of the work presented in this chapter was to study the effects of OPs on the 
proliferation and viability of THP-1 cells. Therefore, optimization of THP-1 cell growth and 
confirmation of the presence of cFXIII-A2 was necessary. Proliferation and viability of THP-
1 cells were studied in the absence and presence of OPs using Trypan Blue and alamarBlue 
assays. Immunoblotting was performed using anti-human FXIII antibody to probe Western 
blots of THP-1 cell lysates.  
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 Results 
6.2.1 THP-1 cell in culture 
To determine the cell growth characteristics of THP-1 monocyte-like cell line, a standard 
growth curve was generated, as described in section 2.2.10.1. Fig 6.1 shows images of THP-
1 cells in culture for up to 13 days. The THP-1 cells exhibited a round shape, grew in 
suspension and formed loose clumps. Cells showed rapid division and proliferation during 
the first few days of seeding. By days 7-9, cell numbers seemed to stabilize as the flask 
becomes crowded. In days 11-13, the colour of the culture medium changed (yellowish) due 
to pH drop and some cells shrank in size.   
Fig 6.2 A, B, C shows cells total count, live cell count, and % viability of the THP-1 cells 
during culturing for 13 days. The THP-1 cell density after 24 hours (day one) of seeding 
culturing was similar to the starting density ~ 2 x 105 cells. However, in the two following 
days, the cell density was shown to gradually increase (Fig 6.2 A & B). At day 8-9, a 
significant increase in cell density to approximately 2 x106 cells/ml was observed and this 
was shown to be steady for 2 more days followed by a decline. On the other handr, cell 
viability started to fall by day 9 (Fig 6.2 C). In conclusion, the optimum growth phase for 
sub culturing and further experimental testing on THP-1 was up to day 7. 
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Figure 6- 1: Images of THP-1 cells during 13 days culturing. 
 
THP-1 cells were plated at a density of 200,000 cells/ml per T75 flask cultured in growth 
medium and incubated for up to 13 days, as described in Materials and Methods.  Cells 
were monitored using an inverted light microscope at (10x) magnification. Scale bar 0.1 
µm. 
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Figure 6- 2:  Growth curve of THP-1 cells.  
 
Cells were plated at a density of 200,000 cells/ml in growth medium and incubated for up to 
13 days.  Shown are the total cell count (A), live cell count (B), and % viability (C) measured 
by Trypan blue exclusion assay. Data are expressed as mean ± SEM for 3 independent 
experiments. 
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6.2.2 Effects of DMSO on THP-1 cells proliferation and viability 
As OPs were dissolved in DMSO, in order to study the OP effect on THP-1 cells it was first 
of all necessary to optimize the DMSO concentration to be sure that any effect on the cells 
was due to the OPs alone. A cell density of 2 x 105 cells/ml was plated in growth medium 
and incubated with a range of DMSO concentrations for up to 7 days, as described in section 
2.2.10.1. The results shown in Fig 6.3 A indicated that proliferation of THP-1 was affected 
by DMSO concentrations of 0.25% and above, while there was no cytotoxic effect on 
viability (Fig 6.3 B). In general, it was optimum to keep DMSO concentration below 0.05%. 
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Figure 6- 3:  Effect of DMSO on THP-1 proliferation and viability. 
 
Cells were plated at a density of 200,000 cells/ml in growth medium and incubated for up 
to 7 days with the concentrations of DMSO indicated or untreated as control.  The cell 
proliferation (A) and % viability (B) were measured by Trypan Blue exclusion assay. Data 
are expressed as mean ± SEM for 3 independent experiments. 
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6.2.3 AlamarBlue assay optimization for THP-1 cell viability  
In order to have another viability assay, the alamarBlue assay was deemed suitable for THP-
1 suspension cells. More than one cell density was plated and incubated for up to 48 h with 
alamarBlue, as described in section 2.2.10.4. The results in Fig 6.4 showed that the standard 
curve was linear between 0-8 hours for lower cell density, while at the higher cell density 
the linearity of the curve was lost in a shorter time than for lower cell density. However, 
there was no longer a linearity relationship above 8 h under any conditions. Eventually, the 
optimum was established to be measuring absorbance for cell density 0.2 x 106 cells/ml after 
8 h and for 0.8 x 106 cells/ml after 4 h.  
 
 
 
 
 
Figure 6- 4:  Optimization of alamarBlue incubation time with THP-1 cells. 
 
Cells were plated at the cell densities indicated and incubated for up to 48 h with 
alamarBlue.  Data are expressed as mean ± SEM for 3 independent experiments. 
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6.2.4 Detection of cFXIII-A2 in THP-1 cell lysates 
This was necessary to elucidate the expression of the cFXIII-A2 in monocyte cells, as its 
presence was confirmed previously (Muszbek et al., 1988; Conkling et al., 1989). Western 
blot analysis was performed as described in (section 2.2.7.3) to confirm cFXIII-A2 
expression in THP-1 cells. The electrophoretic migration of reactive bands was compared 
with purified rFXIII at the 83 kDa position, and with depleted and whole plasma samples 
run in parallel. FXIIIa was detected in the position of an 83 kDa for all samples (Fig 6.5). In 
addition, the observations showed a strong uncleaved intensity band (180 kDa) of FXIII with 
degradation products representing FXIII-A2 from THP-1 lysate and whole plasma sample 
FXIII-A2. However, the uncleaved FXIII band did not appear on blots of depleted plasma 
but the degradation band of cFXIII-A2 was detected. 
In order to confirm that FBS was clear of cFXIII-A2, a Western blot analysis was performed 
as described in (section 2.2.7.3) with 30, 50, 100 µg of FBS protein probed with anti-human 
FXIII. The blot showed only a ca. 50 kDa bans with variable intensity in FBS samples, 
whereas the THP-1 lysate showed cFXIII-A2 at 83 kDa. In conclusion, the cFXIII-A2 
presence in THP-1 cells was confirmed and it is not likely to be due to cross-reactivity with 
protein components in FBS.  
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Figure 6- 5: Detection of FXIII in THP-1 cell lysates. 
 
Pure rFXIIIa (0.25µg), depleted plasma sample (11 µg), cell lysate of THP-1 proteins (50 
µg) and whole plasma protein (15 µg) were separated by SDS-PAGE and Western 
blotting. Blots were probed with anti-human FXIII antibody (1:1000), followed by 
incubation with secondary antibody HRP-conjugated anti-mouse IgG. Immunoreactive 
bands were visualized using a Syngene imager after incubation with ECL reagent. 
 
 
 
Figure 6- 6: Testing for FXIIIa presence in fetal bovine serum.   
 
THP-1 (50 µg), FBS (30 µg), FBS (50 µg), FBS (100 µg). Blot was probed with anti-
human FXIII antibody (1:1000), followed by incubation with secondary antibody anti 
mouse IgG HRP conjugated. Immunoreactive bands were visualized using Syngene 
transillumniator after incubation with BCL reagent. 
 
 
Chapter 6 
149 
 
6.2.5 Effect of OPs on the proliferation and viability of THP-1 cells 
In order to study the effect of OPs on THP-1 cell proliferation and viability, as described in 
(section 2.2.10.1), 2 x 105 cells/ml were plated in growth medium and treated with PSP, DZ, 
DZO, CPF, CPO, PTH, and POX at three final concentration of each (1, 10, and 100 µM) 
and incubated for up to 6 days. The results are shown in Fig 6.7. PSP showed no significant 
effect on proliferation and caused only a slight but significant decrease in viability and 
alamarBlue reduction at selected low concentrations (Fig 6.7 A). The lowest concentration 
of OP (1 µM) induced significant decreases in proliferation in the case of DZ, PTH and  POX 
on day 6 of incubation (Fig 6.7 B, F, G), whereas 10 µM PTH treatment resulted in a 
significant decline by day 4 (Fig 6.7 F) and 10 µM CPF, CPO and PTH had a similar effect 
by day 6 (Fig 6.7 D, E, G). The most significant effect of OPs came from the 100 µM 
concentration, which was observed for PTH on day 2, for DZO, CPF, CPO, PTH and POX 
on day 4 and with DZ, DZO, CPF, PTH and POX) on day 6 (Fig 6.7 B, C, D, E, F, G). In 
addition, THP-1 cell metabolic activity showed significant decline within a few hours of 
incubation from day 0 to day 6 by with PTH, DZ, CPF, DZO and POX, as monitored by the 
alamarBlue assay (Fig 6.7 F, B, D, C, G). On the other hand, some OPs showed significant 
viability decrease from day 2 to 6 (e.g. PTH, CPF) by Trypan blue exclusion (Fig 6.7 F, C). 
In conclusion, most OPs except (CPO day 4) caused significant reductions in THP-1 cell 
proliferation in a concentration- and time-dependent manner, at high concentrations showing 
significant decreases in both proliferation and viability except for PSP, which only showed 
slight effects.  
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Figure 6- 7:  The effect of OPs on THP-1 cell growth and viability. 
 
Cells were plated at a density of 200,000 cells/ml in T25 cell culture flasks and incubated 
for up to 6 days in the absence and presence of PSP (A), DZ (B), DZO (C), CPF (D), CPO 
(E), PTH (F), and POX (G) at three final concentration of each (1, 10, and 100 µM). 
Control sample was treated with 0.01 % (v/v) DMSO. The live cell count, and % viability 
of cells were measured by Trypan blue exclusion assay whereas metabolic effects of each 
toxin were indicated by alamarBlue assay.  Data points of three independent experiments 
represent the mean ± SEM *p<0.05, **p<0.01, ***p< 0.001, ****p< 0.0001 versus non 
OP-treated control. 
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6.2.6 Effect of lower concentration of OPs on the proliferation and 
viability of THP-1 cells 
In order to study the effect of selected OPs at lower concentrations on THP-1 cell 
proliferation and viability, as described in (section 2.2.10.1), 2 x 105 cells/ml were plated in 
growth medium and treated with PSP, DZO, CPF, PTH at three final concentration of each 
(0.1, 1, and 10 µM) and incubated for up to 4 days. The results shown in Fig 6.8 showed that 
exposure to 10 µM PSP had an elevating effect on THP-1 cell proliferation on day 4, the 
other concentration also increased the proliferation on day 4 but without statistical 
significance. Also, PSP caused a significant decrease in metabolic activityat 1 µM on day 2 
and with 0.1, 1 and 10 µM on day 4 (Fig 6.8 A), as determinedby the alamarBlue assay. On 
exposure to DZO THP-1 cells exhibited 20 % decrease inalamarBlue reduction at 1 and 10 
µM on day 2 andwith 0.1, 1 and 10 µM on day 4 (Fig 6.8 B). Moreover, 0.1, 1 and 10 µM 
CPF treatment induced a 50% decline in THP-1 cell proliferation compared to the control 
non OP-treated cells, while the viability measurements in both Trypan Blue exclusion and 
alamarBlue assays showed significant decreases with 10 µM CPF on day 4 (Fig 6.8 C). In 
addition, 10 µM PTH treatment also showed a significant decrease on day 4 in cell 
proliferation and viability on both Trypan blue exclusion and alamarBlue assays (Fig 6.8 D). 
Microscope images for OP effects on THP-1 cells were recorded on day 0 and day 4 (See 
appendix 8.8 & 8.9) In conclusion, CPF was the most toxic compound among the selected 
OPs by (0.1, 1, 10) µM causing significant inhibition of THP-1 proliferation and reduced 
viability. Also, 10 µM of PSP, CPF, and PTH showed a cytotoxic effect on THP-1 cell 
proliferation and metabolic activity.  
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Figure 6- 8: The effect of lower concentration of selected OPs on growth and viability 
of THP-1 cells.  
 
Cells density were plated at a density of 200,000 cells/ml in T75 cell culture flask. Cells 
were incubated for up to 4 days and treated with PSP (A), DZO (B), CPF (C), and PTH 
(D) with three final concentration of each 0.1, 1, and 10 µM. Control sample was treated 
with 0.01 % (v/v) DMSO. The live count, and % viability of cells were measured by trypan 
blue exclusion assay beside to the cell viability indicated by alamarBlue assay of each 
toxin. Data points of three independent experiments represent the mean ± SEM *p<0.05, 
**p<0.01, ***p< 0.001, ****p< 0.0001 versus non OP-treated control. 
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6.2.7 Effect of OPs on cFXIII-A2 of THP-1 lysate 
In order to study the OPs effect on cFXIII-A2 production of THP-1 monocyte cells, 2 x 10
5 
cells/ml were plated in growth medium and treated with PSP, DZO, CPF, PTH at three final 
concentration of each 0.1, 1, and 10 µM and incubated for up to 4 days, as described in 
section 2.2.10.1. Then Western blot analysis was performed for untreated and OP-treated 
THP-1 cell lysates, as described in (section 2.2.7.3). Unfortunately, no bands were detected 
at the 83 kDa position for THP-1cell lysate proteins either for control untreated samples or 
for those treated with OPs (Fig 6.9 A, B). However, purified rFXIIIa was used as positive 
control to confirm anti-human FXIII antibody probing, also β-actin expression (42 kDa 
bands) were detected on probed blots of THP-1 lysates to confirm equal protein loading (Fig 
6.9 A, B). 
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Figure 6- 9: The effect of OPs on FXIIIa of THP-1 cells. 
 
Cells were plated at a density of 200,000 cells/ml in T75 cell culture flasks andincubated 
for up to 4 days in the absenc and presence of PSP or DZO(A) and CPF and PTH (B), at 
final concentration of 0.1, 1, and 10 µM. The control sample was treated with 0.01 % (v/v) 
DMSO. Cell lysates of THP-1 (50 µg) and pure rFXIIIa (0.05µg) were blotted and probed 
with anti-human FXIII antibody (1:1000), followed by incubation with secondary 
antibody HRP-conjugated anti-mouse IgG. Immunoreactive bands were visualized using 
a Syngene imager after incubation with ECL reagent. Lysates were also analysed for β-
actin expression to confirm equal protein loading. 
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6.2.8 Discussion 
Cellular FXIIIa exists as a dimeric catalytic subunit (cFXIII-A2) in a variety of cell types. 
Monocytes/macrophages express cFXIII-A2 antigen and activity (Muszbek et al., 1988; 
Conkling et al., 1989). Cellular FXIII-A2 was not detected in monocytes of patienst with 
cFXIII-A2 deficiency (Muszbek et al., 1988). It has been reported that OPs can significantly 
disrupt some haematological parameters such as CBC including monocytes (Ambali et al., 
2007; Banaee et al., 2008; Andreadis et al., 2014). In the present study, the OP effects on 
monocyte cell growth and viability was studied using the THP-1 monocytic leukaemia cell 
line. Some optimization tests were required before exposing the THP-1 cells to selected OPs. 
The selected OPs: PSP, DZO, CPF, PTH were incubated with THP-1 for up to 4 days and 
there was some effect on live cell count and viability which were monitored by Trypan blue 
exclusion and alamarBlue assays. Also, the microscopic observation of some OP-treated 
cells indicated some morphological changes.  
It was essential to optimise the cell line’s growth and characteristics before performing any 
experiment that require the utilization of the cell line for in vitro investigation, as any unusual 
change of cell growth can have a significant effect on the experimental results (Wang, 2006). 
According to the literature and to the manufacturer’s instruction, 2 x 105 THP-1 cells/ml 
density was selected as the plating density, as monitored and defined in previous work 
(Tsuchiya et al., 1980; Banka et al., 1991; Liu et al., 2009; Aldo et al., 2016). In the current 
study, according to the cell growth standard curve (Fig. 6.2 B) the optimal period for sub-
culturing and further experimental treatments of THP-1 cells was shown to be before day 7 
of cell growth. An ideal standard growth curve for various cultured cell lines has 4 different 
phases including lag, log or growth phase, stationary and decline phases (Wang, 2006). Day 
7 was shown to be at the end of the growth phase of THP-1 cells, in which cells exhibited 
rapid division and proliferation (Fig. 6.1). For that reason, the earlier exponential growth 
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phase (2-5 days) might better as cells are dividing rapidly and not yet near the stationary 
phase. It was recommended in this phase for cell line to be assessed and maintained for 
different cellular functions before they enter the stationary phase (Freshney, 2006) in days 
8-10 (Fig. 6.2 B). Budde et al. (1998) indicated that the setup of the sub-culturing and 
additional experimental treatments of cells is needed to be in the exponential phase to ensure 
cellular viability and enzymatic function, phenotypic and genetic stability. Accordingly, the 
day 7 of cells growth was adopted for sub-culturing and any subsequent experiments. 
Organic solvents such as DMSO are usually used as a vehicle to dissolve hydrophobic 
compounds in biological experiments (Jain & Pento, 1991). Previous in vitro studies 
reported possible toxic effects of some organic solvents including DMSO, in which 
proliferation of cells was inhibited in a time- and dose-dependent manner (Qin et al., 2011; 
Jamalzadeh et al., 2016). It was therefore important in the present study to optimize the 
DMSO concentration, to a level that showed no effect on cell proliferation; this was found 
to be the case for concentrations below 0.05 % (v/v) (Fig 6.3). 
The alamarBlue assay has been used for many years in studies of cytotoxicity and in viability 
assays, and it used for wide range of cell types including suspension cells (Rampersad, 2012). 
It is common to use tetrazolium salts such as MTT for anchorage dependent cells; however, 
reduced MTT is not soluble and the formazan crystals must be solubilized by DMSO after 
the medium has been removed, which is not that straightforward for suspension cells. The 
alamarBlue assay is a more suitable, reproducible and sensitive method for suspension cells, 
using oxidized resazurin as an active and non-toxic ingredient; it is reduced by NADPH and 
changes from blue to a fluorescent pink state. It is typically used on adherent THP-1 cells 
incubated with alamarBlue to measure their metabolic activity (Schmitt et al., 2010; Manna 
et al., 2014). Therefore, in the present study, the alamarBlue assay was optimized for 
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suspension culture (Fig 6.4) and assessed alongside Trypan blue exclusion as a method for 
measuring THP-1 cell viability and/or metabolic activity.  
In the present study, characterization of uncleaved cFXIII-A2 in THP-1 cell line was 
determined by probing Western blots of cell lysates with anti-human FXIII monoclonal 
antibody using. Detection of a reactive band at 83 kDa in probed blots of THP-1 cell lysates, 
which was weaker in intensity compared to depleted plasma and purified FXIII (Fig 6.5), 
confirmed the characteristic expression of a cellular form of FXIII by this cell line. cFXIII-
A2 level was observed to be higher in monocytic leukaemia cells compared to the normal 
blood monocytes (Kappelmayer et al., 2005). Moreover, the uncleaved complete form of 
FXIIIA2B2 at position higher than ~180 kDa plus a lower molecular weight potential 
degradation product were detected on probed blots of THP-1 cell lysates and whole plasma 
(Fig 6.5). However, this higher sized uncleaved FXIIIA2B2, band was not detected on blots 
of depleted plasma, suggesting that it was absorbed by the depletion column. A study by 
Simon et al. (2012) identified uncleaved cFXIII-A2 at ~83 kDa in leukemic promyelocytes 
in de novo AML M3 patients; moreover, cleaved and degradation products of cFXIII-A2 
were identified in lower kDa size ranges with lower expression amount compared to the 
cFXIIIa band at ~83 kDa. Different studies on normal human purified monocytes and 
macrophages identified cFXIIIa without degradation at 80 kDa in monocytes and at ~85 kDa 
in macrophage cells. The observation that, in the present study, FBS used in the growth 
medium was clear of an immunoreactive band at ~83 kDa, ruled out potential contamination 
by serum FXIIIa (Fig 6.6).  
The main observed effect of OPs on THP-1 cells was decreasing cell proliferation in a 
concentration- and time-dependent manner (Fig 6.7). Some parent compounds and their 
metabolite form, such as DZ, DZO, PTH and POX showed stronger effects, decreasing by 
more than 50 % of live cell count by day 6 of incubation compared to control samples, 
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suggesting that might both the parent compound and the oxon metabolite behaved in a 
similar manner with respect to this parameter, unlike their very different potencies against 
their acute toxicity targets. The rank order of the most OP toxic on THP-1 cell proliferation 
was as follows: PTH>POX>CPF>DZO>DZ> CPO> PSP (Fig 6.7 F, G, D, C, B, E). On the 
other hand, the rank order of the most toxic OP towards THP-1 cell viability was as follows: 
PTH>DZ> DZO>CPF>CPO>POX>PSP (Fig 6.7 G, B, C, E, G, A). Therefore, a smaller 
group of OPs (PSP, DZO, CPF, and PTH) were subsequently selected to study their effect 
at lower concentrations (0.1, 1 and 10 µM) and for up to only 4 days incubation (Fig 6.8). 
Similar to the previous experiment the data obtained showed that the effect was 
concentration- and time-dependent. All of selected OPs induced decreases in THP-1 live cell 
counts. This is in agreement with a previous study on diazinon (2-32 mg/l) exposed 
fingerling European catfish, which showed acute toxicity on their hematological parameters, 
including powerful decreases in leukocyte, erythrocyte, hemoglobin, hematocrit, MCV, 
MCH, and MCHC values comparing to non OP-treated groups (Köprücü et al., 2006). 
However, on the selected OPs group only the PSP on day 4 the live cell count was increased 
by increasing concentration of PSP, which could a defence mechanism behaviour; however, 
the metabolic activity of this group in order by lower to higher concentration was decreased 
(Fig 6.8 A).  A study showed that ~ 38 µM of methyl parathion in water was drunk by albino 
rats for month and using a haematological analyser the results showed significant increases 
in WB cells, indicating immune system activation due to methyl parathion intoxication 
(Celik & Suzek, 2008). In another study, two groups of Cyprinus carpio carpio fish were 
exposed to 0.04 and 0.08 mg/l CPF dissolved their environment water for 14 days, resulting 
in a significant elevation in WB cell count, in a concentration-dependent manner compared 
to non OP-treated controls, suggesting that the immune system was responding to CPF 
toxicity (Ural, 2013). Although, the immunotoxicity mechanisms of OPs are not absolutely 
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clarified, several studies suggest that OPs can target molecules related to the immune system 
(Díaz-Resendiz et al., 2015). The observed effects of OPs on THP-1 proliferation suggests 
that there might be an effect on the key prosses of regulation of proliferation either during 
mitosis or the interphase stage, which might affect DNA replication or cell growth.  
On the other hand, the immunoblotting experiment to study the selected OPs effect on 
cFXIII-A2 showed no bands of cFXIII-A2 even in untreated OP control lysates, however 
rFXIII band indicated as a marker of anti-human FXIII antibody and to identify its position 
at ~83 kDa. It could be an issue in performing the lysate buffer or during preparing the 
samples. Due the constraint of time there was no chance to investigate the problem. This part 
of work needs to be completed in future work. 
In conclusion, the results of this chapter indicated that OPs have a potency effect against the 
proliferation or viability of THP-1 cells, which could affect cFXIII-A2 production. Thus, 
further studies are required to elucidate cFXIII-A2 expression level under OPs treatment.  
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7. Chapter 7: General discussion and future 
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 Summary of findings 
This study aimed to determine the effect of parent and activated metabolite OPs on pure and 
plasma cholinesterase, FXIIIa and thrombin activity by enzyme colorimetric assays. It was 
also of interest to establish whether OPs could form covalent adducts with FXIII and 
thrombin protein. Moreover, it was intended to assess the OPs toxicity on the proliferation 
and viability of THP-1 monocyte-like cells. Overall, OPs significantly affected all of these 
haematological parameters. 
7.1.1 OPs effect on cholinesterase  
AChE and BChE activity are widely used used as a biomarker to detect and monitor OP 
exposure since they are the primary targets of many OPs (Nigg & Knaak, 2000; Jońca et al., 
2015). Before investigating the OP effects on haematological parameters (such as FXIIIa, 
thrombin activity and proliferation and viability of monocytic THP-1 cell line) it was 
necessary to validate the effectiveness of OPs of interest against their primary target. 
Therefore, the first part of this thesis aimed to confirm the biological activity of the OPs 
toward pure cholinesterases and their corresponding activities in human plasma, The Ellman 
method (Ellman et al., 1961) was utilized with acetylthiocholine and butyrylthiocholine as 
substrates for AChE and BChE, respectively, to determine cholinesterases activity. 
Blood plasma samples mainly include BChE and the majority of AChE is found in 
erythrocytes, although fetal serum ChE was found to contain 40% AChE (Hahn et al., 1993), 
whereas other studies confirmed that adult plasma has less than 1% of AChE activity 
(Brimijoin & Hammond, 1988; Thompson, 1999; Nigg & Knaak, 2000). On the other hand, 
in many different kinds of samples OP toxicity is typically indicated by testing the level of 
AChE activity (Thompson, 1999). In the current study, substrate specificities were assessed 
in purified AChE and BChE to determine which of the two ChEs (AChE or BChE) was most 
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affected in plasma samples treated with OPs. It is known that acetyl(thio)choline is the 
preferable substrate for AChE and butyryl(thio)choline for BChE (Basova et al., 2018).  In 
the current study the reaction of each enzyme with the other’s intended substrate was tested, 
the purified BChE being able to hydrolyse both acetylthiocholine and butyrylthiocholine 
iodide (with Km values of 0.28 and 0.22 µM, respectively), whereas the purified AChE could 
only hydrolyse the acetylthiocholine iodide. Indeed, BChE was found to hydrolyse 
acetylthiocholine at a rate just two-fold lower than butylrylthiocholine (Wetherell & French, 
1986). One study focussing on substrate selectivity of human BChE and its mutants 
estimated a Km of 33 µM for acetylthiocholine iodide substrate which was hydrolysed by 
the wild-type BChE compared to 17 µM for butyrylthiocholine iodide (Hou et al., 2013). In 
another study, the BChE active site structurally showed a broader substrate specificity than 
AChE (Pohanks, 2011). Therefore, the data obtained in the current study, in agreement with 
previous work, suggest that BChE (but not AChE) can effectively hydrolyse both substrates 
indicating that it may account for most of the ChE activity in plasma samples. In further 
agreement with these findings, a study which measured ChE activity in blood collected from 
healthy male and female volunteers compared to purified human ChE, revealed that the 
neurotransmitter acetylcholine was an outstanding substrate for BChE (Masson & Lockridge, 
2010).  
The results in the present study with both pure enzymes and plasma samples highlighted the 
possibility that BChE activity was significantly disrupted by OP pesticide parent compounds, 
though it was more pronounced when butyrylthiocholine was used as the substrate. The 
ranking of parent OPs in order of toxicity on plasma BChE samples was PTH > DZ > CPF. 
However, in the case of purified BChE it was CPF > PTH > DZ. This difference could be 
due to the biological environment effect on parent OPs, suggesting they may be 
biotransformed in plasma by molecules such as cytochrome P450 in plasma exosomes to 
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produce the more potent oxon form (Fabrizi et al., 1999; Foxeberg et al., 2011; Kumar, 
2015).  Differences could also arise due to differential hydrolysis of specific oxons by plasma 
paraoxonases. BChE is known to have a larger active site pocket than AChE (about 500 Å3 
compare to 300 Å3, respectively,) which makes BChE less substrate-specific than AChE, as 
it can hold bulkier substrates or inhibitors (Masson & Lockridge, 2010). The finding in 
present study that phosphorothioate compounds could inhibit purified BChE activity, agreed 
with the study of Tacal & Lockridge (2010), which also found that DZ formed adducts with 
highly purified human BChE.  
It is well known that the oxon form of organophosphorus compounds are more toxic than 
their parent forms in terms of inhibitory effects on cholinesterase enzyme activities 
(Brimijoin and Hammond, 1988; Čolović et al., 2010; Čolović et al., 2011). It was 
interesting to note that both ChE activities in plasma samples were inhibited by PSP, which 
had no effect on the purified AChE yet plasma ChE activity was significantly inhibited using 
acetylthiocholine as the substrate. One study proposed that tri-o-cresyl phosphate (TOCP), 
when modified to a more toxic product CBDP in vivo exhibited increased inhibition of BChE 
but not AChE, an effect was also observed in vitro using rat-liver slices to produce the same 
toxic effect (Aldrige, 1954). It was subsequently shown that CBDP formed 
organophosphorylated adducts on active site serines (Ser-203 for human AChE and Ser-198 
for human BChE). In vivo the inhibition effect by low dose exposure to CBDP on AChE is 
not as much as it is on BChE, for which reason BChE inhibition is the best biomarker for 
exposure to TOCP (Liyasova et al., 2011).  
In the present study it was confirmed that the oxon metabolite forms of OPs were more toxic 
than the parent compounds in a concentration dependent manner but with different inhibitory 
potencies towards both BChE and AChE. The rank order of toxicity for metabolite (oxon) 
OPs on plasma BChE activity for both substrates was CPO > POX >DZO. The same toxicity 
Chapter 7 
165 
 
order was found on purified BChE. Thus, CPO was the most potent OP against BChE 
activity showing inhibition lower than or about 24 nM with either whole plasma or purified 
protein. A previous study, using purified human BChE (1.3 U/ml) with a higher 
butyrylthiocholine Km (0.5 mM) after 40 min incubation, showed a direct inhibition of 
BChE activity dependent on CPO concentration, confirming that BChE inhibition served as 
a biomarker for CPO toxicity due to the rapid interaction of the enzyme with this OP (Amitai 
et al., 1998). Moreover, in the same study, POX caused about 50% inhibition at 0.055 µM 
(Amitai et al., 1998), which is very similar to its effect on plasma and purified BChE in the 
current study. There are limited studies of DZ and DZO effects on BChE; in the current 
study DZ exposure resulted in almost 60 % inhibition of ChE using butyryl thiocholine as 
the substrate for both plasma and purified BChE, and by more than 20 % using acetyl 
thiocholine as the substrate in plasma samples, the latter of which could be explained by the 
ability of BChE to hydrolyse acetylthiocholine less than butylrylthiocholine (Wetherell & 
French, 1986).  
In the current study, PSP and DZ showed no significant effects on pure AChE activity. The 
lack of the biological effect such the one which is presence in plasma environment could be 
one reason for the lack of inhibition effect for these OPs on pure AChE; moreove; could be 
the same reason for the lower inhibition induced by PTH on purified enzymes compared to 
activities in whole plasma. This is in agreement with a study showing that, in vitro, DZ had 
a much stronger dose-dependent inhibition effect on human lymphocyte, fibroblast and 
erythrocyte AChE than it had on human purified protein, which was almost negligible 
compared to the cellular samples (Čolović et al., 2010). However, the CPF toxic effect on 
purified AChE with no biological protein environment as in plasma sample reduced < 50% 
of AChE activity at 50 µM comparing to the same concentration on plasma AChE.  A study 
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reported that 20 µM CPF effect an almost complete inhibition of the electric eel purified 
AChE (Čolović et al., 2011).  
In the present study, although the expected pattern of greater toxicity for the oxon metabolite 
form of pesticide OPs was consistently observed for both enzymes, all OPs were more potent 
against purified BChE than AChE. 
7.1.1 OP effect on FXIII  
FXIIIa is the transglutaminase coagulation factor that has an important role at the end of the 
blood clotting cascade, where it stabilizes the fibrin mesh by cross-linking lysine-glutamyl 
side chains to form an unbreakable clot (Martins et al., 2014). The second aim of the current 
study was to identify the effect of OPs on FXIIIa and examine the possibility of their binding 
to FXIIIa. Transamidase activity assays and D-dimer ELISA were used to investigate the 
OP effect on FXIIIa activity and clot formation, respectively, whereas covalent binding was 
studied by SDS-PAGE and confirmed by mass spectrophotometry. 
In the present study the effect of OPs on plasma TG showed slight but significant inhibition 
of plasma TG-mediated amine incorporation and peptide crosslinking activities. Moreover, 
the data for most OPs suggested that plasma TG-mediated amine incorporation activity was 
more sensitive to OP toxicity, with CPO being the most effective inhibitor of plasma TG 
activity. CPF showed no significant effect on either activity, whereas DZ and POX had no 
significant effect on peptide crosslinking activity in plasma.  However, the data of OPs effect 
on purified rFXIIIa showed higher sensitivity to OP toxicity in both transamidase activity 
assays than was observed in plasma. In this case, the assay for rFXIIIa-mediated peptide 
crosslinking activity showed more sensitivity to OP toxicity than did the amine incorporation 
assay. Moreover, the parent OPs in both activities of rFXIIIa had more potency than the 
metabolite form of pesticide OPs. For example, the CPF exhibited an IC50 of 2.7µM whereas 
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the IC50 value for CPO was 6.5 µM on rFXIIIa-mediated peptide crosslinking activity. In 
addition, DZ and PTH showed the highest potency in rFXIIIa-mediated amine incorporation 
assays, giving IC50 values of 17 and 18 µM, respectively. The inhibition effect of DZ, CPF, 
PTH could be due to structural interactions according to each chemical structure and their 
metabolites product with and without oxidation. It has been suggested that the toxic effect 
of released phenol groups may be associated with these effects, the strength of toxic impact 
of these phenol compounds being based on the position and the type of substituent atoms 
(Michałowicz & Duda, 2007). Also, it has been reported that metabolite forms of DZ, CPF, 
PTH such as IMHP, 3, 5, 6-TCP and p-nitrophenol, respectively, are classified as Class III 
compounds that have structural features that may represent a safety hazard and pose a 
significant risk of toxicity (Melching-Kollmuß et al., 2010).  Moreover, PSP also showed 
a slight but significant effect on both rFXIIIa and plasma TG -mediated peptide 
crosslinking and amine incorporation activities, respectively. Therefore, the current 
study data showing significant effects of OPs on plasma TG, suggest that TG may represent 
a direct or indirect toxicity target of OPs.  
For example, studies, previous studies suggest that PSP may alter cell signaling, including 
activities of kinases that regulate TG activity in cells and tissues TG (Howden, 2006). In 
studies on cultured N2a neuroblastoma and HepG2 hepatoma cell lines, PSP (3µM) exposure 
resulted in altered tissue transglutaminase-mediated amine incorporation activity, where it 
was decreased in N2a and increased in HepG2 cells (Harris et al., 2009). Moreover, Muñoz, 
et al. (2010) showed that tissue transglutaminase-mediated amine incorporation activity in 
rat C6 glioma cells increased after 24h exposure to 10 µM CPF. In the latter study, increased 
activity of guinea pig liver TG2 in vitro following treatment with OP suggested the 
possibility of a direct interaction between OPs and TG. Although, it has been pointed that 
parent OP insecticide compounds are relatively weak inhibitors of their acute toxicity target 
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AChE and that their bioactivated forms (oxons) are considered to be the primary acute 
toxicants in nerve tissue (Poet et al., 2003), in the current study some of the parent 
compounds showed more inhibitory potential against TG activity than their oxon form, 
suggesting a distinct structure activity relationship for the different enzyme activities.   
In the present study the D-dimer levels were measured to determine whether the fibrin mesh 
exhibited the same level of covalently crosslinked D-dimers within fibrin monomers. The 
clot was created after plasma samples were treated with or without two concentrations (25 
and 50 µM) of OPs. The data suggested that all OPs showed a significant inhibitory effect 
on clot formation by reducing D-dimer formation, a finding which agreed with the 
significant inhibition effect of OPs on TG-mediated transamidase activities. DZ had the most 
potent effect at both concentrations in the D-dimer assay, causing about 50% decrease in D-
dimer level in the sample at 50 µM, whereas DZ had a more significant on TG-mediated 
amine incorporation activity. This could reflect the possibility that DZ may interfere with 
the clotting cascade at least in part through an amine incorporation-mediated pathway. 
Previous studies have reported that there are high levels of natural polyamines in the human 
body, which may serve as natural substrates for transglutaminase in cells and body fluid 
(Folk et al., 1980). 
To examine the possibility of covalent binding of PSP to plasma proteins including FXIII, it 
was necessary first to remove albumin from plasma to improve the detection of low abundant 
proteins, as studies indicated that these low abundant proteins could be disease biomarkers 
(Echan et al., 2005). Binding was confirmed by the detection on 1 D SDS-PAGE of Rh-PSP 
binding to pure FXIIIa, and a similar molecular weight band in depleted plasma. This is the 
first time that covalent binding of OP to FXIIIa has been demonstrated. Also, the depleted 
plasma protein extract incubated with labelled PSP was separated by 2D-PAGE and, 
compared to control samples, showed several labeled PSP-binding spots suggesting that 
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other low abundance proteins in depleted plasma can interact with PSP. Some of the other 
PSP-binding proteins presumably correspond to those previously identified as OP binding, 
namely albumin and ChEs, etc (Marsillach et al., 2013). Further analysis by mass 
spectrometry would help to identify the rest.  
Competition experiments using pure FXIIIa incubated with both labelled PSP and other 
(non-labelled) OPs showed significant competition in binding site in specific cases. For 
example, DZ and POX demonstrated slightly weaker fluorescence compared to the intensity 
of labelled PSP binding alone, suggesting that binding may not be near the PSP binding site. 
However, the other OPs showed higher competition with non-labelled OP and the variation 
in competition could be a sign of more than one binding site or that they might not all bind 
to the same positions. In the current study only the metabolite OP compounds were analysed 
by MS to identify the location of covalent binding site(s) on purified protein FXIII, which 
has an active site cysteine314. The results showed that there may be several modification 
sites and different adducts at different binding sites, by comparing mass shift to the control 
sample. There was a common phosphorylated site in FXIIIa incubated with unlabelled PSP, 
DZO, CPO, and POX on Ser-413, which is located in the catalytic domain of FXIII, 
suggesting this could be a competing site of PSP binding and other OPs. PSP was also 
associated with Thr293-phosphorylated, which is only few amino acids away from the active 
site Cys314 and Ser340-PSP, which is near Asp343. Studies reported that a strong salt bridge 
between Arg11 in AP-FXIII domain and Asp343 in core domain to make Cys314 
inaccessible for substrate and other chemical molecules (Muszbek et al., 2011), indicating 
that other conformational changes in this region may affect catalytic activity However, the 
oxon metabolite OPs showed more adduct binding sites than were observed for PSP. CPO 
presented 50:50 tyrosine and lysine diethylphosphorylated residues distributed between the 
β-sandwich and catalytic core domains, the closest to the catalytic active site being Tyr302, 
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and 311, and formed an ethylphosphorylated adduct on Ala22 in AP-FXIII and Lys570 in β-
barrel 1 domain. Previous studies identified that a major adduct of CPO on albumin is 
tyrosine-diethylphosphorylated and that this becomes irreversibly modified in vivo in 
humans poisoned by CPF (Li et al., 2013). Also in vitro experiments showed that CPO can 
covalently modify tyrosine on other proteins including keratins, tubulin, and transferrin 
(Schopfer et al., 2010). Moreover, DZO and POX exposure resulted in ethylphosphorylated 
and diethylphosphorylated adducts close to Arg11, which could affect the stability of the salt 
bridge between Arg11and Asp343 and as a result affect the catalytic site residue Cys314. A 
major finding in this part of work that DZO, CPO, and POX exposure induced mono 
ethylphosphorylated-adducts on different amino acid spread all over the main four domains 
of FXIIIa, as previous cases of ‘aging’ on non-esterase protein-OP adducts have not been 
reported. 
7.1.2 OPs effect on thrombin  
Thrombin is another coagulation factor that has an important role in the control of 
haemostasis (Huntington, 2005). The third aim of this study was to characterize the effect of 
OPs on thrombin activity and examine their binding to thrombin. Activity assays with Sar-
Pro-Arg-p-nitroanilide substrate were used to investigate the OP effect on thrombin activity 
and covalent binding was studied by SDS-PAGE. 
In the current study, purified and plasma thrombin activities were studied with and without 
OP exposure. Most of the OPs did not show any significant effect on purified thrombin even 
when the enzyme was diluted to 0.05 U/ml. However, CPF at 25 and 50 µM concentrations 
inhibited purified thrombin activity by about 60 % compared to the control, and a slight 
effect was observed for PSP. The strong CPF effect on purified thrombin could be enhanced 
due to the deficiency of a biological environment as in plasma as discussed earlier. As 
indicated in a previous study 50 µM DZ incubated with highly purified 3.6 mg/ml BChE 
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over 15h, caused 52 % reduction of BChE activity suggesting ‘slow’ inhibition, which may 
occur through a thiono-thiolo rearrangement (Tacal & Lockridge, 2010). Thus, the lack of 
effect could be due to the relatively short exposure time in the current study. In assays of 
plasma thrombin activity, showed 25 µM CPF and 50 µM CPF, CPO, and POX were the 
only OPs that had a significant inhibitory effect. The significant potency of CPF was again 
notable, inhibiting 40 % and 50 % of plasma thrombin activity at 25 and 50 µM, respectively. 
Previous studies have reported that the deactivation of CPO by cytochromes and PON1 
produces TCP (Poet et al., 2003; Kumar, 2015), suggesting that the biological environment 
of the plasma thrombin samples could bioactivate or degrade the CPF to its metabolite forms 
that are more toxic (with respect to ChE activity) or one of its breakdown metabolite products, 
such as TCP. This is consistent with current data showing CPO inhibition effect on plasma 
thrombin activity. In a previous study, which examined the effects of 500 µM and 50µM 
POX on 0.05 U/ml purified plasma bovine thrombin using the fluorescent substrate Boc-Asp 
(OBzl)-Pro-Arg-AMC, the results indicated complete inhibition of purified thrombin 
activity at 500 µM, where 50 µM POX showed 70 % inhibition of purified thrombin activity 
(Golderman et al., 2016). However, another study using bovine thrombin (0.2 U) and the 
chromogenic substrate CBZ-Gly-Pro-Arg-4-nitroanilide substrate estimated an IC50 value 
for POX higher than 100 µM (Quistad & Casida, 2000). However, in the current study, 0.05 
U/ml purified and 0.2 mg/ml plasma thrombin were pre-incubated with OPs on ice for 30 
min before adding the chromogenic substrate Sar-Pro-Arg-p-nitroanilde. The decreased 
thrombin sample concentration may explain the enhanced effects observed in fluorometric 
assays (Gargiulo et al. 1981).  Thus, using a fluorometric assay or prolonging the incubation 
time with reduced thrombin enzyme concentration might improve the stoichiometric 
reaction with thrombin enzyme in the chromogenic assay.  
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The binding assay in the current study showed a high intensity of fluorescent bands of 
thrombin after SDS-PAGE, confirming the covalent binding of Rh-PSP on thrombin protein. 
As thrombin is a serine esterase, it is likely that the PSP binding site is the active site serine, 
comparable to that already identified serine esterases, for instance BChE (Marsillach et al., 
2013). Moreover, competition assays between Rh-PSP and other OPs suggested that other 
OPs (including unlabeled PSP) could displace labelled PSP suggesting that competition 
might happen on a single site of thrombin protein. In addition, the presumed covalent binding 
of all OPs to thrombin protein on SDS-PAGE raises the possibility that some OPs can bind 
to thrombin without inhibiting its activity as shown in the purified thrombin activity assay. 
In agreement with this speculation, on study indicated that DFP incubated with egg white 
lysozyme, Taka-amylase A, and papain showed a modified tyrosine residue; however, the 
OP-modified enzymes have their fully activity (Lockridge & Schopfer, 2010). Alternatively, 
it may be that the level of covalent binding is insufficient to cause significant inhibition of 
thrombin under the conditions tested. 
It is interesting to note from the data produced in the current study that, although 
cholinesterase, FXIIIa, thrombin activity and D-dimer evaluation, are associated with 
distinct proteins with different activity mechanisms, CPF was common inhibitor among all 
of the different assays, suggesting a multitude of CPF toxic effects in the biological 
environment (or on pure enzyme) possibly to top its greater ability to interact with these 
enzymes in different ways.  
7.1.3 OPs effect on THP-1 cell line 
Monocytes are a type of white blood cell (leukocyte) that, once the body is invaded, convert 
to macrophages as part of the immune response (Gordon & Taylor, 2005). The fourth aim 
of this study was to identify the effect of OPs on the proliferation and viability of THP-1 
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monocyte-like cells. Proliferation and viability were studied by Trypan Blue exclusion assay 
and the metabolic activity of the cells was monitored by the alamarBlue assay. 
The data obtained in the current study showed that OPs could affect proliferation in a 
concentration and time-dependent manner. In the first set of experiment the 100 µM of DZ, 
DZO, PTH, POX had the strongest effects, where they decreased live cell count by 50 % on 
day 6 of toxin incubation compared to the non OP-treated control samples. This suggested 
that both phosphorothioate and oxon forms of insecticide OPs behaved in similar way with 
respect to monocyte cell growth in contrast to the different toxicities against their main acute 
toxicity targets in nerve tissue. Interestingly, 100 µM CPO on day 4 induced the elevation 
of live cell counts compared to control cells, before causing reduction on day 6, whereas, 
CPF inhibited the proliferation and viability at both time points. The effect observed on day 
4 against the high concentration of CPO could be an immune reaction that had failed by day 
6 because of the high concentration of toxin, as metabolic activity was significantly inhibited 
from day 0.  This possibility is consistent with the findings of a study by Ural (2013), who 
exposed Cyprinus carpio carpio fish to 0.04 and 0.08 mg/l CPF for 14 days resulting in a 
significant increase of WB cell count suggestive of an immune response. Moreover, in the 
current study, PTH was the most toxic compound with respect to the reduction of cell 
proliferation and viability. A smaller group of OPs with lower concentration were selected 
and incubated with cells for up to 4 days only, giving further confirmation that OP effects 
on THP-1 cells are concentration and time-dependent. All selected OPs induced decline in 
THP-1 proliferation.   
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 Future work  
The present study evaluated the effect of OPs on plasma TG (FXIIIa) transamidase activities 
and the possible OP adducts on FXIIIa protein. The results showed significant inhibitory 
effects of several OPs on plasma TG or rFXIII-mediated amine and peptide incorporation 
activity, demonstrated the covalent binding of FXIIIa with labelled PSP, its displacement by 
unlabelled OPs, and the location of sites of adduct formation for PSP and the oxon forms of 
pesticide OPs. The data also showed the ability of specific OPs to inhibit and/or covalently 
bind to pure and plasma thrombin. Based on the current study’s findings, I would make the 
following recommendations for future research: - 
It would be of interest in future work to investigate the potential role of natural polyamine 
adduct formation (such as spermidine or spermine) in clotting and in OP toxicity, as these 
serve as a substrate for transglutaminases in body cells and fluid (Folk et al., 1980). It would 
also be of value to identify novel proteins forming OP adducts in depleted plasma from by 
SDS-PAGE, 2D-PAGE and MS analysis. 
In addition, since the organophosphorothioates CPF, DZ and PTH also showed inhibition 
effects on rFXIII and thrombin, these compounds (like PSP and the oxons) could also form 
adducts on these proteins and this would be worthy of further study using MS analysis with 
rFXIIIa and thrombin incubated with parent OPs.  
 According to the current study, the effect of OPs on pure thrombin activity using 
chromogenic substrate appeared only after dilution to 0.5 U/ml, in agreement with Gargiulo 
et al. (1981) who used a fluorescent substrate. Further work with lower enzyme 
concentration, higher OP: thrombin ratio and longer incubation time, possibly using a more 
sensitive fluorescent substrate would be worthwhile. As the competition assays performed 
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in the current work suggested covalent binding to a common site for all OPs, confirmation 
of the binding site(s) location by MS would be of interest.  
Since most OPs had an obvious effect on THP-1 cell proliferation, in some cases in the 
absence of cell death, these OPs could affect key processes that modulate cell proliferation. 
For example, as many studies have used antibodies to PCNA and Ki67 to study proliferation 
of THP-1cells (Sun et al., 2016), a similar approach could be applied to study their 
expression in OP-treated THP-1 cells to confirm the effect of OPs on these and other 
intracellular proliferation regulatory molecules. A non-targeted proteomic approach (e.g. 
2D-PAGE of cell lysates and MS of identification of protein showing expression changes on 
OP treatment) would help to determine the proteomic basis of OP effects. Quantitative RT-
PCR would then establish which protein changes were affected by altered gene expression. 
Moreover, given the observed effects of OPs on FXIIIa-mediated transamidase activity, it 
would be useful to study the effect of OPs on FXIII activity, production and secretion in 
THP-1 monocyte-like cells or in cells induced to differentiate into macrophages, in which 
FXIII expression is higher than in monocytes, (Conkling et al., 1989; Sárváry et al., 2004). 
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 Concluding remarks 
The present study addressed the question of whether OPs could disrupt the coagulation 
process through modulation of FXIIIa and thrombin activity, and by disturbing monocyte 
cell growth. Several OPs were shown to disrupt these haematological parameters. The 
findings demonstrated a potential ability of OPs to inhibit transamidase activities of both 
plasma TG and purified rFXIIIa. The ability of OPs to disrupt the coagulation cascade was 
further demonstrated when reduced levels of D-dimer were detected by ELISA. MS analysis 
revealed that PSP and the 3 oxon OPs formed a variety of covalent adducts with various 
amino acids in rFXIIIa. Plasma thrombin activity was inhibited by 25 and 50 µM 
concentrations of several OPs. Selected OPs induced increased proliferation at early 
exposure times, which could reflect an immune response. However, most of the OPs tested 
inhibited THP-1 monocyte-like cell proliferation and reduced metabolic activity at sub-lethal 
concentrations, suggesting that OPs can interfere with proliferation mechanisms of white 
cells. Therefore, more research about OPs on coagulation cascade factors would be useful to 
understand more fully how OPs can disrupt haemostasis. This knowledge would introduce a 
valuable insight into how proteins other than cholinesterases are affected by OPs and how 
such toxicity affects their function.  
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8. Appendix 
 
Figure 8- 1: OPs IC50 for plasma acetylcholinesterase activity. 
 
Diluted human plasma samples (~1.5 mg/ml) were incubated 30 min on ice with a range of 
OPs concentrations as indicated in graphs prior to being subjected to the Ellman assay as 
described in materials and methods. A) PSP, B) diazoxon, C) parathion, D) chlorpyrifos 
oxon, E) paraoxon. Data points represent the mean ± SEM of butyrylcholinesterase specific 
activity from three independent experiments. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 versus non OP-treated control (=100%). 
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Figure 8- 2: OP IC50 for pure acetylcholinesterase activity. 
 
Pure electric eel acetylcholinesterase (0.4 µg/ml) samples were incubated 30 min on ice with 
a range of OPs as indicated prior to being subjected to the Ellman assay as described in 
materials and methods. A) chlorpyrifos, B) chlorpyrifos oxon, C) diazoxon, D) paraoxon. 
Data points represent the mean ± SEM of acetylcholinesterase specific activity from three 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus non OP-
treated control (=100%). 
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Figure 8- 3: OPs IC50 for plasma butyrylcholinesterase activity. 
 
Diluted human plasma samples (~1.5 mg/ml) were incubated 30 min on ice with a range of 
OPs concentrations as indicated in graphs prior to being subjected to the Ellman assay as 
described in materials and methods. A) PSP, B) diazinon, C) chlorpyrifos, D) parathion. E) 
diazoxon, F) chlorpyrifos oxon and G) parathion. Data points represent the mean ± SEM of 
utyrylcholinesterase specific activity from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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Figure 8- 4: OPs IC50 for pure butyrylcholinesterase activity. 
 
Pure equine butyrylcholinesterase (0.4 µg/ml) samples were incubated 30 min on ice with a 
range of OPs as indicated prior to being subjected to the Ellman assay as described in 
materials and methods. A) PSP, B) diazinon, C) chlorpyrifos, D) parathion, E) diazoxon, F) 
chlorpyrifos oxon, G) paraoxon. Data points represent the mean ± SEM of 
butyrylcholinesterase specific activity from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 versus non OP-treated control (=100%). 
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Figure 8- 5: OPs IC50 of pure rFXIII-mediated amine incorporation activity. 
 
Human rFXIII (~0.02 ng/µl) was pre-incubated for 30 min on ice with the indicated 
concentrations of each OP in the biotin-cadaverine incorporation assay, as described in 
Materials and Methods. Plots shown are for: A) PSP, B) diazinon, C) chlorpyrifos, D) 
diazoxon, F) parathion. Data points represent the mean ± SEM of normalized pure rFXIII 
activity from three independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p< 
0.0001 versus non OP-treated control (=100%). 
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Figure 8- 6: OPs IC50 of pure rFXIII-mediated peptide crosslinking activity. 
 
 
Human rFXIII (~0.005 ng/µl) was pre-incubated for 30 min on ice with the indicated 
concentrations of each OP in the biotin-labelled peptide F11KA crosslinking assay, 
as described in Materials and Methods. Plots shown are for: A) PSP, B) diazinon, C) 
chlorpyrifos, D) parathion, E) diazoxon, F) chlorpyrifos oxon and G) paraoxon. Data 
points represent the mean ± SEM of normalized pure rFXIII activity from three 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 versus 
non OP-treated control (=100%). 
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Figure 8- 7:  Images of treated THP-1 cells with OPs day 0. 
 
THP-1 cells were plated in equal density of 200,000 cells/ml per 75 flasks cultured in 
growth medium. The cells were treated with PSP, DZO, CPF, and PTH with three final 
concentration of each 0.1, 1, and 10 µM. Control sample was treated with 0.01 % (v/v) 
DMSO. Cells were monitored under the inverted light microscope at (10x) magnification. 
Scale bar 0.1 µm. 
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Figure 8- 8: Images of treated THP-1 cells with OPs day 4. 
 
THP-1 cells were plated in equal density of 200,000 cells/ml per 75 flasks cultured in 
growth medium. The Cells were incubated for up to 4 days and treated with PSP, DZO, 
CPF, and PTH with three final concentration of each 0.1, 1, and 10 µM. Control sample 
was treated with 0.01 % (v/v) DMSO. Cells were monitored under the inverted light 
microscope at (10x) magnification. Scale bar 0.1 µm. 
